FYI-0903-01456

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

National Institutes of Health
National Institute of
Environmental Health Sciences
P. O. Box 12233
Research Triangle Park, NC 27709

August 22, 2003

Document Control Office (7407)
Attn: TSCA Section 8(e) Or (FYI)
Room G99 East Tower
Ofc. Of Pollution Prevention & Toxics
401 M St SW
Washington, DC 20460-0001

Contain NO CBI

03 SEP -5 AM 9:21

Dear Document Control Office (7407):

In compliance with the National Toxicology Program's (NTP) mission to keep our colleagues informed of the current NTP findings during ongoing studies, a copy of the Pathology Working Group (PWG) report and the Summary Pathology Tables for the chronic Water study on WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE) (7775-09-9) are enclosed for your review.

The NTP assembles a Pathology Working Group to review every study and to resolve any differences between the study laboratory and quality assessment pathology evaluations. Please note that the PWG conclusion of the study results is based solely on the pathology for this study and may not reflect final NTP conclusions. In determining final conclusions, the NTP assesses a broad array of information that includes other results from this study and historical control data.

The Summary Pathology Tables contain the Incidence Rates of Neoplastic and Non-neoplastic Lesion data and the Statistical Analysis of Primary Tumors data pertaining to the laboratory animals. All study data are subject to an NTP retrospective audit and the interpretation may be modified based on the findings.

A wide variety of NTP information is also available in electronic format on the world-wide web, for example, the NTP Annual Plan, abstracts of NTP Reports, study data, and the status of all NTP studies. To view this information requires access to the internet and a Web browser such as Netscape Navigator or Internet Explorer. To access the NTP home page, use the URL http://ntp-server.niehs.nih.gov/. Comments on the usefulness of this site and suggestions for improvement are encouraged.

Please contact Central Data Management (CDM) at (919)541-3419 if you have any questions. You may also fax your requests for information to CDM at (919)541-3687 or send them via e-mail to cdm@niehs.nih.gov.

2003 SEP 23 AM 11:15

269391

Hard copies of documents such as NTP Technical Reports, short-term Toxicity Reports, and the Report on Carcinogens are available from the Environmental Health Information Service (EHIS). You can contact EHIS by phone at (919) 541-3841, by fax at (919)541-0273, or by e-mail at ehis@niehs.nih.gov.

Sincerely,

William Eastin

William Eastin, Ph.D.
Head, Information Systems & Central Files
Environmental Toxicology Program

Encls: PWG Report and Pathology Summary Tables for Rats and Mice
cc: Central Data Management

TR-517 - Water Disinfection Byproducts (Sodium Chlorate)

Pathology Tables - Rats

* P03 - Incidence Rates of Non-Neoplastic Lesions
* P05 - Incidence Rates of Neoplasms by Anatomic Site (systemic lesions abridged)
* P08 - Statistical Analysis of Primary Tumors
* P18 - Incidence Rates of Non-Neoplastic Lesions

Pathology Tables - Mice

* P03 - Incidence Rates of Non-Neoplastic Lesions
* P05 - Incidence Rates of Neoplasms by Anatomic Site (systemic lesions abridged)
* P08 - Statistical Analysis of Primary Tumors
* P18 - Incidence Rates of Non-Neoplastic Lesions

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FINAL#1/RATS

Facility: Southern Research Institute

Chemical CAS #: 7775-09-9

Lock Date: 10/16/01

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Natural Death	3	3	6	5
Moribund Sacrifice	10	11	11	4
Survivors				
Terminal Sacrifice	37	34	32	40
Natural Death			1	1
Moribund Sacrifice		2		
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Small, Duodenum	(50)	(49)	(45)	(49)
Amyloid Deposition		1 (2%)		
Epithelium, Cyst				1 (2%)
Liver	(50)	(50)	(50)	(50)
Angiectasis, Focal			2 (4%)	
Basophilic Focus	42 (84%)	44 (88%)	41 (82%)	42 (84%)
Cholangiofibrosis	1 (2%)		1 (2%)	3 (6%)
Clear Cell Focus	6 (12%)	16 (32%)	18 (36%)	10 (20%)
Congestion	6 (12%)	2 (4%)	2 (4%)	1 (2%)
Degeneration, Cystic, Focal	1 (2%)		1 (2%)	3 (6%)
Eosinophilic Focus		1 (2%)	1 (2%)	2 (4%)
Fibrosis, Focal				1 (2%)
Hemorrhage	1 (2%)			
Hepatodiaphragmatic Nodule	7 (14%)	4 (8%)	8 (16%)	3 (6%)
Hyperplasia, Focal, Histiocytic	20 (40%)	19 (38%)	16 (32%)	23 (46%)
Hyperplasia, Focal, Regenerative	1 (2%)			1 (2%)
Hyperplasia, Regenerative				2 (4%)
Infarct, Multiple		1 (2%)		
Infiltration Cellular, Focal, Polymorphonuclear			1 (2%)	
Infiltration Cellular, Polymorphonuclear		1 (2%)		
Infiltration Cellular, Mixed Cell	39 (78%)	38 (76%)	35 (70%)	41 (82%)
Mixed Cell Focus	12 (24%)	6 (12%)	7 (14%)	8 (16%)
Thrombosis		1 (2%)		
Bile Duct, Cyst		1 (2%)		
Bile Duct, Hyperplasia	29 (58%)	24 (48%)	34 (68%)	26 (52%)
Capsule, Cyst	1 (2%)			
Hepatocyte, Karyomegaly		1 (2%)		

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Hepatocyte, Necrosis, Focal		2 (4%)		1 (2%)
Hepatocyte, Vacuolization Cytoplasmic			2 (4%)	
Hepatocyte, Vacuolization Cytoplasmic, Diffuse	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Hepatocyte, Vacuolization Cytoplasmic, Focal	17 (34%)	10 (20%)	10 (20%)	10 (20%)
Hepatocyte, Periportal, Vacuolization Cytoplasmic		2 (4%)		
Hepatocyte, Periportal, Centrilobular, Vacuolization Cytoplasmic			1 (2%)	
Hepatocyte, Centrilobular, Necrosis	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Hepatocyte, Centrilobular, Vacuolization Cytoplasmic	5 (10%)	3 (6%)	8 (16%)	3 (6%)
Hepatocyte, Midzonal, Vacuolization Cytoplasmic		2 (4%)		
Mesentery	(18)	(10)	(13)	(16)
Inflammation, Chronic, Focal		1 (10%)		
Fat, Necrosis	4 (22%)	2 (20%)	1 (8%)	
Fat, Necrosis, Focal	12 (67%)	5 (50%)	9 (69%)	13 (81%)
Pancreas	(50)	(49)	(49)	(49)
Lipomatosis				1 (2%)
Acinus, Atrophy, Diffuse				1 (2%)
Acinus, Atrophy, Focal	15 (30%)	8 (16%)	9 (18%)	16 (33%)
Duct, Cyst, Focal	1 (2%)	2 (4%)	4 (8%)	1 (2%)
Duct, Cyst, Focal, Multiple	10 (20%)	14 (29%)	11 (22%)	18 (37%)
Duct, Hyperplasia, Focal				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy, Focal	2 (4%)			
Stomach, Forestomach	(50)	(50)	(50)	(50)
Edema		1 (2%)	1 (2%)	1 (2%)
Erosion		1 (2%)		
Inflammation, Chronic		2 (4%)	1 (2%)	
Inflammation, Chronic, Focal			1 (2%)	
Perforation			1 (2%)	
Ulcer	2 (4%)	7 (14%)		1 (2%)
Epithelium, Hyperplasia	2 (4%)	4 (8%)	6 (12%)	1 (2%)
Stomach, Glandular	(50)	(49)	(49)	(50)
Erosion	2 (4%)		2 (4%)	2 (4%)
Erosion, Focal	1 (2%)			
Inflammation, Chronic		1 (2%)		
Necrosis, Focal		1 (2%)		
Pigmentation, Focal	1 (2%)			
Ulcer		1 (2%)		
Tooth		(2)	(2)	(1)

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Malformation			1 (50%)	
Dentine, Malformation		1 (50%)		
Peridontal Tissue, Inflammation, Chronic		1 (50%)	2 (100%)	
Peridontal Tissue, Inflammation, Chronic, Focal				1 (100%)
CARDIOVASCULAR SYSTEM				
Blood Vessel		(1)		(1)
Thrombosis		1 (100%)		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	4 (8%)	2 (4%)		2 (4%)
Infiltration Cellular, Mixed Cell		1 (2%)	1 (2%)	4 (8%)
Thrombosis	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	2 (4%)	3 (6%)	5 (10%)	2 (4%)
Angiectasis	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Cytoplasmic Alteration, Focal	1 (2%)	2 (4%)	3 (6%)	2 (4%)
Degeneration, Cystic, Focal		1 (2%)		1 (2%)
Fibrosis, Focal			1 (2%)	
Hematopoietic Cell Proliferation		1 (2%)		
Hemorrhage	1 (2%)	1 (2%)		2 (4%)
Infiltration Cellular, Mixed Cell		1 (2%)		
Necrosis, Focal		1 (2%)		
Vacuolization Cytoplasmic, Focal	7 (14%)	13 (26%)	7 (14%)	8 (16%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Angiectasis				1 (2%)
Hyperplasia, Focal	3 (6%)	4 (8%)	1 (2%)	1 (2%)
Infiltration Cellular, Focal, Lymphoid				1 (2%)
Islets, Pancreatic	(50)	(49)	(49)	(50)
Hyperplasia, Focal			1 (2%)	
Parathyroid Gland	(47)	(47)	(48)	(47)
Hyperplasia, Focal			1 (2%)	
Pituitary Gland	(49)	(49)	(50)	(50)
Angiectasis	10 (20%)	6 (12%)	2 (4%)	13 (26%)
Pigmentation, Focal	1 (2%)			
Pars Distalis, Angiectasis	1 (2%)	2 (4%)	2 (4%)	
Pars Distalis, Cyst	2 (4%)	2 (4%)	1 (2%)	2 (4%)

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Pars Distalis, Cytoplasmic Alteration, Focal	3 (6%)	1 (2%)	2 (4%)	3 (6%)
Pars Distalis, Degeneration, Cystic, Focal	11 (22%)	14 (29%)	11 (22%)	3 (6%)
Pars Distalis, Hemorrhage, Focal	9 (18%)	6 (12%)	10 (20%)	2 (4%)
Pars Distalis, Hyperplasia, Focal	7 (14%)	5 (10%)	10 (20%)	4 (8%)
Pars Distalis, Infiltration Cellular, Focal			1 (2%)	
Pars Nervosa, Hyperplasia, Atypical, Focal		1 (2%)		
Rathke's Cleft, Cyst	1 (2%)	2 (4%)		
Rathke's Cleft, Hemorrhage	1 (2%)	2 (4%)	2 (4%)	6 (12%)
Rathke's Cleft, Hyperplasia, Cystic			1 (2%)	
Thyroid Gland	(47)	(47)	(43)	(46)
Congestion				1 (2%)
Ultimobranchial Cyst	1 (2%)		1 (2%)	
C-Cell, Hyperplasia	43 (91%)	45 (96%)	43 (100%)	44 (96%)
Follicle, Mineralization, Focal	25 (53%)	26 (55%)	40 (93%)	44 (96%)
Follicular Cell, Hyperplasia, Cystic, Focal	1 (2%)			
Follicular Cell, Hypertrophy	3 (6%)	7 (15%)	27 (63%)	42 (91%)
GENERAL BODY SYSTEM				
Tissue NOS	(1)	(2)	(4)	(6)
Mediastinum, Cyst			1 (25%)	
Mediastinum, Thrombosis				1 (17%)
Oral, Foreign Body, Focal				1 (17%)
Oral, Necrosis, Focal				1 (17%)
GENITAL SYSTEM				
Clitoral Gland	(49)	(50)	(50)	(49)
Cyst	1 (2%)			
Degeneration, Cystic	5 (10%)	2 (4%)	6 (12%)	1 (2%)
Hyperplasia				1 (2%)
Hyperplasia, Cystic	1 (2%)	4 (8%)	3 (6%)	1 (2%)
Hyperplasia, Cystic, Focal		1 (2%)		
Inflammation, Chronic	6 (12%)	2 (4%)	1 (2%)	3 (6%)
Duct, Inflammation, Chronic	1 (2%)			
Ovary	(50)	(50)	(49)	(50)
Cyst	5 (10%)	1 (2%)	1 (2%)	4 (8%)
Corpus Luteum, Hyperplasia				1 (2%)
Interstitial Cell, Hyperplasia		1 (2%)	1 (2%)	
Periovarian Tissue, Cyst	4 (8%)	4 (8%)	2 (4%)	1 (2%)
Uterus	(50)	(50)	(49)	(50)

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
GENITAL SYSTEM - CONT				
Hemorrhage		1 (2%)		1 (2%)
Hydrometra	1 (2%)			
Inflammation, Chronic			1 (2%)	
Inflammation, Focal, Suppurative				1 (2%)
Inflammation, Suppurative		1 (2%)		1 (2%)
Ulcer, Chronic Active				1 (2%)
Endometrium, Hyperplasia, Cystic	16 (32%)	7 (14%)	16 (33%)	11 (22%)
Vagina	(6)	(3)	(3)	(1)
Cyst	2 (33%)	1 (33%)	1 (33%)	1 (100%)
Inflammation, Chronic	1 (17%)			
Inflammation, Suppurative		1 (33%)	1 (33%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(50)
Angiectasis			1 (2%)	
Hemorrhage				1 (2%)
Hyperplasia	2 (4%)	1 (2%)	1 (2%)	
Hyperplasia, Focal, Histiocytic			2 (4%)	2 (4%)
Myeloid Cell, Hyperplasia	7 (14%)	3 (6%)	2 (4%)	6 (12%)
Myeloid Cell, Erythroid Cell, Hyperplasia		2 (4%)	2 (4%)	3 (6%)
Lymph Node	(36)	(34)	(30)	(39)
Hyperplasia, Plasma Cell	1 (3%)			
Pigmentation				1 (3%)
Deep Cervical, Hemorrhage	1 (3%)			
Deep Cervical, Hyperplasia, Lymphoid	1 (3%)			
Deep Cervical, Hyperplasia, Plasma Cell				1 (3%)
Mediastinal, Angiectasis			1 (3%)	
Mediastinal, Congestion	1 (3%)			
Mediastinal, Ectasia	2 (6%)	4 (12%)	2 (7%)	4 (10%)
Mediastinal, Hemorrhage	6 (17%)	6 (18%)	5 (17%)	3 (8%)
Mediastinal, Hyperplasia, Histiocytic	1 (3%)	4 (12%)	2 (7%)	3 (8%)
Mediastinal, Hyperplasia, Lymphoid	1 (3%)	2 (6%)	2 (7%)	3 (8%)
Mediastinal, Hyperplasia, Plasma Cell		1 (3%)		
Mediastinal, Infiltration Cellular, Mixed Cell			1 (3%)	
Mediastinal, Pigmentation			1 (3%)	
Pancreatic, Angiectasis		1 (3%)		
Pancreatic, Ectasia	1 (3%)			1 (3%)
Pancreatic, Hemorrhage	5 (14%)	3 (9%)		5 (13%)
Pancreatic, Hyperplasia, Histiocytic	31 (86%)	22 (65%)	15 (50%)	25 (64%)
Pancreatic, Hyperplasia, Lymphoid			1 (3%)	

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - CONT				
Pancreatic, Pigmentation	1 (3%)	7 (21%)	3 (10%)	6 (15%)
Lymph Node, Mandibular	(4)	(6)	(4)	(5)
Ectasia		1 (17%)		
Lymph Node, Mesenteric	(50)	(49)	(49)	(50)
Hemorrhage				1 (2%)
Hyperplasia, Focal, Histiocytic			1 (2%)	
Hyperplasia, Histiocytic	2 (4%)	4 (8%)		4 (8%)
Hyperplasia, Lymphoid	1 (2%)			
Spleen	(50)	(50)	(50)	(50)
Angiectasis, Focal		1 (2%)		1 (2%)
Fibrosis, Focal		1 (2%)		1 (2%)
Hematopoietic Cell Proliferation	16 (32%)	21 (42%)	8 (16%)	17 (34%)
Hemorrhage	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Hyperplasia, Focal, Histiocytic	2 (4%)	4 (8%)	2 (4%)	5 (10%)
Infarct				1 (2%)
Pigmentation, Focal			1 (2%)	
Red Pulp, Fibrosis, Diffuse				1 (2%)
Thymus	(49)	(48)	(48)	(48)
Angiectasis	2 (4%)	1 (2%)		
Cyst		1 (2%)		
Hemorrhage	1 (2%)		2 (4%)	1 (2%)
Hyperplasia, Lymphoid	1 (2%)			1 (2%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Dilatation	37 (74%)	39 (78%)	34 (68%)	38 (76%)
Ectasia	4 (8%)	1 (2%)	3 (6%)	2 (4%)
Fibrosis	2 (4%)	1 (2%)	1 (2%)	4 (8%)
Fibrosis, Focal	1 (2%)			
Hyperplasia	7 (14%)	11 (22%)	10 (20%)	9 (18%)
Hyperplasia, Focal	1 (2%)			1 (2%)
Inflammation, Chronic				1 (2%)
Skin	(50)	(50)	(50)	(50)
Inflammation, Chronic, Focal		1 (2%)		
Ulcer				1 (2%)
Subcutaneous Tissue, Fibrosis, Focal	1 (2%)			
MUSCULOSKELETAL SYSTEM				
None				

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
NERVOUS SYSTEM				
Brain	(49)	(50)	(50)	(50)
Compression, Focal	9 (18%)	9 (18%)	10 (20%)	9 (18%)
Hemorrhage, Focal		4 (8%)	3 (6%)	2 (4%)
Necrosis, Focal		1 (2%)		
Thalamus, Mineralization, Focal	1 (2%)			
Thalamus, Necrosis, Focal	1 (2%)			
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Congestion			2 (4%)	1 (2%)
Hemorrhage, Focal	1 (2%)		1 (2%)	2 (4%)
Hyperplasia, Focal, Histiocytic	1 (2%)	1 (2%)		2 (4%)
Hyperplasia, Histiocytic	4 (8%)	6 (12%)	5 (10%)	2 (4%)
Infiltration Cellular, Polymorphonuclear		1 (2%)		
Infiltration Cellular, Mixed Cell	2 (4%)	3 (6%)	2 (4%)	1 (2%)
Inflammation, Chronic, Focal	2 (4%)		4 (8%)	2 (4%)
Metaplasia, Focal, Osseous			1 (2%)	
Alveolar Epithelium, Hyperplasia	1 (2%)			
Alveolar Epithelium, Hyperplasia, Focal	4 (8%)	2 (4%)	3 (6%)	2 (4%)
Interstitium, Edema				1 (2%)
Mediastinum, Edema			1 (2%)	
Peribronchiolar, Hyperplasia, Lymphoid			1 (2%)	
Nose	(50)	(50)	(50)	(50)
Inflammation, Suppurative	1 (2%)	2 (4%)		
Nasolacrimal Duct, Inflammation		1 (2%)		1 (2%)
Respiratory Epithelium, Metaplasia, Focal, Squamous				1 (2%)
SPECIAL SENSES SYSTEM				
Eye	(50)	(49)	(47)	(50)
Atrophy	1 (2%)			
Cataract	2 (4%)	3 (6%)	1 (2%)	2 (4%)
Hemorrhage		1 (2%)		
Retinal Detachment	1 (2%)			
Bilateral, Atrophy				1 (2%)
Cornea, Inflammation, Chronic	1 (2%)	1 (2%)		
Cornea, Necrosis, Focal	1 (2%)			

a Number of animals examined microscopically at site and number of animals with lesion

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
SPECIAL SENSES SYSTEM - CONT				
Retina, Degeneration	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia, Cystic, Focal	1 (2%)			
Hyperplasia, Focal				1 (2%)
Hyperplasia, Focal, Histiocytic	2 (4%)		1 (2%)	
Inflammation, Chronic, Focal		1 (2%)	1 (2%)	2 (4%)
Metaplasia, Focal, Squamous			1 (2%)	
Epithelium, Hyperplasia, Focal	1 (2%)			
URINARY SYSTEM				
Kidney	(50)	(49)	(47)	(47)
Atrophy, Diffuse		1 (2%)		
Atrophy, Focal	1 (2%)			2 (4%)
Cyst			1 (2%)	1 (2%)
Hyperplasia, Lymphoid			1 (2%)	
Infarct		1 (2%)	1 (2%)	
Infiltration Cellular, Polymorphonuclear		1 (2%)		
Inflammation, Chronic	1 (2%)	2 (4%)		
Inflammation, Chronic, Focal, Granulomatous				1 (2%)
Nephropathy	43 (86%)	41 (84%)	37 (79%)	38 (81%)
Pelvis, Inflammation, Chronic		1 (2%)		
Pelvis, Transitional Epithelium, Hyperplasia		1 (2%)		
Renal Tubule, Accumulation, Hyaline Droplet	5 (10%)	12 (24%)	11 (23%)	5 (11%)
Renal Tubule, Pigmentation	2 (4%)	1 (2%)	4 (9%)	4 (9%)

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	10	13	11	14
Natural Death	3	10	8	8
Accidently Killed	1			
Survivors				
Terminal Sacrifice	36	27	31	28
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(48)	(47)	(44)	(49)
Edema				2 (4%)
Intestine Large, Rectum	(48)	(47)	(47)	(50)
Congestion				1 (2%)
Edema				1 (2%)
Hemorrhage				1 (2%)
Intestine Large, Cecum	(47)	(46)	(43)	(47)
Edema		1 (2%)		1 (2%)
Ulcer				1 (2%)
Intestine Small, Duodenum	(49)	(46)	(46)	(47)
Ulcer		1 (2%)		
Epithelium, Hyperplasia				1 (2%)
Intestine Small, Jejunum	(47)	(46)	(42)	(44)
Epithelium, Necrosis			1 (2%)	
Intestine Small, Ileum	(47)	(46)	(42)	(47)
Ulcer	1 (2%)			
Liver	(50)	(50)	(48)	(50)
Angiectasis, Focal	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Basophilic Focus	27 (54%)	30 (60%)	33 (69%)	29 (58%)
Cholangiofibrosis	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Clear Cell Focus	21 (42%)	18 (36%)	29 (60%)	15 (30%)
Congestion		2 (4%)		
Degeneration, Cystic, Focal	13 (26%)	9 (18%)	12 (25%)	14 (28%)
Eosinophilic Focus	2 (4%)	3 (6%)		2 (4%)
Fibrosis, Focal		1 (2%)		1 (2%)
Hemorrhage, Focal	1 (2%)			
Hepatodiaphragmatic Nodule	6 (12%)	2 (4%)	3 (6%)	5 (10%)
Hyperplasia, Focal, Histiocytic	6 (12%)	2 (4%)	8 (17%)	5 (10%)
Hyperplasia, Focal, Lymphoid			1 (2%)	1 (2%)

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Infarct	1 (2%)			
Infiltration Cellular, Mixed Cell	36 (72%)	29 (58%)	33 (69%)	28 (56%)
Mixed Cell Focus	13 (26%)	11 (22%)	3 (6%)	8 (16%)
Bile Duct, Hyperplasia	48 (96%)	49 (98%)	46 (96%)	50 (100%)
Centrilobular, Congestion		1 (2%)		
Hepatocyte, Necrosis, Focal		1 (2%)		2 (4%)
Hepatocyte, Vacuolization Cytoplasmic, Diffuse	3 (6%)	3 (6%)		4 (8%)
Hepatocyte, Vacuolization Cytoplasmic, Focal	26 (52%)	15 (30%)	14 (29%)	18 (36%)
Hepatocyte, Periportal, Necrosis		1 (2%)		
Hepatocyte, Periportal, Vacuolization Cytoplasmic		1 (2%)	1 (2%)	
Hepatocyte, Centrilobular, Atrophy				1 (2%)
Hepatocyte, Centrilobular, Necrosis	1 (2%)	3 (6%)	6 (13%)	4 (8%)
Hepatocyte, Centrilobular, Vacuolization Cytoplasmic	4 (8%)	9 (18%)	12 (25%)	11 (22%)
Hepatocyte, Midzonal, Necrosis	1 (2%)			
Hepatocyte, Midzonal, Vacuolization Cytoplasmic	6 (12%)	1 (2%)		1 (2%)
Hepatocyte, Midzonal, Vacuolization Cytoplasmic, Focal		1 (2%)		
Portal, Fibrosis		1 (2%)		
Portal, Hemorrhage		1 (2%)		
Mesentery	(19)	(20)	(19)	(23)
Angiectasis		1 (5%)		
Hemorrhage	1 (5%)		1 (5%)	
Inflammation, Chronic			1 (5%)	
Inflammation, Chronic, Focal				1 (4%)
Fat, Necrosis	2 (11%)		2 (11%)	2 (9%)
Fat, Necrosis, Focal	12 (63%)	10 (50%)	13 (68%)	14 (61%)
Pancreas	(49)	(49)	(49)	(50)
Inflammation, Chronic	1 (2%)			
Acinus, Atrophy, Diffuse				1 (2%)
Acinus, Atrophy, Focal	23 (47%)	23 (47%)	27 (55%)	15 (30%)
Acinus, Hyperplasia, Focal	1 (2%)	1 (2%)		
Duct, Cyst, Focal			1 (2%)	1 (2%)
Duct, Cyst, Focal, Multiple	15 (31%)	13 (27%)	18 (37%)	15 (30%)
Salivary Glands	(49)	(50)	(50)	(50)
Atrophy				1 (2%)
Hyperplasia, Focal, Histiocytic				1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Edema	1 (2%)	1 (2%)		4 (8%)
Erosion			1 (2%)	

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Inflammation, Chronic		4 (8%)		1 (2%)
Inflammation, Chronic, Focal			1 (2%)	
Inflammation, Focal		1 (2%)	1 (2%)	
Ulcer	1 (2%)	5 (10%)	2 (4%)	4 (8%)
Epithelium, Cyst	1 (2%)			
Epithelium, Hyperplasia	2 (4%)	8 (16%)	1 (2%)	7 (14%)
Epithelium, Hyperplasia, Focal			1 (2%)	
Stomach, Glandular	(49)	(48)	(48)	(50)
Erosion	3 (6%)	2 (4%)	4 (8%)	4 (8%)
Perforation				1 (2%)
Pigmentation, Focal		1 (2%)	1 (2%)	
Ulcer	1 (2%)			3 (6%)
Epithelium, Hyperplasia, Focal		1 (2%)		
Tongue	(1)	(1)	(1)	(1)
Epithelium, Hyperplasia	1 (100%)			
Tooth		(1)	(1)	
Malformation			1 (100%)	
Peridontal Tissue, Hyperplasia, Squamous		1 (100%)		
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	6 (12%)	3 (6%)	7 (14%)	10 (20%)
Infiltration Cellular, Mixed Cell	2 (4%)	1 (2%)		2 (4%)
Inflammation, Chronic, Focal				1 (2%)
Thrombosis	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Artery, Inflammation, Chronic, Focal	1 (2%)			
Endocardium, Valve, Inflammation, Chronic, Focal	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule	1 (2%)	7 (14%)	4 (8%)	3 (6%)
Atrophy			1 (2%)	
Cytoplasmic Alteration, Focal	3 (6%)	3 (6%)	2 (4%)	4 (8%)
Degeneration, Cystic, Focal			2 (4%)	
Hyperplasia, Diffuse			1 (2%)	
Infiltration Cellular, Mixed Cell				1 (2%)
Necrosis, Focal			1 (2%)	
Vacuolization Cytoplasmic, Diffuse		1 (2%)		

a Number of animals examined microscopically at site and number of animals with lesion

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Vacuolization Cytoplasmic, Focal	12 (24%)	8 (16%)	7 (14%)	6 (12%)
Capsule, Fibrosis, Focal		1 (2%)		
Adrenal Medulla	(49)	(49)	(50)	(50)
Hyperplasia, Focal	5 (10%)	12 (24%)	9 (18%)	13 (26%)
Islets, Pancreatic	(50)	(49)	(49)	(50)
Hyperplasia		2 (4%)		
Hyperplasia, Focal	1 (2%)	1 (2%)		
Parathyroid Gland	(49)	(50)	(47)	(49)
Hyperplasia, Focal				1 (2%)
Pituitary Gland	(48)	(50)	(49)	(50)
Angiectasis	2 (4%)	4 (8%)	1 (2%)	3 (6%)
Hemorrhage		1 (2%)		
Hemorrhage, Focal				1 (2%)
Pars Distalis, Cyst	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Pars Distalis, Cytoplasmic Alteration, Focal	3 (6%)	7 (14%)	3 (6%)	8 (16%)
Pars Distalis, Degeneration, Cystic, Focal	2 (4%)	2 (4%)		
Pars Distalis, Hemorrhage, Focal	2 (4%)	2 (4%)	1 (2%)	3 (6%)
Pars Distalis, Hyperplasia, Focal	4 (8%)	2 (4%)	3 (6%)	1 (2%)
Pars Distalis, Pars Nervosa, Hemorrhage, Focal			1 (2%)	
Pars Intermedia, Hemorrhage, Focal			1 (2%)	
Rathke's Cleft, Cyst				1 (2%)
Rathke's Cleft, Hemorrhage	1 (2%)		2 (4%)	2 (4%)
Rathke's Cleft, Hyperplasia, Cystic		1 (2%)		
Thyroid Gland	(47)	(44)	(43)	(47)
C-Cell, Hyperplasia	45 (96%)	42 (95%)	41 (95%)	44 (94%)
C-Cell, Hyperplasia, Focal			1 (2%)	
Follicle, Cyst	1 (2%)		1 (2%)	2 (4%)
Follicle, Degeneration, Cystic, Focal	2 (4%)			
Follicle, Mineralization, Focal	45 (96%)	43 (98%)	42 (98%)	42 (89%)
Follicular Cell, Hypertrophy	4 (9%)	13 (30%)	33 (77%)	40 (85%)
Follicular Cell, Hypertrophy, Focal	1 (2%)			
GENERAL BODY SYSTEM				
Tissue NOS	(5)	(6)	(2)	(7)
Abdominal, Fibrosis			1 (50%)	
Mediastinum, Hemorrhage		1 (17%)		
GENITAL SYSTEM				

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
GENITAL SYSTEM - CONT				
Epididymis	(50)	(50)	(50)	(50)
Fibrosis				1 (2%)
Inflammation, Chronic	1 (2%)	1 (2%)		2 (4%)
Penis		(2)		
Thrombosis		1 (50%)		
Preputial Gland	(48)	(49)	(50)	(50)
Atrophy				1 (2%)
Cyst		1 (2%)	1 (2%)	
Degeneration, Cystic		2 (4%)	1 (2%)	2 (4%)
Hyperplasia, Cystic		1 (2%)		1 (2%)
Inflammation, Chronic	22 (46%)	12 (24%)	18 (36%)	20 (40%)
Necrosis				1 (2%)
Prostate	(50)	(49)	(50)	(50)
Inflammation, Chronic	21 (42%)	23 (47%)	29 (58%)	30 (60%)
Mineralization, Focal	3 (6%)	2 (4%)	3 (6%)	4 (8%)
Epithelium, Hyperplasia, Focal	11 (22%)	4 (8%)	2 (4%)	11 (22%)
Testes	(50)	(50)	(50)	(50)
Atrophy	4 (8%)	10 (20%)	9 (18%)	6 (12%)
Bilateral, Atrophy		1 (2%)		
Germinal Epithelium, Atrophy				1 (2%)
Germinal Epithelium, Degeneration	1 (2%)			
Interstitial Cell, Hyperplasia, Focal	1 (2%)	1 (2%)	1 (2%)	3 (6%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(48)	(48)	(50)	(49)
Angiectasis		1 (2%)		
Atrophy				1 (2%)
Fibrosis	2 (4%)			
Hyperplasia	28 (58%)	35 (73%)	41 (82%)	40 (82%)
Myeloid Cell, Erythroid Cell, Hyperplasia	2 (4%)			
Lymph Node	(34)	(24)	(26)	(34)
Ectasia	1 (3%)			
Hemorrhage				1 (3%)
Deep Cervical, Hemorrhage			1 (4%)	
Deep Cervical, Hyperplasia, Plasma Cell	1 (3%)			
Mediastinal, Angiectasis			1 (4%)	
Mediastinal, Ectasia	5 (15%)	7 (29%)	5 (19%)	3 (9%)
Mediastinal, Hemorrhage	3 (9%)	2 (8%)	2 (8%)	1 (3%)
Mediastinal, Hyperplasia, Histiocytic		3 (13%)	2 (8%)	1 (3%)
Mediastinal, Hyperplasia, Lymphoid	1 (3%)		1 (4%)	3 (9%)
Mediastinal, Hyperplasia, Plasma Cell	1 (3%)		2 (8%)	

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - CONT				
Mediastinal, Infiltration Cellular, Polymorphonuclear		1 (4%)		
Mediastinal, Inflammation, Chronic Active				1 (3%)
Mediastinal, Inflammation, Suppurative		1 (4%)		
Pancreatic, Angiectasis	2 (6%)			
Pancreatic, Ectasia	3 (9%)	3 (13%)	3 (12%)	6 (18%)
Pancreatic, Hemorrhage	5 (15%)	3 (13%)	1 (4%)	1 (3%)
Pancreatic, Hyperplasia, Histiocytic	8 (24%)	5 (21%)	9 (35%)	6 (18%)
Pancreatic, Hyperplasia, Lymphoid	1 (3%)	1 (4%)		
Pancreatic, Pigmentation	1 (3%)	1 (4%)	1 (4%)	
Renal, Hemorrhage			1 (4%)	
Renal, Hyperplasia, Focal, Histiocytic		1 (4%)		
Renal, Hyperplasia, Lymphoid		1 (4%)		
Lymph Node, Mesenteric	(49)	(50)	(49)	(50)
Amyloid Deposition				1 (2%)
Ectasia	1 (2%)	1 (2%)	1 (2%)	3 (6%)
Hemorrhage		2 (4%)	3 (6%)	
Hyperplasia, Focal, Histiocytic	1 (2%)			
Hyperplasia, Histiocytic	3 (6%)	3 (6%)		1 (2%)
Hyperplasia, Lymphoid	2 (4%)	1 (2%)		1 (2%)
Spleen	(48)	(49)	(49)	(50)
Amyloid Deposition		1 (2%)		
Angiectasis, Focal		2 (4%)	1 (2%)	3 (6%)
Atrophy				1 (2%)
Congestion	1 (2%)			1 (2%)
Fibrosis, Focal		2 (4%)	2 (4%)	4 (8%)
Hematopoietic Cell Proliferation	2 (4%)	6 (12%)	4 (8%)	11 (22%)
Hemorrhage	1 (2%)	1 (2%)		
Hyperplasia, Focal, Histiocytic	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Infarct, Multiple				1 (2%)
Metaplasia, Focal, Lipocyte			1 (2%)	
Necrosis	1 (2%)			
Pigmentation				1 (2%)
Pigmentation, Focal			1 (2%)	
Capsule, Accessory Spleen, Focal	1 (2%)			
Capsule, Fibrosis, Focal				1 (2%)
Lymphoid Follicle, Atrophy		1 (2%)		
Thymus	(48)	(48)	(49)	(47)
Angiectasis			1 (2%)	
Cyst		1 (2%)		
Hemorrhage	1 (2%)	2 (4%)	3 (6%)	
Hyperplasia, Lymphoid			2 (4%)	1 (2%)

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
INTEGUMENTARY SYSTEM				
Mammary Gland	(45)	(43)	(47)	(44)
Cyst				1 (2%)
Dilatation	7 (16%)	7 (16%)	7 (15%)	2 (5%)
Hyperplasia		1 (2%)	2 (4%)	2 (5%)
Inflammation, Chronic, Focal	1 (2%)			1 (2%)
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	3 (6%)	1 (2%)	3 (6%)	1 (2%)
Fibrosis, Focal		2 (4%)		
Hyperkeratosis, Focal	1 (2%)		1 (2%)	
Inflammation, Chronic, Focal		2 (4%)		
Ulcer		1 (2%)		
Artery, Subcutaneous Tissue, Thrombosis		1 (2%)		
Epidermis, Hyperplasia, Focal	1 (2%)			
Lip, Inflammation, Chronic, Focal		1 (2%)		
Subcutaneous Tissue, Cyst		1 (2%)		
Subcutaneous Tissue, Cyst Epithelial Inclusion			1 (2%)	
Subcutaneous Tissue, Hyperplasia, Focal, Histiocytic				1 (2%)
Subcutaneous Tissue, Inflammation, Chronic, Focal		1 (2%)		
Subcutaneous Tissue, Inflammation, Chronic, Focal, Suppurative			1 (2%)	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Cranium, Hyperostosis		1 (2%)		
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Compression, Focal	6 (12%)	6 (12%)	7 (14%)	6 (12%)
Hemorrhage, Focal	2 (4%)	2 (4%)	4 (8%)	6 (12%)
Cerebrum, Ventricle, Hydrocephalus		1 (2%)		
RESPIRATORY SYSTEM				

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
RESPIRATORY SYSTEM - CONT				
Lung	(50)	(50)	(50)	(50)
Congestion	2 (4%)	1 (2%)	3 (6%)	
Foreign Body, Focal	1 (2%)			
Hemorrhage			1 (2%)	
Hemorrhage, Focal	3 (6%)	1 (2%)	2 (4%)	2 (4%)
Hyperplasia, Focal, Histiocytic		1 (2%)	1 (2%)	
Hyperplasia, Histiocytic	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Infiltration Cellular, Mixed Cell	1 (2%)	3 (6%)	1 (2%)	2 (4%)
Inflammation, Chronic, Focal	5 (10%)	2 (4%)	3 (6%)	3 (6%)
Inflammation, Focal, Suppurative		1 (2%)		
Alveolar Epithelium, Hyperplasia, Focal	8 (16%)	5 (10%)	3 (6%)	4 (8%)
Alveolar Epithelium, Metaplasia, Squamous		1 (2%)		
Alveolus, Edema, Focal			1 (2%)	
Alveolus, Hyperplasia, Focal, Histiocytic	1 (2%)			
Interstitium, Edema		1 (2%)		1 (2%)
Mediastinum, Edema		1 (2%)	1 (2%)	
Nose	(49)	(49)	(49)	(50)
Foreign Body		1 (2%)	2 (4%)	1 (2%)
Inflammation, Chronic	1 (2%)			
Inflammation, Suppurative	1 (2%)	1 (2%)	6 (12%)	1 (2%)
Nasolacrimal Duct, Inflammation	1 (2%)	3 (6%)		1 (2%)
Olfactory Epithelium, Hyperplasia, Focal			1 (2%)	
Respiratory Epithelium, Hyperplasia, Focal			1 (2%)	
Trachea	(50)	(49)	(50)	(50)
Peritracheal Tissue, Edema		1 (2%)		
SPECIAL SENSES SYSTEM				
Eye	(50)	(48)	(46)	(50)
Atrophy				2 (4%)
Cataract		2 (4%)	1 (2%)	2 (4%)
Exudate		1 (2%)		
Cornea, Inflammation, Chronic			1 (2%)	
Cornea, Retrobulbar, Inflammation, Chronic Active				1 (2%)
Retina, Degeneration		2 (4%)	1 (2%)	2 (4%)
Harderian Gland	(49)	(49)	(49)	(50)
Fibrosis, Focal				1 (2%)
Hyperplasia, Focal, Histiocytic		1 (2%)	1 (2%)	1 (2%)
Inflammation, Chronic, Focal		1 (2%)	1 (2%)	1 (2%)
Inflammation, Chronic Active, Diffuse				1 (2%)
Epithelium, Hyperplasia, Focal	1 (2%)			

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
URINARY SYSTEM				
Kidney	(47)	(46)	(49)	(49)
Cyst			1 (2%)	
Cyst, Multiple		1 (2%)		
Hydronephrosis		1 (2%)		
Infarct			1 (2%)	
Infarct, Multiple	1 (2%)	1 (2%)		
Metaplasia, Focal, Lipocyte		1 (2%)		
Nephropathy	45 (96%)	44 (96%)	48 (98%)	47 (96%)
Cortex, Medulla, Atrophy		1 (2%)		
Pelvis, Infiltration Cellular, Mixed Cell				1 (2%)
Pelvis, Transitional Epithelium, Hyperplasia		1 (2%)	1 (2%)	
Renal Tubule, Accumulation, Hyaline Droplet		1 (2%)	4 (8%)	2 (4%)
Renal Tubule, Hyperplasia, Focal		1 (2%)		
Renal Tubule, Pigmentation	4 (9%)	4 (9%)	1 (2%)	4 (8%)
Urinary Bladder	(48)	(49)	(47)	(50)
Calculus Micro Observation Only		1 (2%)		
Edema				2 (4%)
Hemorrhage			2 (4%)	
Inflammation, Chronic			1 (2%)	
Serosa, Inflammation, Focal				1 (2%)
Transitional Epithelium, Hyperplasia, Diffuse		1 (2%)		

a Number of animals examined microscopically at site and number of animals with lesion

END OF REPORT

FINAL#1/RATS

Facility: Southern Research Institute

Chemical CAS #: 7775-09-9

Lock Date: 10/16/01

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially in Study	50	50	50	50
Early Deaths				
Natural Death	3	3	6	5
Moribund Sacrifice	10	11	11	4
Survivors				
Terminal Sacrifice	37	34	32	40
Natural Death			1	1
Moribund Sacrifice		2		
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(50)	(48)	(46)	(49)
Leiomyosarcoma	1 (2%)			
Intestine Small, Jejunum	(49)	(47)	(44)	(45)
Leiomyoma		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Cholangiocarcinoma		1 (2%)		
Histiocytic Sarcoma		1 (2%)		
Histiocytic Sarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Mesentery	(18)	(10)	(13)	(16)
Carcinoma				1 (6%)
Oral Mucosa			(1)	(1)
Squamous Cell Carcinoma				1 (100%)
Pancreas	(50)	(49)	(49)	(49)
Acinus, Adenoma	2 (4%)			
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Tooth		(2)	(2)	(1)
Odontoma		1 (50%)		
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Malignant		1 (2%)		1 (2%)
Pheochromocytoma Complex				1 (2%)
Pheochromocytoma Benign	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Islets, Pancreatic	(50)	(49)	(49)	(50)
Adenoma	2 (4%)	1 (2%)		
Carcinoma	1 (2%)	1 (2%)		1 (2%)
Pituitary Gland	(49)	(49)	(50)	(50)
Pars Distalis, Adenoma	23 (47%)	18 (37%)	17 (34%)	24 (48%)
Pars Distalis, Adenoma, Multiple				1 (2%)
Pars Distalis, Carcinoma	1 (2%)	3 (6%)		
Pars Intermedia, Adenoma	1 (2%)	1 (2%)		1 (2%)
Thyroid Gland	(47)	(47)	(43)	(46)
Bilateral, C-Cell, Adenoma	1 (2%)	2 (4%)		
C-Cell, Adenoma	11 (23%)	8 (17%)	11 (26%)	9 (20%)
C-Cell, Carcinoma	1 (2%)	3 (6%)	1 (2%)	3 (7%)
Follicular Cell, Adenoma				2 (4%)
Follicular Cell, Carcinoma	1 (2%)		1 (2%)	2 (4%)
GENERAL BODY SYSTEM				
Tissue NOS	(1)	(2)	(4)	(6)
Mediastinum, Carcinoma, Metastatic, Thyroid Gland		1 (50%)		
Mediastinum, Carcinoma, Metastatic, Zymbal's Gland			1 (25%)	
Mediastinum, Histiocytic Sarcoma			1 (25%)	
Mediastinum, Sarcoma				1 (17%)
GENITAL SYSTEM				
Clitoral Gland	(49)	(50)	(50)	(49)
Adenoma	11 (22%)	5 (10%)	12 (24%)	4 (8%)
Carcinoma	3 (6%)	1 (2%)		
Sarcoma				1 (2%)
Ovary	(50)	(50)	(49)	(50)
Granulosa Cell Tumor Benign	1 (2%)			
Sarcoma				1 (2%)
Oviduct			(2)	

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
GENITAL SYSTEM - cont				
Uterus	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Mesentery				1 (2%)
Sarcoma Stromal	1 (2%)			
Endometrium, Polyp Stromal	8 (16%)	8 (16%)	7 (14%)	7 (14%)
Endometrium, Polyp Stromal, Multiple	1 (2%)		2 (4%)	
Endometrium, Sarcoma				1 (2%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(50)
Lymph Node	(36)	(34)	(30)	(39)
Mediastinal, Histiocytic Sarcoma			1 (3%)	
Mediastinal, Sarcoma				1 (3%)
Lymph Node, Mandibular	(4)	(6)	(4)	(5)
Lymph Node, Mesenteric	(50)	(49)	(49)	(50)
Spleen	(50)	(50)	(50)	(50)
Sarcoma				1 (2%)
Thymus	(49)	(48)	(48)	(48)
Sarcoma				1 (2%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Adenoma	3 (6%)			2 (4%)
Carcinoma	2 (4%)	1 (2%)		2 (4%)
Carcinoma, Multiple	1 (2%)			
Fibroadenoma	23 (46%)	26 (52%)	23 (46%)	27 (54%)
Fibroadenoma, Multiple	10 (20%)	3 (6%)	8 (16%)	6 (12%)
Histiocytic Sarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Skin	(50)	(50)	(50)	(50)
Basal Cell Carcinoma	1 (2%)			
Keratoacanthoma				1 (2%)
Trichoepithelioma	2 (4%)			
Pinna, Neural Crest Tumor	1 (2%)			
Subcutaneous Tissue, Carcinoma, Metastatic, Mammary Gland		1 (2%)		
Subcutaneous Tissue, Fibroma	4 (8%)	1 (2%)	1 (2%)	1 (2%)
Subcutaneous Tissue, Fibrosarcoma		1 (2%)		
Subcutaneous Tissue, Histiocytic Sarcoma		1 (2%)		
Subcutaneous Tissue, Histiocytic Sarcoma,				

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
INTEGUMENTARY SYSTEM - cont				
Metastatic, Skeletal Muscle		1 (2%)		
Subcutaneous Tissue, Lipoma	1 (2%)			
Subcutaneous Tissue, Sarcoma				1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma		1 (2%)		
Skeletal Muscle		(2)	(1)	(1)
Histiocytic Sarcoma		1 (50%)		
Rhabdomyosarcoma		1 (50%)		
NERVOUS SYSTEM				
Brain	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Pituitary Gland		2 (4%)		
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	1 (2%)		
Alveolar/Bronchiolar Carcinoma	1 (2%)			
Carcinoma, Metastatic, Mammary Gland	1 (2%)			
Histiocytic Sarcoma		1 (2%)		
Histiocytic Sarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma				1 (2%)
Nose	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(49)	(47)	(50)
Harderian Gland	(50)	(50)	(50)	(50)
Histiocytic Sarcoma		1 (2%)		
Squamous Cell Carcinoma, Metastatic, Oral Mucosa				1 (2%)
Zymbal's Gland	(1)		(1)	(1)
Carcinoma			1 (100%)	

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
URINARY SYSTEM				
Kidney	(50)	(49)	(47)	(47)
Sarcoma				1 (2%)
Urinary Bladder	(50)	(48)	(50)	(50)
Transitional Epithelium, Papilloma				1 (2%)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		2 (4%)	1 (2%)	
Leukemia Mononuclear	11 (22%)	9 (18%)	13 (26%)	9 (18%)
Lymphoma Malignant			1 (2%)	
Mesothelioma Malignant			1 (2%)	

* Number of animals with any tissue examined microscopically

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
TUMOR SUMMARY				
Total Animals with Primary Neoplasms (b)	49	48	46	48
Total Primary Neoplasms	133	102	101	118
Total Animals with Benign Neoplasms	46	42	44	47
Total Benign Neoplasms	107	77	82	87
Total Animals with Malignant Neoplasms	21	22	19	22
Total Malignant Neoplasms	25	25	19	31
Total Animals with Metastatic Neoplasms	1	5	2	2
Total Metastatic Neoplasm	1	8	2	2
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain-Benign or Malignant	1			
Total Uncertain Neoplasms	1			

a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	10	13	11	14
Natural Death	3	10	8	8
Accidently Killed	1			
Survivors				
Terminal Sacrifice	36	27	31	28
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(48)	(47)	(44)	(49)
Intestine Large, Cecum	(47)	(46)	(43)	(47)
Intestine Small, Duodenum	(49)	(46)	(46)	(47)
Intestine Small, Jejunum	(47)	(46)	(42)	(44)
Intestine Small, Ileum	(47)	(46)	(42)	(47)
Liver	(50)	(50)	(48)	(50)
Hemangiosarcoma		1 (2%)		
Hepatocellular Adenoma		3 (6%)		
Histiocytic Sarcoma	1 (2%)	1 (2%)		
Mesentery	(19)	(20)	(19)	(23)
Carcinoma, Metastatic, Pancreas		1 (5%)		
Hemangiosarcoma, Metastatic, Liver		1 (5%)		
Histiocytic Sarcoma	1 (5%)	1 (5%)		
Osteosarcoma	1 (5%)			
Pancreas	(49)	(49)	(49)	(50)
Hemangiosarcoma, Metastatic, Liver		1 (2%)		
Acinus, Adenoma		2 (4%)	1 (2%)	
Acinus, Adenoma, Multiple		1 (2%)		
Acinus, Carcinoma		1 (2%)		
Salivary Glands	(49)	(50)	(50)	(50)
Fibrosarcoma			1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)
Schwannoma Malignant	1 (2%)			
Squamous Cell Papilloma				1 (2%)
Stomach, Glandular	(49)	(48)	(48)	(50)
Tongue	(1)	(1)	(1)	(1)
Sarcoma			1 (100%)	
Squamous Cell Carcinoma		1 (100%)		

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - cont				
Squamous Cell Papilloma				1 (100%)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(1)		(2)	
Aorta, Osteosarcoma	1 (100%)			
Heart	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Zymbal's Gland				1 (2%)
Schwannoma Benign			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(49)	(50)	(50)
Carcinoma				1 (2%)
Osteosarcoma, Metastatic, Bone	1 (2%)			
Adrenal Medulla	(49)	(49)	(50)	(50)
Ganglioneuroma		1 (2%)		
Pheochromocytoma Malignant	3 (6%)		1 (2%)	1 (2%)
Pheochromocytoma Benign	6 (12%)	3 (6%)	3 (6%)	5 (10%)
Bilateral, Ganglioneuroma				1 (2%)
Bilateral, Pheochromocytoma Benign		1 (2%)		3 (6%)
Islets, Pancreatic	(50)	(49)	(49)	(50)
Adenoma	3 (6%)	4 (8%)	3 (6%)	5 (10%)
Carcinoma	2 (4%)	1 (2%)		2 (4%)
Pituitary Gland	(48)	(50)	(49)	(50)
Pars Distalis, Adenoma	16 (33%)	15 (30%)	20 (41%)	15 (30%)
Pars Intermedia, Adenoma		1 (2%)		1 (2%)
Thyroid Gland	(47)	(44)	(43)	(47)
Bilateral, C-Cell, Adenoma, Multiple			1 (2%)	
C-Cell, Adenoma	9 (19%)	9 (20%)	5 (12%)	9 (19%)
C-Cell, Carcinoma	2 (4%)	2 (5%)		1 (2%)
Follicular Cell, Adenoma	1 (2%)			2 (4%)
Follicular Cell, Carcinoma				4 (9%)
GENERAL BODY SYSTEM				
Peritoneum		(1)	(1)	
Tissue NOS	(5)	(6)	(2)	(7)
Abdominal, Paraganglioma	1 (20%)			
Mediastinum, Carcinoma, Metastatic, Zymbal's				

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
GENERAL BODY SYSTEM - cont				
Gland		1 (17%)		
Mediastinum, Squamous Cell Carcinoma, Metastatic, Lung		1 (17%)		
Pelvic, Leiomyoma	1 (20%)			
Thoracic, Fibroma				1 (14%)
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Preputial Gland	(48)	(49)	(50)	(50)
Adenoma	1 (2%)	6 (12%)	5 (10%)	5 (10%)
Carcinoma	3 (6%)	1 (2%)	2 (4%)	2 (4%)
Prostate	(50)	(49)	(50)	(50)
Seminal Vesicle	(50)	(49)	(50)	(50)
Testes	(50)	(50)	(50)	(50)
Bilateral, Interstitial Cell, Adenoma				1 (2%)
Bilateral, Interstitial Cell, Adenoma, Multiple	40 (80%)	43 (86%)	42 (84%)	39 (78%)
Interstitial Cell, Adenoma	2 (4%)	1 (2%)		2 (4%)
Interstitial Cell, Adenoma, Multiple	3 (6%)	5 (10%)	2 (4%)	3 (6%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(48)	(48)	(50)	(49)
Lymph Node	(34)	(24)	(26)	(34)
Histiocytic Sarcoma	1 (3%)			
Deep Cervical, Histiocytic Sarcoma	1 (3%)			
Mediastinal, Carcinoma, Metastatic, Zymbal's Gland		1 (4%)		
Lymph Node, Mandibular	(3)	(2)	(3)	(4)
Lymph Node, Mesenteric	(49)	(50)	(49)	(50)
Spleen	(48)	(49)	(49)	(50)
Histiocytic Sarcoma	1 (2%)			
Capsule, Carcinoma, Metastatic, Pancreas		1 (2%)		
Thymus	(48)	(48)	(49)	(47)
Carcinoma, Metastatic, Zymbal's Gland		1 (2%)		
Thymoma Benign			1 (2%)	

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
INTEGUMENTARY SYSTEM				
Mammary Gland	(45)	(43)	(47)	(44)
Carcinoma		1 (2%)	1 (2%)	
Fibroadenoma	2 (4%)	1 (2%)	4 (9%)	4 (9%)
Skin	(50)	(50)	(50)	(50)
Basal Cell Carcinoma		1 (2%)		2 (4%)
Basal Cell Carcinoma, Multiple		1 (2%)		
Keratoacanthoma	4 (8%)	2 (4%)	1 (2%)	1 (2%)
Trichoepithelioma	1 (2%)			
Subcutaneous Tissue, Fibroma	9 (18%)	9 (18%)	4 (8%)	7 (14%)
Subcutaneous Tissue, Fibroma, Multiple		1 (2%)	1 (2%)	1 (2%)
Subcutaneous Tissue, Fibrosarcoma	1 (2%)	2 (4%)		
Subcutaneous Tissue, Histiocytic Sarcoma		1 (2%)		
Subcutaneous Tissue, Lipoma		1 (2%)		
Subcutaneous Tissue, Neural Crest Tumor	1 (2%)			
Subcutaneous Tissue, Osteosarcoma				1 (2%)
Subcutaneous Tissue, Sarcoma			1 (2%)	
Subcutaneous Tissue, Schwannoma Malignant			1 (2%)	1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma	1 (2%)			
Periosteum, Cranium, Fibrosarcoma, Metastatic, Skin		1 (2%)		
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Zymbal's Gland				1 (2%)
Glioma Malignant		1 (2%)		
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	1 (2%)	2 (4%)	
Alveolar/Bronchiolar Carcinoma	2 (4%)	2 (4%)		1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)			
Carcinoma, Metastatic, Zymbal's Gland				1 (2%)
Histiocytic Sarcoma, Metastatic, Uncertain				

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
RESPIRATORY SYSTEM - cont				
Primary Site	1 (2%)			
Osteosarcoma, Metastatic, Bone	1 (2%)			
Squamous Cell Carcinoma		1 (2%)		
Nose	(49)	(49)	(49)	(50)
Trachea	(50)	(49)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(48)	(46)	(50)
Retrobulbar, Fibrosarcoma, Metastatic, Skin		1 (2%)		
Harderian Gland	(49)	(49)	(49)	(50)
Carcinoma	1 (2%)			
Zymbal's Gland		(1)	(1)	(3)
Carcinoma		1 (100%)	1 (100%)	1 (33%)
URINARY SYSTEM				
Kidney	(47)	(46)	(49)	(49)
Lipoma		1 (2%)		1 (2%)
Mesenchymal Tumor Benign			1 (2%)	
Renal Tubule, Adenoma		1 (2%)		
Urinary Bladder	(48)	(49)	(47)	(50)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	1 (2%)		
Leukemia Mononuclear	13 (26%)	21 (42%)	16 (32%)	23 (46%)
Lymphoma Malignant	1 (2%)			
Mesothelioma Malignant		1 (2%)	2 (4%)	2 (4%)

* Number of animals with any tissue examined microscopically

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
TUMOR SUMMARY				
Total Animals with Primary Neoplasms (b)	49	50	50	50
Total Primary Neoplasms	135	152	124	150
Total Animals with Benign Neoplasms	48	49	47	47
Total Benign Neoplasms	100	112	97	108
Total Animals with Malignant Neoplasms	27	32	24	32
Total Malignant Neoplasms	34	40	27	42
Total Animals with Metastatic Neoplasms	2	5		1
Total Metastatic Neoplasm	3	10		3
Total Animals with Malignant Neoplasms Uncertain Primary Site	1			
Total Animals with Neoplasms Uncertain-Benign or Malignant	1			
Total Uncertain Neoplasms	1			

a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors

END OF REPORT

FINAL#1/RATS

REASONS FOR REMOVAL: ALL

REMOVAL DATE RANGE: ALL

TREATMENT GROUPS: INCLUDE ALL

NTP
LAB: Southern Research Inst
EXPERIMENT: 96010 TEST: 03
TEST TYPE: CHRONIC
CONT: N01-ES-85420
PATHOLOGIST: FARNELL, DANIEL R.
Rats(FISCHER 344)

STATISTICAL ANALYSIS OF PRIMARY TUMORS
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

CAGES FROM 0000 TO LAST CAGE
ROUTE: DOSED WATER

REPORT: PEIRPT08
DATE: 05/27/03
TIME: 13:29:04

NTP C#: 96010A
CAS: 7775-09-9

FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.

Adrenal Cortex
Adrenal Medulla
Brain
Clitoral/Preputial Gland
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pancreas
Pituitary Gland
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder

NTP
LAB: Southern Research Inst
EXPERIMENT: 96010 TEST: 03
TEST TYPE: CHRONIC
CONT: N01-ES-85420
PATHOLOGIST: FARNELL, DANIEL R.

STATISTICAL ANALYSIS OF PRIMARY TUMORS
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

CAGES FROM 0000 TO LAST CAGE
ROUTE: DOSED WATER

REPORT: PEIRPT08
DATE: 05/27/03
TIME: 13:29:04

NTP C#: 96010A
CAS: 7775-09-9

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF WATER DISINFECTION BYPRODUCTS (SODIUM

Male Rats

Organ	Morphology
Clitoral/Preputial Gland	Adenoma
Pancreas	Carcinoma or Adenoma
Testes	Adenoma
Thyroid Gland: Follicular Cell	Carcinoma
	Carcinoma or Adenoma
All Organs	Leukemia: Lymphocytic, Monocytic, Mononuclear, or Undifferentiated
	Osteosarcoma
	Osteosarcoma or Osteoma
	Benign Tumors

Female Rats

Organ	Morphology
Clitoral/Preputial Gland	Adenoma
	Carcinoma
	Carcinoma or Adenoma
Mammary Gland	Carcinoma or Adenoma
Pancreas	Adenoma
	Carcinoma or Adenoma
Skin	Basal Cell Carcinoma, Basal Cell Adenoma, Basosquamous Tumor (benign, malignant or NOS), or Trichoepithelioma
	Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom
	Trichoepithelioma
Thyroid Gland: Follicular Cell	Adenoma
	Carcinoma or Adenoma

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Adrenal Medulla Pheochromocytoma Benign								
TUMOR RATES								
OVERALL (a)	6/49 (12%)	4/49 (8%)	3/50 (6%)	8/50 (16%)	2/50 (4%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	6/43.39	4/43.76	3/43.85	8/43.70	2/44.75	1/43.69	1/43.24	1/47.00
POLY-3 PERCENT (g)	13.8%	9.1%	6.8%	18.3%	4.5%	2.3%	2.3%	2.1%
TERMINAL (d)	6/36 (17%)	3/27 (11%)	2/31 (7%)	5/28 (18%)	2/37 (5%)	1/36 (3%)	1/33 (3%)	1/41 (2%)
FIRST INCIDENCE	729 (T)	555	698	699	729 (T)	729 (T)	729 (T)	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.169	P=0.531N	P=0.316N	P=0.229	P=0.405N	P=0.510N	P=0.540N	P=0.464N
POLY 3	P=0.229	P=0.364N	P=0.236N	P=0.391	P=0.423N	P=0.508N	P=0.512N	P=0.483N
POLY 1.5	P=0.234	P=0.361N	P=0.234N	P=0.399	P=0.428N	P=0.506N	P=0.506N	P=0.489N
POLY 6	P=0.223	P=0.378N	P=0.243N	P=0.373	P=0.418N	P=0.511N	P=0.522N	P=0.477N
LOGISTIC REGRESSION	P=0.218	P=0.378N	P=0.274N	P=0.310	P=0.405N	P=0.510N	P=0.540N	P=0.464N
COCH-ARM / FISHERS	P=0.241	P=0.370N	P=0.233N	P=0.403	P=0.437N	P=0.500N	P=0.500N	P=0.500N
ORDER RESTRICTED	P=0.177	(e)	(e)	(e)	P=0.393N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Adrenal Medulla Pheochromocytoma Malignant								
TUMOR RATES								
OVERALL (a)	3/49 (6%)	0/49 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	3/43.39	0/43.20	1/43.97	1/43.44	0/44.75	1/44.28	0/43.24	1/47.00
POLY-3 PERCENT (g)	6.9%	0.0%	2.3%	2.3%	0.0%	2.3%	0.0%	2.1%
TERMINAL (d)	3/36 (8%)	0/27 (0%)	0/31 (0%)	1/28 (4%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	1/41 (2%)
FIRST INCIDENCE	729 (T)	---	667	729 (T)	---	541	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.443N	P=0.176N	P=0.347N	P=0.398N	P=0.495	P=0.496	(e)	P=0.520
POLY 3	P=0.404N	P=0.119N	P=0.300N	P=0.305N	P=0.488	P=0.498	(e)	P=0.510
POLY 1.5	P=0.405N	P=0.118N	P=0.299N	P=0.300N	P=0.484	P=0.498	(e)	P=0.506
POLY 6	P=0.400N	P=0.125N	P=0.305N	P=0.315N	P=0.492	P=0.498	(e)	P=0.513
LOGISTIC REGRESSION	P=0.414N	(e)	P=0.305N	P=0.398N	P=0.422	P=0.570	(e)	P=0.520
COCH-ARM / FISHERS	P=0.401N	P=0.121N	P=0.301N	P=0.301N	P=0.478	P=0.500	(e)	P=0.500
ORDER RESTRICTED	P=0.101N	(e)	(e)	(e)	P=0.261	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Adrenal Medulla Pheochromocytoma: Benign, Complex, Malignant, NOS								
TUMOR RATES								
OVERALL (a)	9/49 (18%)	4/49 (8%)	4/50 (8%)	9/50 (18%)	2/50 (4%)	2/50 (4%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	9/43.39	4/43.76	4/44.09	9/43.70	2/44.75	2/44.28	1/43.24	3/47.00
POLY-3 PERCENT (g)	20.7%	9.1%	9.1%	20.6%	4.5%	4.5%	2.3%	6.4%
TERMINAL (d)	9/36 (25%)	3/27 (11%)	2/31 (7%)	6/28 (21%)	2/37 (5%)	1/36 (3%)	1/33 (3%)	3/41 (7%)
FIRST INCIDENCE	729 (T)	555	667	699	729 (T)	541	729 (T)	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.250	P=0.237N	P=0.175N	P=0.389	P=0.454	P=0.684	P=0.540N	P=0.547
POLY 3	P=0.331	P=0.110N	P=0.107N	P=0.598N	P=0.430	P=0.690	P=0.512N	P=0.522
POLY 1.5	P=0.336	P=0.109N	P=0.108N	P=0.588N	P=0.423	P=0.691	P=0.506N	P=0.514
POLY 6	P=0.327	P=0.117N	P=0.110N	P=0.591	P=0.435	P=0.690	P=0.522N	P=0.530
LOGISTIC REGRESSION	P=0.317	P=0.126N	P=0.126N	P=0.498	P=0.426	P=0.691N	P=0.540N	P=0.547
COCH-ARM / FISHERS	P=0.347	P=0.116N	P=0.109N	P=0.584N	P=0.411	P=0.691N	P=0.500N	P=0.500
ORDER RESTRICTED	P=0.240N	(e)	(e)	(e)	P=0.430	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Clitoral/Preputial Gland Adenoma								
TUMOR RATES								
OVERALL (a)	1/48 (2%)	6/49 (12%)	5/50 (10%)	5/50 (10%)	11/49 (22%)	5/50 (10%)	12/50 (24%)	4/49 (8%)
POLY-3 RATE (b)	1/42.39	6/43.79	5/44.22	5/44.37	11/44.20	5/43.69	12/44.69	4/46.00
POLY-3 PERCENT (g)	2.4%	13.7%	11.3%	11.3%	24.9%	11.4%	26.9%	8.7%
TERMINAL (d)	1/35 (3%)	5/27 (19%)	3/31 (10%)	3/28 (11%)	10/36 (28%)	5/36 (14%)	8/33 (24%)	4/40 (10%)
FIRST INCIDENCE	729 (T)	542	626	465	595	729 (T)	511	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.227	P=0.031 *	P=0.086	P=0.075	P=0.132N	P=0.083N	P=0.418	P=0.028N*
POLY 3	P=0.287	P=0.060	P=0.111	P=0.111	P=0.131N	P=0.085N	P=0.512	P=0.035N*
POLY 1.5	P=0.289	P=0.062	P=0.111	P=0.113	P=0.147N	P=0.083N	P=0.518	P=0.038N*
POLY 6	P=0.277	P=0.056	P=0.108	P=0.107	P=0.119N	P=0.089N	P=0.499	P=0.033N*
LOGISTIC REGRESSION	P=0.287	P=0.062	P=0.110	P=0.112	P=0.150N	P=0.086N	P=0.499	P=0.034N*
COCH-ARM / FISHERS	P=0.287	P=0.059	P=0.112	P=0.112	P=0.179N	P=0.079N	P=0.522	P=0.045N*
ORDER RESTRICTED	P=0.096	(e)	(e)	(e)	P=0.028N*	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Clitoral/Preputial Gland Carcinoma								
TUMOR RATES								
OVERALL (a)	3/48 (6%)	1/49 (2%)	2/50 (4%)	2/50 (4%)	3/49 (6%)	1/50 (2%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	3/43.05	1/43.20	2/43.76	2/43.91	3/43.75	1/43.69	0/43.24	0/46.00
POLY-3 PERCENT (g)	7.0%	2.3%	4.6%	4.6%	6.9%	2.3%	0.0%	0.0%
TERMINAL (d)	2/35 (6%)	1/27 (4%)	1/31 (3%)	1/28 (4%)	3/36 (8%)	1/36 (3%)	0/33 (0%)	0/40 (0%)
FIRST INCIDENCE	511	729 (T)	721	590	729 (T)	729 (T)	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.573	P=0.369N	P=0.539N	P=0.554N	P=0.054N	P=0.305N	P=0.136N	P=0.103N
POLY 3	P=0.555N	P=0.304N	P=0.492N	P=0.491N	P=0.054N	P=0.305N	P=0.120N	P=0.110N
POLY 1.5	P=0.554N	P=0.299N	P=0.488N	P=0.485N	P=0.055N	P=0.303N	P=0.118N	P=0.113N
POLY 6	P=0.555N	P=0.317N	P=0.504N	P=0.503N	P=0.054N	P=0.307N	P=0.125N	P=0.107N
LOGISTIC REGRESSION	P=0.549N	P=0.308N	P=0.481N	P=0.488N	P=0.054N	P=0.305N	(e)	(e)
COCH-ARM / FISHERS	P=0.551N	P=0.301N	P=0.480N	P=0.480N	P=0.058N	P=0.301N	P=0.117N	P=0.121N
ORDER RESTRICTED	P=0.386N	(e)	(e)	(e)	P=0.018N*	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Clitoral/Preputial Gland Carcinoma or Adenoma								
TUMOR RATES								
OVERALL (a)	4/48 (8%)	7/49 (14%)	7/50 (14%)	6/50 (12%)	14/49 (29%)	6/50 (12%)	12/50 (24%)	4/49 (8%)
POLY-3 RATE (b)	4/43.05	7/43.79	7/44.25	6/44.84	14/44.20	6/43.69	12/44.69	4/46.00
POLY-3 PERCENT (g)	9.3%	16.0%	15.8%	13.4%	31.7%	13.7%	26.9%	8.7%
TERMINAL (d)	3/35 (9%)	6/27 (22%)	4/31 (13%)	3/28 (11%)	13/36 (36%)	6/36 (17%)	8/33 (24%)	4/40 (10%)
FIRST INCIDENCE	511	542	626	465	595	729 (T)	511	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.372	P=0.162	P=0.218	P=0.296	P=0.039N*	P=0.036N*	P=0.502N	P=0.004N**
POLY 3	P=0.461	P=0.270	P=0.276	P=0.395	P=0.036N*	P=0.037N*	P=0.395N	P=0.005N**
POLY 1.5	P=0.463	P=0.276	P=0.280	P=0.398	P=0.042N*	P=0.036N*	P=0.389N	P=0.006N**
POLY 6	P=0.454	P=0.251	P=0.266	P=0.384	P=0.031N*	P=0.039N*	P=0.408N	P=0.005N**
LOGISTIC REGRESSION	P=0.463	P=0.273	P=0.283	P=0.389	P=0.044N*	P=0.039N*	P=0.417N	P=0.006N**
COCH-ARM / FISHERS	P=0.462	P=0.274	P=0.286	P=0.397	P=0.059N	P=0.035N*	P=0.387N	P=0.009N**
ORDER RESTRICTED	P=0.344	(e)	(e)	(e)	P=0.003N**	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Islets, Pancreatic Adenoma								
TUMOR RATES								
OVERALL (a)	3/50 (6%)	4/49 (8%)	3/49 (6%)	5/50 (10%)	2/50 (4%)	1/49 (2%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/43.72	4/43.59	3/43.52	5/43.62	2/44.75	1/43.02	0/42.24	0/47.00
POLY-3 PERCENT (g)	6.9%	9.2%	6.9%	11.5%	4.5%	2.3%	0.0%	0.0%
TERMINAL (d)	3/36 (8%)	2/27 (7%)	2/31 (7%)	4/28 (14%)	2/37 (5%)	1/36 (3%)	0/32 (0%)	0/41 (0%)
FIRST INCIDENCE	729 (T)	663	714	681	729 (T)	729 (T)	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.274	P=0.381	P=0.597	P=0.238	P=0.102N	P=0.510N	P=0.271N	P=0.216N
POLY 3	P=0.335	P=0.498	P=0.661	P=0.355	P=0.104N	P=0.514N	P=0.250N	P=0.226N
POLY 1.5	P=0.338	P=0.499	P=0.658	P=0.358	P=0.105N	P=0.512N	P=0.246N	P=0.230N
POLY 6	P=0.327	P=0.488	P=0.657	P=0.343	P=0.104N	P=0.515N	P=0.257N	P=0.223N
LOGISTIC REGRESSION	P=0.321	P=0.482	P=0.626	P=0.310	P=0.102N	P=0.510N	(e)	(e)
COCH-ARM / FISHERS	P=0.339	P=0.489	P=0.651	P=0.357	P=0.106N	P=0.508N	P=0.253N	P=0.247N
ORDER RESTRICTED	P=0.355	(e)	(e)	(e)	P=0.067N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Islets, Pancreatic Carcinoma								
TUMOR RATES								
OVERALL (a)	2/50 (4%)	1/49 (2%)	0/49 (0%)	2/50 (4%)	1/50 (2%)	1/49 (2%)	0/49 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/43.72	1/43.20	0/43.46	2/43.55	1/44.75	1/43.02	0/42.24	1/47.00
POLY-3 PERCENT (g)	4.6%	2.3%	0.0%	4.6%	2.2%	2.3%	0.0%	2.1%
TERMINAL (d)	2/36 (6%)	1/27 (4%)	0/31 (0%)	1/28 (4%)	1/37 (3%)	1/36 (3%)	0/32 (0%)	1/41 (2%)
FIRST INCIDENCE	729 (T)	729 (T)	---	701	729 (T)	729 (T)	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.523	P=0.600N	P=0.272N	P=0.614	P=0.553N	P=0.756	P=0.529N	P=0.739N
POLY 3	P=0.564	P=0.504N	P=0.238N	P=0.693	P=0.577N	P=0.752	P=0.511N	P=0.750N
POLY 1.5	P=0.564	P=0.503N	P=0.239N	P=0.693N	P=0.577N	P=0.753	P=0.508N	P=0.754N
POLY 6	P=0.564	P=0.513N	P=0.241N	P=0.685	P=0.578N	P=0.751	P=0.517N	P=0.746N
LOGISTIC REGRESSION	P=0.546	P=0.600N	(e)	P=0.671	P=0.553N	P=0.756	(e)	P=0.739N
COCH-ARM / FISHERS	P=0.565	P=0.508N	P=0.253N	P=0.691N	P=0.579N	P=0.747	P=0.505N	P=0.753N
ORDER RESTRICTED	P=0.413	(e)	(e)	(e)	P=0.522N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Islets, Pancreatic								
Carcinoma or Adenoma								
TUMOR RATES								
OVERALL (a)	5/50 (10%)	5/49 (10%)	3/49 (6%)	7/50 (14%)	3/50 (6%)	2/49 (4%)	0/49 (0%)	1/50 (2%)
POLY-3 RATE (b)	5/43.72	5/43.59	3/43.52	7/43.73	3/44.75	2/43.02	0/42.24	1/47.00
POLY-3 PERCENT (g)	11.4%	11.5%	6.9%	16.0%	6.7%	4.7%	0.0%	2.1%
TERMINAL (d)	5/36 (14%)	3/27 (11%)	2/31 (7%)	5/28 (18%)	3/37 (8%)	2/36 (6%)	0/32 (0%)	1/41 (2%)
FIRST INCIDENCE	729 (T)	663	714	681	729 (T)	729 (T)	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.259	P=0.472	P=0.436N	P=0.234	P=0.144N	P=0.513N	P=0.147N	P=0.269N
POLY 3	P=0.331	P=0.629	P=0.358N	P=0.379	P=0.153N	P=0.518N	P=0.129N	P=0.288N
POLY 1.5	P=0.333	P=0.629	P=0.361N	P=0.382	P=0.154N	P=0.516N	P=0.126N	P=0.294N
POLY 6	P=0.325	P=0.618	P=0.363N	P=0.365	P=0.152N	P=0.519N	P=0.135N	P=0.282N
LOGISTIC REGRESSION	P=0.311	P=0.597	P=0.407N	P=0.324	P=0.144N	P=0.513N	(e)	P=0.269N
COCH-ARM / FISHERS	P=0.335	P=0.617	P=0.369N	P=0.380	P=0.157N	P=0.510N	P=0.125N	P=0.309N
ORDER RESTRICTED	P=0.296	(e)	(e)	(e)	P=0.101N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Liver								
Hepatocellular Adenoma								
TUMOR RATES								
OVERALL (a)	0/50 (0%)	3/50 (6%)	0/48 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.72	3/43.80	0/42.88	0/43.44	0/44.75	0/43.69	0/43.24	0/47.00
POLY-3 PERCENT (g)	0.0%	6.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	3/27 (11%)	0/31 (0%)	0/28 (0%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	---	729 (T)	---	---	---	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.161N	P=0.075	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	P=0.141N	P=0.119	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	P=0.140N	P=0.120	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	P=0.146N	P=0.113	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	P=0.075	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.146N	P=0.121	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	P=0.164N	(e)	(e)	(e)	(e)	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Lung								
Alveolar/Bronchiolar Adenoma								
TUMOR RATES								
OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.72	1/43.80	2/43.73	0/43.44	1/44.75	1/43.69	0/43.24	0/47.00
POLY-3 PERCENT (g)	2.3%	2.3%	4.6%	0.0%	2.2%	2.3%	0.0%	0.0%
TERMINAL (d)	1/36 (3%)	1/27 (4%)	2/31 (7%)	0/28 (0%)	1/37 (3%)	1/36 (3%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---	729 (T)	729 (T)	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.414N	P=0.697	P=0.448	P=0.550N	P=0.195N	P=0.756	P=0.523N	P=0.480N
POLY 3	P=0.379N	P=0.760N	P=0.500	P=0.501N	P=0.204N	P=0.755	P=0.507N	P=0.490N
POLY 1.5	P=0.378N	P=0.758N	P=0.501	P=0.500N	P=0.204N	P=0.757	P=0.504N	P=0.494N
POLY 6	P=0.383N	P=0.754	P=0.495	P=0.506N	P=0.205N	P=0.754	P=0.512N	P=0.487N
LOGISTIC REGRESSION	P=0.414N	P=0.697	P=0.448	(e)	P=0.195N	P=0.756	(e)	(e)
COCH-ARM / FISHERS	P=0.376N	P=0.753N	P=0.500	P=0.500N	P=0.203N	P=0.753N	P=0.500N	P=0.500N
ORDER RESTRICTED	P=0.273N	(e)	(e)	(e)	P=0.237N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Lung								
Alveolar/Bronchiolar Carcinoma								
TUMOR RATES								
OVERALL (a)	3/50 (6%)	2/50 (4%)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/43.72	2/43.80	0/43.73	1/43.44	1/44.75	0/43.69	0/43.24	0/47.00
POLY-3 PERCENT (g)	6.9%	4.6%	0.0%	2.3%	2.2%	0.0%	0.0%	0.0%
TERMINAL (d)	3/36 (8%)	2/27 (7%)	0/31 (0%)	1/28 (4%)	1/37 (3%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.186N	P=0.631N	P=0.148N	P=0.398N	P=0.352N	P=0.505N	P=0.523N	P=0.480N
POLY 3	P=0.159N	P=0.499N	P=0.118N	P=0.307N	P=0.365N	P=0.505N	P=0.507N	P=0.490N
POLY 1.5	P=0.159N	P=0.496N	P=0.118N	P=0.305N	P=0.364N	P=0.503N	P=0.504N	P=0.494N
POLY 6	P=0.158N	P=0.513N	P=0.121N	P=0.316N	P=0.366N	P=0.506N	P=0.512N	P=0.487N
LOGISTIC REGRESSION	P=0.186N	P=0.631N	(e)	P=0.398N	P=0.352N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.158N	P=0.500N	P=0.121N	P=0.309N	P=0.363N	P=0.500N	P=0.500N	P=0.500N
ORDER RESTRICTED	P=0.108N	(e)	(e)	(e)	P=0.111N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Lung Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma								
TUMOR RATES								
OVERALL (a)	4/50 (8%)	3/50 (6%)	2/50 (4%)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	4/43.72	3/43.80	2/43.73	1/43.44	2/44.75	1/43.69	0/43.24	0/47.00
POLY-3 PERCENT (g)	9.2%	6.9%	4.6%	2.3%	4.5%	2.3%	0.0%	0.0%
TERMINAL (d)	4/36 (11%)	3/27 (11%)	2/31 (7%)	1/28 (4%)	2/37 (5%)	1/36 (3%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)	729 (T)	729 (T)	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.147N	P=0.656	P=0.407N	P=0.261N	P=0.101N	P=0.510N	P=0.264N	P=0.216N
POLY 3	P=0.119N	P=0.499N	P=0.337N	P=0.180N	P=0.104N	P=0.508N	P=0.245N	P=0.226N
POLY 1.5	P=0.119N	P=0.495N	P=0.336N	P=0.178N	P=0.105N	P=0.506N	P=0.241N	P=0.230N
POLY 6	P=0.119N	P=0.516N	P=0.343N	P=0.187N	P=0.104N	P=0.511N	P=0.251N	P=0.223N
LOGISTIC REGRESSION	P=0.147N	P=0.656	P=0.407N	P=0.261N	P=0.101N	P=0.510N	(e)	(e)
COCH-ARM / FISHERS	P=0.117N	P=0.500N	P=0.339N	P=0.181N	P=0.106N	P=0.500N	P=0.247N	P=0.247N
ORDER RESTRICTED	P=0.131N	(e)	(e)	(e)	P=0.067N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Mammary Gland Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.72	0/43.80	0/43.73	0/43.44	3/44.75	0/43.69	0/43.24	2/47.00
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	6.7%	0.0%	0.0%	4.3%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	0/28 (0%)	3/37 (8%)	0/36 (0%)	0/33 (0%)	2/41 (5%)
FIRST INCIDENCE	---	---	---	---	729 (T)	---	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.594N	P=0.126N	P=0.142N	P=0.453N
POLY 3	(e)	(e)	(e)	(e)	P=0.609	P=0.123N	P=0.125N	P=0.478N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.603	P=0.122N	P=0.122N	P=0.486N
POLY 6	(e)	(e)	(e)	(e)	P=0.614	P=0.124N	P=0.130N	P=0.470N
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.594N	(e)	(e)	P=0.453N
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.591	P=0.121N	P=0.121N	P=0.500N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.094N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Mammary Gland Carcinoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)	3/50 (6%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.72	1/43.81	1/43.73	0/43.44	3/46.46	1/44.28	0/43.24	2/47.00
POLY-3 PERCENT (g)	0.0%	2.3%	2.3%	0.0%	6.5%	2.3%	0.0%	4.3%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	1/31 (3%)	0/28 (0%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	2/41 (5%)
FIRST INCIDENCE	---	726	729 (T)	---	462	541	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.553N	P=0.450	P=0.470	(e)	P=0.460N	P=0.320N	P=0.129N	P=0.470N
POLY 3	P=0.523N	P=0.500	P=0.500	(e)	P=0.483N	P=0.323N	P=0.132N	P=0.495N
POLY 1.5	P=0.522N	P=0.502	P=0.500	(e)	P=0.484N	P=0.317N	P=0.126N	P=0.496N
POLY 6	P=0.530N	P=0.494	P=0.497	(e)	P=0.484N	P=0.329N	P=0.141N	P=0.494N
LOGISTIC REGRESSION	P=0.545N	P=0.472	P=0.470	(e)	P=0.587	P=0.183N	P=0.091N	P=0.685N
COCH-ARM / FISHERS	P=0.522N	P=0.500	P=0.500	(e)	P=0.487N	P=0.309N	P=0.121N	P=0.500N
ORDER RESTRICTED	P=0.400	(e)	(e)	(e)	P=0.191N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Mammary Gland Carcinoma or Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)	6/50 (12%)	1/50 (2%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	0/43.72	1/43.81	1/43.73	0/43.44	6/46.46	1/44.28	0/43.24	4/47.00
POLY-3 PERCENT (g)	0.0%	2.3%	2.3%	0.0%	12.9%	2.3%	0.0%	8.5%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	1/31 (3%)	0/28 (0%)	3/37 (8%)	0/36 (0%)	0/33 (0%)	4/41 (10%)
FIRST INCIDENCE	---	726	729 (T)	---	462	541	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.553N	P=0.450	P=0.470	(e)	P=0.461N	P=0.069N	P=0.024N*	P=0.321N
POLY 3	P=0.523N	P=0.500	P=0.500	(e)	P=0.494N	P=0.064N	P=0.019N*	P=0.362N
POLY 1.5	P=0.522N	P=0.502	P=0.500	(e)	P=0.497N	P=0.061N	P=0.018N*	P=0.365N
POLY 6	P=0.530N	P=0.494	P=0.497	(e)	P=0.494N	P=0.067N	P=0.022N*	P=0.362N
LOGISTIC REGRESSION	P=0.545N	P=0.472	P=0.470	(e)	P=0.576N	P=0.037N*	P=0.013N*	P=0.452N
COCH-ARM / FISHERS	P=0.522N	P=0.500	P=0.500	(e)	P=0.505N	P=0.056N	P=0.013N*	P=0.370N
ORDER RESTRICTED	P=0.400	(e)	(e)	(e)	P=0.038N*	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Mammary Gland Fibroadenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	4/50 (8%)	4/50 (8%)	33/50 (66%)	29/50 (58%)	31/50 (62%)	33/50 (66%)
POLY-3 RATE (b)	2/43.72	1/43.80	4/44.26	4/43.48	33/47.28	29/45.65	31/45.14	33/47.81
POLY-3 PERCENT (g)	4.6%	2.3%	9.0%	9.2%	69.8%	63.5%	68.7%	69.0%
TERMINAL (d)	2/36 (6%)	1/27 (4%)	3/31 (10%)	3/28 (11%)	26/37 (70%)	25/36 (69%)	24/33 (73%)	29/41 (71%)
FIRST INCIDENCE	729 (T)	729 (T)	566	718	423	365	547	636
STATISTICAL TESTS								
LIFE TABLE	P=0.090	P=0.600N	P=0.287	P=0.234	P=0.429N	P=0.335N	P=0.476	P=0.335N
POLY 3	P=0.118	P=0.499N	P=0.343	P=0.334	P=0.437	P=0.333N	P=0.544N	P=0.557N
POLY 1.5	P=0.119	P=0.497N	P=0.341	P=0.338	P=0.414	P=0.304N	P=0.487N	P=0.566N
POLY 6	P=0.116	P=0.510N	P=0.338	P=0.323	P=0.462	P=0.376N	P=0.567	P=0.551N
LOGISTIC REGRESSION	P=0.115	P=0.600N	P=0.337	P=0.261	P=0.531	P=0.300N	P=0.483N	P=0.469N
COCH-ARM / FISHERS	P=0.121	P=0.500N	P=0.339	P=0.339	P=0.379	P=0.268N	P=0.418N	P=0.583N
ORDER RESTRICTED	P=0.210	(e)	(e)	(e)	P=0.599N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Mammary Gland Fibroma, Fibroadenoma or Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	4/50 (8%)	4/50 (8%)	35/50 (70%)	29/50 (58%)	31/50 (62%)	34/50 (68%)
POLY-3 RATE (b)	2/43.72	1/43.80	4/44.26	4/43.48	35/47.28	29/45.65	31/45.14	34/47.81
POLY-3 PERCENT (g)	4.6%	2.3%	9.0%	9.2%	74.0%	63.5%	68.7%	71.1%
TERMINAL (d)	2/36 (6%)	1/27 (4%)	3/31 (10%)	3/28 (11%)	28/37 (76%)	25/36 (69%)	24/33 (73%)	30/41 (73%)
FIRST INCIDENCE	729 (T)	729 (T)	566	718	423	365	547	636
STATISTICAL TESTS								
LIFE TABLE	P=0.090	P=0.600N	P=0.287	P=0.234	P=0.399N	P=0.206N	P=0.533N	P=0.254N
POLY 3	P=0.118	P=0.499N	P=0.343	P=0.334	P=0.466	P=0.184N	P=0.362N	P=0.464N
POLY 1.5	P=0.119	P=0.497N	P=0.341	P=0.338	P=0.441	P=0.167N	P=0.315N	P=0.477N
POLY 6	P=0.116	P=0.510N	P=0.338	P=0.323	P=0.494	P=0.214N	P=0.438N	P=0.455N
LOGISTIC REGRESSION	P=0.115	P=0.600N	P=0.337	P=0.261	P=0.510N	P=0.170N	P=0.316N	P=0.366N
COCH-ARM / FISHERS	P=0.121	P=0.500N	P=0.339	P=0.339	P=0.402	P=0.149N	P=0.263N	P=0.500N
ORDER RESTRICTED	P=0.210	(e)	(e)	(e)	P=0.391N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Mammary Gland Fibroma, Fibroadenoma, Carcinoma, or Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	5/50 (10%)	4/50 (8%)	37/50 (74%)	30/50 (60%)	31/50 (62%)	35/50 (70%)
POLY-3 RATE (b)	2/43.72	2/43.81	5/44.26	4/43.48	37/48.68	30/46.24	31/45.14	35/47.81
POLY-3 PERCENT (g)	4.6%	4.6%	11.3%	9.2%	76.0%	64.9%	68.7%	73.2%
TERMINAL (d)	2/36 (6%)	1/27 (4%)	4/31 (13%)	3/28 (11%)	28/37 (76%)	25/36 (69%)	24/33 (73%)	31/41 (76%)
FIRST INCIDENCE	729 (T)	726	566	718	423	365	547	636
STATISTICAL TESTS								
LIFE TABLE	P=0.134	P=0.590	P=0.172	P=0.234	P=0.334N	P=0.169N	P=0.386N	P=0.198N
POLY 3	P=0.173	P=0.693N	P=0.221	P=0.334	P=0.466	P=0.161N	P=0.280N	P=0.466N
POLY 1.5	P=0.176	P=0.690N	P=0.220	P=0.338	P=0.470	P=0.134N	P=0.214N	P=0.445N
POLY 6	P=0.168	P=0.684	P=0.216	P=0.323	P=0.460	P=0.198N	P=0.378N	P=0.491N
LOGISTIC REGRESSION	P=0.168	P=0.621	P=0.216	P=0.261	P=0.474N	P=0.109N	P=0.162N	P=0.350N
COCH-ARM / FISHERS	P=0.177	P=0.691N	P=0.218	P=0.339	P=0.474	P=0.101N	P=0.142N	P=0.412N
ORDER RESTRICTED	P=0.248	(e)	(e)	(e)	P=0.338N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Pancreas Adenoma								
TUMOR RATES								
OVERALL (a)	0/49 (0%)	3/49 (6%)	1/49 (2%)	0/50 (0%)	2/50 (4%)	0/49 (0%)	0/49 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.39	3/43.20	1/43.46	0/43.44	2/44.75	0/43.02	0/42.24	0/46.34
POLY-3 PERCENT (g)	0.0%	6.9%	2.3%	0.0%	4.5%	0.0%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	3/27 (11%)	1/31 (3%)	0/28 (0%)	2/37 (5%)	0/36 (0%)	0/32 (0%)	0/41 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.243N	P=0.075	P=0.470	(e)	P=0.168N	P=0.244N	P=0.271N	P=0.216N
POLY 3	P=0.214N	P=0.118	P=0.500	(e)	P=0.172N	P=0.246N	P=0.250N	P=0.229N
POLY 1.5	P=0.211N	P=0.120	P=0.501	(e)	P=0.172N	P=0.245N	P=0.246N	P=0.234N
POLY 6	P=0.224N	P=0.112	P=0.497	(e)	P=0.172N	P=0.246N	P=0.257N	P=0.225N
LOGISTIC REGRESSION	(e)	P=0.075	P=0.470	(e)	P=0.168N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.212N	P=0.121	P=0.500	(e)	P=0.175N	P=0.253N	P=0.253N	P=0.253N
ORDER RESTRICTED	P=0.218N	(e)	(e)	(e)	P=0.027N*	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Pancreas Carcinoma or Adenoma								
TUMOR RATES								
OVERALL (a)	0/49 (0%)	4/49 (8%)	1/49 (2%)	0/50 (0%)	2/50 (4%)	0/49 (0%)	0/49 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.39	4/43.20	1/43.46	0/43.44	2/44.75	0/43.02	0/42.24	0/46.34
POLY-3 PERCENT (g)	0.0%	9.3%	2.3%	0.0%	4.5%	0.0%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	4/27 (15%)	1/31 (3%)	0/28 (0%)	2/37 (5%)	0/36 (0%)	0/32 (0%)	0/41 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.164N	P=0.032 *	P=0.470	(e)	P=0.168N	P=0.244N	P=0.271N	P=0.216N
POLY 3	P=0.138N	P=0.059	P=0.500	(e)	P=0.172N	P=0.246N	P=0.250N	P=0.229N
POLY 1.5	P=0.135N	P=0.061	P=0.501	(e)	P=0.172N	P=0.245N	P=0.246N	P=0.234N
POLY 6	P=0.146N	P=0.055	P=0.497	(e)	P=0.172N	P=0.246N	P=0.257N	P=0.225N
LOGISTIC REGRESSION	(e)	P=0.032 *	P=0.470	(e)	P=0.168N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.138N	P=0.059	P=0.500	(e)	P=0.175N	P=0.253N	P=0.253N	P=0.253N
ORDER RESTRICTED	P=0.148N	(e)	(e)	(e)	P=0.027N*	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Pituitary Gland: Pars Distalis or Unspecified Site Adenoma								
TUMOR RATES								
OVERALL (a)	16/48 (33%)	15/50 (30%)	20/49 (41%)	15/50 (30%)	23/49 (47%)	18/49 (37%)	17/50 (34%)	25/50 (50%)
POLY-3 RATE (b)	16/43.05	15/44.42	20/45.67	15/44.68	23/46.10	18/43.93	17/46.64	25/48.71
POLY-3 PERCENT (g)	37.2%	33.8%	43.8%	33.6%	49.9%	41.0%	36.5%	51.3%
TERMINAL (d)	13/36 (36%)	11/27 (41%)	12/31 (39%)	8/28 (29%)	16/36 (44%)	15/36 (42%)	9/33 (27%)	20/41 (49%)
FIRST INCIDENCE	630	652	561	651	511	626	511	475
STATISTICAL TESTS								
LIFE TABLE	P=0.375	P=0.351	P=0.166	P=0.423	P=0.430	P=0.233N	P=0.260N	P=0.516N
POLY 3	P=0.516N	P=0.457N	P=0.337	P=0.449N	P=0.367	P=0.261N	P=0.134N	P=0.526
POLY 1.5	P=0.522N	P=0.441N	P=0.318	P=0.442N	P=0.334	P=0.240N	P=0.132N	P=0.503
POLY 6	P=0.510N	P=0.506N	P=0.344	P=0.470N	P=0.395	P=0.284N	P=0.141N	P=0.543
LOGISTIC REGRESSION	P=0.528	P=0.528N	P=0.293	P=0.484N	P=0.296	P=0.215N	P=0.127N	P=0.461
COCH-ARM / FISHERS	P=0.527N	P=0.445N	P=0.290	P=0.445N	P=0.277	P=0.206N	P=0.134N	P=0.459
ORDER RESTRICTED	P=0.507N	(e)	(e)	(e)	P=0.297	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Pituitary Gland: Pars Distalis or Unspecified Site Carcinoma								
TUMOR RATES								
OVERALL (a)	0/48 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)	1/49 (2%)	3/49 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.47	0/43.80	0/43.46	0/43.44	1/44.06	3/43.88	0/43.24	0/47.00
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	2.3%	6.8%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	0/28 (0%)	0/36 (0%)	1/36 (3%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	---	---	---	---	644	636	---	---
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.074N	P=0.299	P=0.520N	P=0.482N
POLY 3	(e)	(e)	(e)	(e)	P=0.074N	P=0.304	P=0.504N	P=0.487N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.074N	P=0.303	P=0.500N	P=0.490N
POLY 6	(e)	(e)	(e)	(e)	P=0.074N	P=0.305	P=0.510N	P=0.485N
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.082N	P=0.315	P=0.488N	P=0.550N
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.076N	P=0.309	P=0.495N	P=0.495N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.104N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Pituitary Gland: Pars Distalis or Unspecified Site Carcinoma or Adenoma								
TUMOR RATES								
OVERALL (a)	16/48 (33%)	15/50 (30%)	20/49 (41%)	15/50 (30%)	24/49 (49%)	21/49 (43%)	17/50 (34%)	25/50 (50%)
POLY-3 RATE (b)	16/43.05	15/44.42	20/45.67	15/44.68	24/46.41	21/44.57	17/46.64	25/48.71
POLY-3 PERCENT (g)	37.2%	33.8%	43.8%	33.6%	51.7%	47.1%	36.5%	51.3%
TERMINAL (d)	13/36 (36%)	11/27 (41%)	12/31 (39%)	8/28 (29%)	16/36 (44%)	16/36 (44%)	9/33 (27%)	20/41 (49%)
FIRST INCIDENCE	630	652	561	651	511	626	511	475
STATISTICAL TESTS								
LIFE TABLE	P=0.375	P=0.351	P=0.166	P=0.423	P=0.452N	P=0.373N	P=0.212N	P=0.443N
POLY 3	P=0.516N	P=0.457N	P=0.337	P=0.449N	P=0.527N	P=0.409N	P=0.099N	P=0.566N
POLY 1.5	P=0.522N	P=0.441N	P=0.318	P=0.442N	P=0.521	P=0.386N	P=0.095N	P=0.578
POLY 6	P=0.510N	P=0.506N	P=0.344	P=0.470N	P=0.515N	P=0.430N	P=0.109N	P=0.560N
LOGISTIC REGRESSION	P=0.528	P=0.528N	P=0.293	P=0.484N	P=0.477	P=0.355N	P=0.089N	P=0.533
COCH-ARM / FISHERS	P=0.527N	P=0.445N	P=0.290	P=0.445N	P=0.463	P=0.343N	P=0.095N	P=0.540
ORDER RESTRICTED	P=0.507N	(e)	(e)	(e)	P=0.355N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Basal Cell Carcinoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.72	2/43.80	0/43.73	2/43.44	1/44.75	0/43.69	0/43.24	0/47.00
POLY-3 PERCENT (g)	0.0%	4.6%	0.0%	4.6%	2.2%	0.0%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	2/27 (7%)	0/31 (0%)	2/28 (7%)	1/37 (3%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	---	729 (T)	---	729 (T)	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.307	P=0.177	(e)	P=0.185	P=0.352N	P=0.505N	P=0.523N	P=0.480N
POLY 3	P=0.345	P=0.237	(e)	P=0.236	P=0.365N	P=0.505N	P=0.507N	P=0.490N
POLY 1.5	P=0.347	P=0.239	(e)	P=0.237	P=0.364N	P=0.503N	P=0.504N	P=0.494N
POLY 6	P=0.338	P=0.230	(e)	P=0.230	P=0.366N	P=0.506N	P=0.512N	P=0.487N
LOGISTIC REGRESSION	(e)	P=0.177	(e)	P=0.185	P=0.352N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.347	P=0.247	(e)	P=0.247	P=0.363N	P=0.500N	P=0.500N	P=0.500N
ORDER RESTRICTED	P=0.115	(e)	(e)	(e)	P=0.111N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Basal Cell Carcinoma, Basal Cell Adenoma, Basosquamous Tumor (benign, malignant or NOS), or Trichoepithelioma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	2/50 (4%)	3/50 (6%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.72	2/43.80	0/43.73	2/43.44	3/44.75	0/43.69	0/43.24	0/47.00
POLY-3 PERCENT (g)	2.3%	4.6%	0.0%	4.6%	6.7%	0.0%	0.0%	0.0%
TERMINAL (d)	1/36 (3%)	2/27 (7%)	0/31 (0%)	2/28 (7%)	3/37 (8%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.489	P=0.400	P=0.530N	P=0.412	P=0.086N	P=0.126N	P=0.142N	P=0.104N
POLY 3	P=0.533	P=0.501	P=0.500N	P=0.498	P=0.084N	P=0.123N	P=0.125N	P=0.110N
POLY 1.5	P=0.535	P=0.503	P=0.500N	P=0.500	P=0.085N	P=0.122N	P=0.122N	P=0.113N
POLY 6	P=0.528	P=0.490	P=0.503N	P=0.489	P=0.083N	P=0.124N	P=0.130N	P=0.107N
LOGISTIC REGRESSION	P=0.489	P=0.400	(e)	P=0.412	P=0.086N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.535	P=0.500	P=0.500N	P=0.500	P=0.091N	P=0.121N	P=0.121N	P=0.121N
ORDER RESTRICTED	P=0.410	(e)	(e)	(e)	P=0.006N**	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	5/50 (10%)	4/50 (8%)	1/50 (2%)	3/50 (6%)	3/50 (6%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	5/44.15	4/43.99	1/43.73	3/43.48	3/44.75	0/43.69	0/43.24	1/47.34
POLY-3 PERCENT (g)	11.3%	9.1%	2.3%	6.9%	6.7%	0.0%	0.0%	2.1%
TERMINAL (d)	3/36 (8%)	2/27 (7%)	1/31 (3%)	2/28 (7%)	3/37 (8%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	636	695	729 (T)	718	729 (T)	---	---	635
STATISTICAL TESTS								
LIFE TABLE	P=0.270N	P=0.624N	P=0.137N	P=0.470N	P=0.322N	P=0.126N	P=0.142N	P=0.269N
POLY 3	P=0.224N	P=0.502N	P=0.103N	P=0.364N	P=0.337N	P=0.123N	P=0.125N	P=0.285N
POLY 1.5	P=0.223N	P=0.496N	P=0.102N	P=0.358N	P=0.340N	P=0.122N	P=0.122N	P=0.293N
POLY 6	P=0.227N	P=0.524N	P=0.108N	P=0.381N	P=0.335N	P=0.124N	P=0.130N	P=0.278N
LOGISTIC REGRESSION	P=0.227N	P=0.507N	P=0.103N	P=0.367N	P=0.338N	(e)	(e)	P=0.300N
COCH-ARM / FISHERS	P=0.220N	P=0.500N	P=0.102N	P=0.357N	P=0.347N	P=0.121N	P=0.121N	P=0.309N
ORDER RESTRICTED	P=0.177N	(e)	(e)	(e)	P=0.033N*	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Fibroma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	9/50 (18%)	10/50 (20%)	5/50 (10%)	8/50 (16%)	4/50 (8%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	9/43.97	10/45.25	5/44.26	8/44.06	4/45.12	1/43.75	1/43.24	1/47.00
POLY-3 PERCENT (g)	20.5%	22.1%	11.3%	18.2%	8.9%	2.3%	2.3%	2.1%
TERMINAL (d)	7/36 (19%)	6/27 (22%)	3/31 (10%)	5/28 (18%)	3/37 (8%)	0/36 (0%)	1/33 (3%)	1/41 (2%)
FIRST INCIDENCE	695	555	607	651	623	714	729 (T)	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.377N	P=0.313	P=0.274N	P=0.539	P=0.173N	P=0.190N	P=0.213N	P=0.152N
POLY 3	P=0.300N	P=0.528	P=0.187N	P=0.498N	P=0.175N	P=0.188N	P=0.191N	P=0.167N
POLY 1.5	P=0.297N	P=0.524	P=0.189N	P=0.495N	P=0.180N	P=0.185N	P=0.186N	P=0.171N
POLY 6	P=0.306N	P=0.513	P=0.192N	P=0.514N	P=0.172N	P=0.191N	P=0.202N	P=0.163N
LOGISTIC REGRESSION	P=0.298N	P=0.504	P=0.196N	P=0.524N	P=0.176N	P=0.184N	P=0.188N	P=0.173N
COCH-ARM / FISHERS	P=0.294N	P=0.500	P=0.194N	P=0.500N	P=0.188N	P=0.181N	P=0.181N	P=0.181N
ORDER RESTRICTED	P=0.335N	(e)	(e)	(e)	P=0.066N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	10/50 (20%)	12/50 (24%)	6/50 (12%)	8/50 (16%)	4/50 (8%)	2/50 (4%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	10/44.83	12/45.53	6/45.23	8/44.06	4/45.12	2/43.76	1/43.24	2/47.23
POLY-3 PERCENT (g)	22.3%	26.4%	13.3%	18.2%	8.9%	4.6%	2.3%	4.2%
TERMINAL (d)	7/36 (19%)	7/27 (26%)	3/31 (10%)	5/28 (18%)	3/37 (8%)	0/36 (0%)	1/33 (3%)	1/41 (2%)
FIRST INCIDENCE	381	555	209	651	623	714	729 (T)	670
STATISTICAL TESTS								
LIFE TABLE	P=0.242N	P=0.238	P=0.289N	P=0.562N	P=0.267N	P=0.351N	P=0.213N	P=0.294N
POLY 3	P=0.180N	P=0.420	P=0.198N	P=0.412N	P=0.277N	P=0.351N	P=0.191N	P=0.316N
POLY 1.5	P=0.176N	P=0.419	P=0.199N	P=0.404N	P=0.283N	P=0.347N	P=0.186N	P=0.324N
POLY 6	P=0.188N	P=0.404	P=0.205N	P=0.431N	P=0.273N	P=0.356N	P=0.202N	P=0.310N
LOGISTIC REGRESSION	P=0.170N	P=0.401	P=0.205N	P=0.397N	P=0.277N	P=0.346N	P=0.188N	P=0.339N
COCH-ARM / FISHERS	P=0.172N	P=0.405	P=0.207N	P=0.398N	P=0.293N	P=0.339N	P=0.181N	P=0.339N
ORDER RESTRICTED	P=0.243N	(e)	(e)	(e)	P=0.168N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Fibrosarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/44.58	2/44.08	0/43.73	0/43.44	0/44.75	1/43.70	0/43.24	0/47.00
POLY-3 PERCENT (g)	2.2%	4.5%	0.0%	0.0%	0.0%	2.3%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	1/27 (4%)	0/31 (0%)	0/28 (0%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	381	652	---	---	---	727	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.131N	P=0.470	P=0.504N	P=0.500N	P=0.415N	P=0.495	(e)	(e)
POLY 3	P=0.126N	P=0.496	P=0.504N	P=0.505N	P=0.431N	P=0.495	(e)	(e)
POLY 1.5	P=0.125N	P=0.500	P=0.502N	P=0.502N	P=0.428N	P=0.497	(e)	(e)
POLY 6	P=0.129N	P=0.486	P=0.508N	P=0.511N	P=0.434N	P=0.494	(e)	(e)
LOGISTIC REGRESSION	P=0.111N	P=0.334	P=0.358N	(e)	P=0.414N	P=0.492	(e)	(e)
COCH-ARM / FISHERS	P=0.124N	P=0.500	P=0.500N	P=0.500N	P=0.423N	P=0.500	(e)	(e)
ORDER RESTRICTED	P=0.170N	(e)	(e)	(e)	P=0.367N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/44.58	2/44.08	1/44.71	0/43.44	0/44.75	1/43.70	0/43.24	1/47.23
POLY-3 PERCENT (g)	2.2%	4.5%	2.2%	0.0%	0.0%	2.3%	0.0%	2.1%
TERMINAL (d)	0/36 (0%)	1/27 (4%)	0/31 (0%)	0/28 (0%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	381	652	209	---	---	727	---	670
STATISTICAL TESTS								
LIFE TABLE	P=0.203N	P=0.470	P=0.758	P=0.500N	P=0.498	P=0.495	(e)	P=0.519
POLY 3	P=0.198N	P=0.496	P=0.760N	P=0.505N	P=0.489	P=0.495	(e)	P=0.511
POLY 1.5	P=0.196N	P=0.500	P=0.759N	P=0.502N	P=0.485	P=0.497	(e)	P=0.507
POLY 6	P=0.203N	P=0.486	P=0.758	P=0.511N	P=0.494	P=0.494	(e)	P=0.515
LOGISTIC REGRESSION	P=0.161N	P=0.334	(e)	(e)	P=0.480	P=0.492	(e)	P=0.471
COCH-ARM / FISHERS	P=0.193N	P=0.500	P=0.753N	P=0.500N	P=0.478	P=0.500	(e)	P=0.500
ORDER RESTRICTED	P=0.228N	(e)	(e)	(e)	P=0.261	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin Keratoacanthoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	4/50 (8%)	2/50 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	4/44.15	2/43.99	1/43.73	1/43.48	0/44.75	0/43.69	0/43.24	1/47.34
POLY-3 PERCENT (g)	9.1%	4.6%	2.3%	2.3%	0.0%	0.0%	0.0%	2.1%
TERMINAL (d)	2/36 (6%)	0/27 (0%)	1/31 (3%)	0/28 (0%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	636	695	729 (T)	718	---	---	---	635
STATISTICAL TESTS								
LIFE TABLE	P=0.156N	P=0.418N	P=0.220N	P=0.238N	P=0.205	(e)	(e)	P=0.527
POLY 3	P=0.132N	P=0.338N	P=0.181N	P=0.183N	P=0.195	(e)	(e)	P=0.511
POLY 1.5	P=0.132N	P=0.334N	P=0.180N	P=0.180N	P=0.191	(e)	(e)	P=0.507
POLY 6	P=0.133N	P=0.354N	P=0.188N	P=0.192N	P=0.199	(e)	(e)	P=0.516
LOGISTIC REGRESSION	P=0.132N	P=0.335N	P=0.179N	P=0.180N	P=0.145	(e)	(e)	P=0.438
COCH-ARM / FISHERS	P=0.130N	P=0.339N	P=0.181N	P=0.181N	P=0.185	(e)	(e)	P=0.500
ORDER RESTRICTED	P=0.098N	(e)	(e)	(e)	P=0.131	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Skin								
Trichoepithelioma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.72	0/43.80	0/43.73	0/43.44	2/44.75	0/43.69	0/43.24	0/47.00
POLY-3 PERCENT (g)	2.3%	0.0%	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%
TERMINAL (d)	1/36 (3%)	0/27 (0%)	0/31 (0%)	0/28 (0%)	2/37 (5%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	729 (T)	---	---	---	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.381N	P=0.557N	P=0.530N	P=0.550N	P=0.167N	P=0.244N	P=0.264N	P=0.216N
POLY 3	P=0.363N	P=0.500N	P=0.500N	P=0.501N	P=0.169N	P=0.242N	P=0.245N	P=0.226N
POLY 1.5	P=0.365N	P=0.498N	P=0.500N	P=0.500N	P=0.170N	P=0.241N	P=0.241N	P=0.230N
POLY 6	P=0.357N	P=0.506N	P=0.503N	P=0.506N	P=0.169N	P=0.244N	P=0.251N	P=0.223N
LOGISTIC REGRESSION	P=0.381N	(e)	(e)	(e)	P=0.167N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.363N	P=0.500N	P=0.500N	P=0.500N	P=0.173N	P=0.247N	P=0.247N	P=0.247N
ORDER RESTRICTED	P=0.121N	(e)	(e)	(e)	P=0.026N*	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Testes								
Adenoma								
TUMOR RATES								
OVERALL (a)	45/50 (90%)	49/50 (98%)	44/50 (88%)	45/50 (90%)				
POLY-3 RATE (b)	45/47.98	49/49.46	44/47.14	45/48.49				
POLY-3 PERCENT (g)	93.8%	99.1%	93.3%	92.8%				
TERMINAL (d)	34/36 (94%)	27/27 (100%)	30/31 (97%)	27/28 (96%)				
FIRST INCIDENCE	469	542	561	443				
STATISTICAL TESTS								
LIFE TABLE	P=0.383	P=0.018 *	P=0.282	P=0.101				
POLY 3	P=0.198N	P=0.164	P=0.644N	P=0.593N				
POLY 1.5	P=0.196N	P=0.137	P=0.592N	P=0.590N				
POLY 6	P=0.239N	P=0.186	P=0.671	P=0.639N				
LOGISTIC REGRESSION	P=0.208N	P=0.215	P=0.391N	P=0.576N				
COCH-ARM / FISHERS	P=0.229N	P=0.102	P=0.500N	P=0.630N				
ORDER RESTRICTED	P=0.285N	(e)	(e)	(e)				

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Thyroid Gland: C-Cell Adenoma								
TUMOR RATES								
OVERALL (a)	9/47 (19%)	9/44 (20%)	6/43 (14%)	9/47 (19%)	12/47 (26%)	9/47 (19%)	11/43 (26%)	9/46 (20%)
POLY-3 RATE (b)	9/42.76	9/40.47	6/40.05	9/41.77	12/42.92	9/42.52	11/38.90	9/43.71
POLY-3 PERCENT (g)	21.1%	22.2%	15.0%	21.6%	28.0%	21.2%	28.3%	20.6%
TERMINAL (d)	7/36 (19%)	7/27 (26%)	4/31 (13%)	8/28 (29%)	10/36 (28%)	6/36 (17%)	11/32 (34%)	9/40 (23%)
FIRST INCIDENCE	636	619	660	718	661	644	729 (T)	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.506	P=0.388	P=0.383N	P=0.395	P=0.293N	P=0.326N	P=0.563	P=0.223N
POLY 3	P=0.485N	P=0.553	P=0.334N	P=0.583	P=0.368N	P=0.317N	P=0.585	P=0.292N
POLY 1.5	P=0.477N	P=0.554	P=0.343N	P=0.595	P=0.384N	P=0.317N	P=0.591	P=0.306N
POLY 6	P=0.503N	P=0.539	P=0.329N	P=0.553	P=0.359N	P=0.312N	P=0.568	P=0.281N
LOGISTIC REGRESSION	P=0.486N	P=0.547	P=0.336N	P=0.548	P=0.340N	P=0.324N	P=0.557	P=0.265N
COCH-ARM / FISHERS	P=0.466N	P=0.542	P=0.354N	P=0.603N	P=0.418N	P=0.311N	P=0.593	P=0.330N
ORDER RESTRICTED	P=0.550N	(e)	(e)	(e)	P=0.331N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Thyroid Gland: C-Cell Carcinoma								
TUMOR RATES								
OVERALL (a)	2/47 (4%)	2/44 (5%)	0/43 (0%)	1/47 (2%)	1/47 (2%)	3/47 (6%)	1/43 (2%)	3/46 (7%)
POLY-3 RATE (b)	2/42.29	2/39.82	0/39.66	1/41.73	1/42.66	3/42.30	1/39.38	3/43.71
POLY-3 PERCENT (g)	4.7%	5.0%	0.0%	2.4%	2.3%	7.1%	2.5%	6.9%
TERMINAL (d)	2/36 (6%)	2/27 (7%)	0/31 (0%)	1/28 (4%)	1/36 (3%)	2/36 (6%)	0/32 (0%)	3/40 (8%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)	729 (T)	626	587	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.292N	P=0.588	P=0.272N	P=0.588N	P=0.431	P=0.309	P=0.747	P=0.343
POLY 3	P=0.254N	P=0.673	P=0.251N	P=0.505N	P=0.394	P=0.302	P=0.743	P=0.314
POLY 1.5	P=0.254N	P=0.674	P=0.254N	P=0.501N	P=0.387	P=0.302	P=0.742	P=0.308
POLY 6	P=0.253N	P=0.666	P=0.250N	P=0.513N	P=0.400	P=0.303	P=0.742	P=0.320
LOGISTIC REGRESSION	P=0.292N	P=0.588	(e)	P=0.588N	P=0.369	P=0.302	P=0.740	P=0.343
COCH-ARM / FISHERS	P=0.254N	P=0.666	P=0.270N	P=0.500N	P=0.374	P=0.308	P=0.730	P=0.300
ORDER RESTRICTED	P=0.259N	(e)	(e)	(e)	P=0.254	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Thyroid Gland: C-Cell Carcinoma or Adenoma								
TUMOR RATES								
OVERALL (a)	11/47 (23%)	11/44 (25%)	6/43 (14%)	10/47 (21%)	13/47 (28%)	11/47 (23%)	12/43 (28%)	12/46 (26%)
POLY-3 RATE (b)	11/42.76	11/40.47	6/40.05	10/41.77	13/42.92	11/42.89	12/39.38	12/43.71
POLY-3 PERCENT (g)	25.7%	27.2%	15.0%	23.9%	30.3%	25.7%	30.5%	27.5%
TERMINAL (d)	9/36 (25%)	9/27 (33%)	4/31 (13%)	9/28 (32%)	11/36 (31%)	7/36 (19%)	11/32 (34%)	12/40 (30%)
FIRST INCIDENCE	636	619	660	718	661	626	587	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.453N	P=0.342	P=0.221N	P=0.461	P=0.423N	P=0.420N	P=0.555	P=0.381N
POLY 3	P=0.339N	P=0.539	P=0.174N	P=0.524N	P=0.526N	P=0.406N	P=0.588	P=0.479N
POLY 1.5	P=0.332N	P=0.540	P=0.182N	P=0.509N	P=0.541N	P=0.411N	P=0.588	P=0.495N
POLY 6	P=0.354N	P=0.523	P=0.169N	P=0.559N	P=0.521N	P=0.394N	P=0.579	P=0.465N
LOGISTIC REGRESSION	P=0.344N	P=0.527	P=0.175N	P=0.577N	P=0.500N	P=0.424N	P=0.570	P=0.442N
COCH-ARM / FISHERS	P=0.323N	P=0.526	P=0.191N	P=0.500N	P=0.506	P=0.407N	P=0.582	P=0.525N
ORDER RESTRICTED	P=0.355N	(e)	(e)	(e)	P=0.598N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Thyroid Gland: Follicular Cell Adenoma								
TUMOR RATES								
OVERALL (a)	1/47 (2%)	0/44 (0%)	0/43 (0%)	2/47 (4%)	0/47 (0%)	0/47 (0%)	0/43 (0%)	2/46 (4%)
POLY-3 RATE (b)	1/42.38	0/39.82	0/39.66	2/41.73	0/42.66	0/41.93	0/38.90	2/44.12
POLY-3 PERCENT (g)	2.4%	0.0%	0.0%	4.8%	0.0%	0.0%	0.0%	4.5%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	2/28 (7%)	0/36 (0%)	0/36 (0%)	0/32 (0%)	0/40 (0%)
FIRST INCIDENCE	705	---	---	729 (T)	---	---	---	644
STATISTICAL TESTS								
LIFE TABLE	P=0.176	P=0.529N	P=0.523N	P=0.422	P=0.052	(e)	(e)	P=0.255
POLY 3	P=0.206	P=0.512N	P=0.513N	P=0.495	P=0.044 *	(e)	(e)	P=0.245
POLY 1.5	P=0.206	P=0.512N	P=0.515N	P=0.498	P=0.043 *	(e)	(e)	P=0.240
POLY 6	P=0.205	P=0.517N	P=0.512N	P=0.485	P=0.045 *	(e)	(e)	P=0.250
LOGISTIC REGRESSION	P=0.196	P=0.512N	P=0.517N	P=0.478	P=0.033 *	(e)	(e)	P=0.200
COCH-ARM / FISHERS	P=0.207	P=0.516N	P=0.522N	P=0.500	P=0.042 *	(e)	(e)	P=0.242
ORDER RESTRICTED	P=0.130	(e)	(e)	(e)	P=0.032 *	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Thyroid Gland: Follicular Cell Carcinoma								
TUMOR RATES								
OVERALL (a)	0/47 (0%)	0/44 (0%)	0/43 (0%)	4/47 (9%)	1/47 (2%)	0/47 (0%)	1/43 (2%)	2/46 (4%)
POLY-3 RATE (b)	0/42.29	0/39.82	0/39.66	4/41.73	1/42.66	0/41.93	1/39.01	2/43.71
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	9.6%	2.3%	0.0%	2.6%	4.6%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	4/28 (14%)	1/36 (3%)	0/36 (0%)	0/32 (0%)	2/40 (5%)
FIRST INCIDENCE	---	---	---	729 (T)	729 (T)	---	703	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.002 **	(e)	(e)	P=0.035 *	P=0.219	P=0.500N	P=0.732	P=0.537
POLY 3	P=0.003 **	(e)	(e)	P=0.058	P=0.203	P=0.503N	P=0.741	P=0.508
POLY 1.5	P=0.003 **	(e)	(e)	P=0.059	P=0.198	P=0.503N	P=0.741	P=0.503
POLY 6	P=0.003 **	(e)	(e)	P=0.055	P=0.207	P=0.504N	P=0.739	P=0.514
LOGISTIC REGRESSION	(e)	(e)	(e)	P=0.035 *	P=0.204	(e)	P=0.742	P=0.537
COCH-ARM / FISHERS	P=0.003 **	(e)	(e)	P=0.058	P=0.187	P=0.500N	P=0.730	P=0.492
ORDER RESTRICTED	P=0.002 **	(e)	(e)	(e)	P=0.236	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Thyroid Gland: Follicular Cell Carcinoma or Adenoma								
TUMOR RATES								
OVERALL (a)	1/47 (2%)	0/44 (0%)	0/43 (0%)	6/47 (13%)	1/47 (2%)	0/47 (0%)	1/43 (2%)	4/46 (9%)
POLY-3 RATE (b)	1/42.38	0/39.82	0/39.66	6/41.73	1/42.66	0/41.93	1/39.01	4/44.12
POLY-3 PERCENT (g)	2.4%	0.0%	0.0%	14.4%	2.3%	0.0%	2.6%	9.1%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	6/28 (21%)	1/36 (3%)	0/36 (0%)	0/32 (0%)	2/40 (5%)
FIRST INCIDENCE	705	---	---	729 (T)	729 (T)	---	703	644
STATISTICAL TESTS								
LIFE TABLE	P<0.001 **	P=0.529N	P=0.523N	P=0.028 *	P=0.034 *	P=0.500N	P=0.732	P=0.212
POLY 3	P=0.002 **	P=0.512N	P=0.513N	P=0.052	P=0.026 *	P=0.503N	P=0.741	P=0.189
POLY 1.5	P=0.002 **	P=0.512N	P=0.515N	P=0.055	P=0.024 *	P=0.503N	P=0.741	P=0.182
POLY 6	P=0.002 **	P=0.517N	P=0.512N	P=0.048 *	P=0.027 *	P=0.504N	P=0.739	P=0.196
LOGISTIC REGRESSION	P<0.001 **	P=0.512N	P=0.517N	P=0.037 *	P=0.024 *	(e)	P=0.742	P=0.172
COCH-ARM / FISHERS	P=0.002 **	P=0.516N	P=0.522N	P=0.055	P=0.023 *	P=0.500N	P=0.730	P=0.174
ORDER RESTRICTED	P<0.001 **	(e)	(e)	(e)	P=0.029 *	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Uterus Polyp Stromal								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)					9/50 (18%)	8/50 (16%)	9/50 (18%)	7/50 (14%)
POLY-3 RATE (b)					9/45.06	8/44.03	9/45.03	7/47.57
POLY-3 PERCENT (g)					20.0%	18.2%	20.0%	14.7%
TERMINAL (d)					8/37 (22%)	7/36 (19%)	4/33 (12%)	5/41 (12%)
FIRST INCIDENCE					644	636	514	635
STATISTICAL TESTS								
LIFE TABLE					P=0.303N	P=0.524N	P=0.518	P=0.312N
POLY 3					P=0.318N	P=0.521N	P=0.603	P=0.347N
POLY 1.5					P=0.341N	P=0.514N	P=0.602N	P=0.365N
POLY 6					P=0.297N	P=0.527N	P=0.596	P=0.331N
LOGISTIC REGRESSION					P=0.358N	P=0.527N	P=0.599	P=0.357N
COCH-ARM / FISHERS					P=0.380N	P=0.500N	P=0.602N	P=0.393N
ORDER RESTRICTED					P=0.403N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
Uterus Sarcoma Stromal or Polyp Stromal								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)					10/50 (20%)	8/50 (16%)	9/50 (18%)	7/50 (14%)
POLY-3 RATE (b)					10/45.06	8/44.03	9/45.03	7/47.57
POLY-3 PERCENT (g)					22.2%	18.2%	20.0%	14.7%
TERMINAL (d)					9/37 (24%)	7/36 (19%)	4/33 (12%)	5/41 (12%)
FIRST INCIDENCE					644	636	514	635
STATISTICAL TESTS								
LIFE TABLE					P=0.245N	P=0.422N	P=0.585N	P=0.226N
POLY 3					P=0.255N	P=0.417N	P=0.501N	P=0.255N
POLY 1.5					P=0.277N	P=0.411N	P=0.499N	P=0.271N
POLY 6					P=0.236N	P=0.423N	P=0.508N	P=0.239N
LOGISTIC REGRESSION					P=0.291N	P=0.423N	P=0.507N	P=0.262N
COCH-ARM / FISHERS					P=0.314N	P=0.398N	P=0.500N	P=0.298N
ORDER RESTRICTED					P=0.280N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Histiocytic Sarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/44.39	1/43.80	0/43.73	0/43.44	0/44.75	2/44.02	1/43.24	0/47.00
POLY-3 PERCENT (g)	2.3%	2.3%	0.0%	0.0%	0.0%	4.5%	2.3%	0.0%
TERMINAL (d)	0/36 (0%)	1/27 (4%)	0/31 (0%)	0/28 (0%)	0/37 (0%)	1/36 (3%)	1/33 (3%)	0/41 (0%)
FIRST INCIDENCE	503	729 (T)	---	---	---	639	729 (T)	---
STATISTICAL TESTS								
LIFE TABLE	P=0.215N	P=0.736	P=0.496N	P=0.500N	P=0.316N	P=0.234	P=0.477	(e)
POLY 3	P=0.205N	P=0.758	P=0.503N	P=0.504N	P=0.324N	P=0.233	P=0.493	(e)
POLY 1.5	P=0.205N	P=0.760N	P=0.502N	P=0.502N	P=0.328N	P=0.234	P=0.496	(e)
POLY 6	P=0.206N	P=0.750	P=0.507N	P=0.510N	P=0.321N	P=0.233	P=0.488	(e)
LOGISTIC REGRESSION	P=0.195N	P=0.710	P=0.450N	P=0.597N	P=0.330N	P=0.239	P=0.477	(e)
COCH-ARM / FISHERS	P=0.203N	P=0.753N	P=0.500N	P=0.500N	P=0.333N	P=0.247	P=0.500	(e)
ORDER RESTRICTED	P=0.253N	(e)	(e)	(e)	P=0.309N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Leukemia: Lymphocytic, Monocytic, Mononuclear, or Undifferentiated								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	13/50 (26%)	21/50 (42%)	16/50 (32%)	23/50 (46%)	11/50 (22%)	9/50 (18%)	13/50 (26%)	9/50 (18%)
POLY-3 RATE (b)	13/45.60	21/46.69	16/45.67	23/47.49	11/45.75	9/44.07	13/44.89	9/47.79
POLY-3 PERCENT (g)	28.5%	45.0%	35.0%	48.4%	24.0%	20.4%	29.0%	18.8%
TERMINAL (d)	8/36 (22%)	8/27 (30%)	8/31 (26%)	10/28 (36%)	7/37 (19%)	8/36 (22%)	7/33 (21%)	6/41 (15%)
FIRST INCIDENCE	545	574	561	465	594	623	615	636
STATISTICAL TESTS								
LIFE TABLE	P=0.084	P=0.037 *	P=0.255	P=0.020 *	P=0.387N	P=0.430N	P=0.318	P=0.325N
POLY 3	P=0.111	P=0.074	P=0.328	P=0.036 *	P=0.408N	P=0.437N	P=0.385	P=0.359N
POLY 1.5	P=0.106	P=0.075	P=0.329	P=0.034 *	P=0.436N	P=0.424N	P=0.395	P=0.375N
POLY 6	P=0.111	P=0.067	P=0.315	P=0.035 *	P=0.381N	P=0.452N	P=0.370	P=0.345N
LOGISTIC REGRESSION	P=0.098	P=0.069	P=0.330	P=0.029 *	P=0.452N	P=0.421N	P=0.396	P=0.399N
COCH-ARM / FISHERS	P=0.097	P=0.069	P=0.330	P=0.030 *	P=0.484N	P=0.402N	P=0.408	P=0.402N
ORDER RESTRICTED	P=0.031 *	(e)	(e)	(e)	P=0.404N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Mesothelioma: Benign, Malignant, NOS								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.72	1/44.06	2/44.36	2/43.44	0/44.75	0/43.69	1/43.76	0/47.00
POLY-3 PERCENT (g)	0.0%	2.3%	4.5%	4.6%	0.0%	0.0%	2.3%	0.0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	2/28 (7%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	---	660	607	729 (T)	---	---	573	---
STATISTICAL TESTS								
LIFE TABLE	P=0.157	P=0.500	P=0.237	P=0.185	P=0.647	(e)	P=0.504	(e)
POLY 3	P=0.164	P=0.502	P=0.240	P=0.236	P=0.667	(e)	P=0.496	(e)
POLY 1.5	P=0.166	P=0.503	P=0.239	P=0.237	P=0.656	(e)	P=0.498	(e)
POLY 6	P=0.158	P=0.496	P=0.239	P=0.230	P=0.677	(e)	P=0.491	(e)
LOGISTIC REGRESSION	P=0.166	P=0.484	P=0.239	P=0.185	P=0.571	(e)	P=0.513	(e)
COCH-ARM / FISHERS	P=0.166	P=0.500	P=0.247	P=0.247	P=0.637	(e)	P=0.500	(e)
ORDER RESTRICTED	P=0.153	(e)	(e)	(e)	P=0.377	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Mesothelioma: Malignant								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.72	1/44.06	2/44.36	2/43.44	0/44.75	0/43.69	1/43.76	0/47.00
POLY-3 PERCENT (g)	0.0%	2.3%	4.5%	4.6%	0.0%	0.0%	2.3%	0.0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	2/28 (7%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	---	660	607	729 (T)	---	---	573	---
STATISTICAL TESTS								
LIFE TABLE	P=0.157	P=0.500	P=0.237	P=0.185	P=0.647	(e)	P=0.504	(e)
POLY 3	P=0.164	P=0.502	P=0.240	P=0.236	P=0.667	(e)	P=0.496	(e)
POLY 1.5	P=0.166	P=0.503	P=0.239	P=0.237	P=0.656	(e)	P=0.498	(e)
POLY 6	P=0.158	P=0.496	P=0.239	P=0.230	P=0.677	(e)	P=0.491	(e)
LOGISTIC REGRESSION	P=0.166	P=0.484	P=0.239	P=0.185	P=0.571	(e)	P=0.513	(e)
COCH-ARM / FISHERS	P=0.166	P=0.500	P=0.247	P=0.247	P=0.637	(e)	P=0.500	(e)
ORDER RESTRICTED	P=0.153	(e)	(e)	(e)	P=0.377	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Osteosarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/44.64	0/43.80	0/43.73	1/43.44	0/44.75	1/44.23	0/43.24	0/47.00
POLY-3 PERCENT (g)	6.7%	0.0%	0.0%	2.3%	0.0%	2.3%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	1/28 (4%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	469	---	---	729 (T)	---	563	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.377N	P=0.141N	P=0.138N	P=0.365N	P=0.415N	P=0.496	(e)	(e)
POLY 3	P=0.344N	P=0.122N	P=0.122N	P=0.315N	P=0.429N	P=0.498	(e)	(e)
POLY 1.5	P=0.347N	P=0.119N	P=0.121N	P=0.309N	P=0.427N	P=0.498	(e)	(e)
POLY 6	P=0.336N	P=0.129N	P=0.127N	P=0.327N	P=0.432N	P=0.498	(e)	(e)
LOGISTIC REGRESSION	P=0.344N	P=0.150N	P=0.115N	P=0.315N	P=0.509N	P=0.556	(e)	(e)
COCH-ARM / FISHERS	P=0.347N	P=0.121N	P=0.121N	P=0.309N	P=0.423N	P=0.500	(e)	(e)
ORDER RESTRICTED	P=0.041N*	(e)	(e)	(e)	P=0.370N	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Osteosarcoma or Osteoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/44.64	0/43.80	0/43.73	1/43.44	0/44.75	1/44.23	0/43.24	0/47.00
POLY-3 PERCENT (g)	6.7%	0.0%	0.0%	2.3%	0.0%	2.3%	0.0%	0.0%
TERMINAL (d)	0/36 (0%)	0/27 (0%)	0/31 (0%)	1/28 (4%)	0/37 (0%)	0/36 (0%)	0/33 (0%)	0/41 (0%)
FIRST INCIDENCE	469	---	---	729 (T)	---	563	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.377N	P=0.141N	P=0.138N	P=0.365N	P=0.415N	P=0.496	(e)	(e)
POLY 3	P=0.344N	P=0.122N	P=0.122N	P=0.315N	P=0.429N	P=0.498	(e)	(e)
POLY 1.5	P=0.347N	P=0.119N	P=0.121N	P=0.309N	P=0.427N	P=0.498	(e)	(e)
POLY 6	P=0.336N	P=0.129N	P=0.127N	P=0.327N	P=0.432N	P=0.498	(e)	(e)
LOGISTIC REGRESSION	P=0.344N	P=0.150N	P=0.115N	P=0.315N	P=0.509N	P=0.556	(e)	(e)
COCH-ARM / FISHERS	P=0.347N	P=0.121N	P=0.121N	P=0.309N	P=0.423N	P=0.500	(e)	(e)
ORDER RESTRICTED	P=0.041N*	(e)	(e)	(e)	P=0.370N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Benign Tumors								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	48/50 (96%)	49/50 (98%)	47/50 (94%)	47/50 (94%)	46/50 (92%)	42/50 (84%)	44/50 (88%)	47/50 (94%)
POLY-3 RATE (b)	48/48.34	49/49.46	47/48.09	47/48.82	46/48.80	42/47.38	44/48.83	47/49.41
POLY-3 PERCENT (g)	99.3%	99.1%	97.7%	96.3%	94.3%	88.7%	90.1%	95.1%
TERMINAL (d)	36/36 (100%)	27/27 (100%)	31/31 (100%)	27/28 (96%)	35/37 (95%)	33/36 (92%)	29/33 (88%)	39/41 (95%)
FIRST INCIDENCE	469	542	561	443	423	365	511	475
STATISTICAL TESTS								
LIFE TABLE	P=0.337	P=0.048 *	P=0.270	P=0.129	P=0.408N	P=0.360N	P=0.408	P=0.303N
POLY 3	P=0.128N	P=0.955N	P=0.608N	P=0.346N	P=0.319	P=0.248N	P=0.342N	P=0.609
POLY 1.5	P=0.162N	P=0.826	P=0.580N	P=0.384N	P=0.261	P=0.208N	P=0.356N	P=0.567
POLY 6	P=0.126N	P=1.000N	P=0.707N	P=0.386N	P=0.402	P=0.323N	P=0.326N	P=0.650
LOGISTIC REGRESSION	P=0.210N	P=0.355N	P=0.240N	P=0.346N	P=0.313	P=0.216N	P=0.396N	P=0.641
COCH-ARM / FISHERS	P=0.249N	P=0.500	P=0.500N	P=0.500N	P=0.202	P=0.178N	P=0.370N	P=0.500
ORDER RESTRICTED	P=0.135N	(e)	(e)	(e)	P=0.334	(e)	(e)	(e)

Dose	Males 0 MG/L	125 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	125 MG/L	1000MG/L	2000MG/L
All Organs Malignant Tumors								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	27/50 (54%)	32/50 (64%)	24/50 (48%)	32/50 (64%)	21/50 (42%)	22/50 (44%)	19/50 (38%)	22/50 (44%)
POLY-3 RATE (b)	27/48.71	32/47.98	24/48.25	32/48.14	21/47.47	22/46.55	19/47.04	22/48.35
POLY-3 PERCENT (g)	55.4%	66.7%	49.7%	66.5%	44.2%	47.3%	40.4%	45.5%
TERMINAL (d)	16/36 (44%)	14/27 (52%)	11/31 (36%)	16/28 (57%)	14/37 (38%)	14/36 (39%)	8/33 (24%)	17/41 (42%)
FIRST INCIDENCE	381	562	209	465	462	541	547	635
STATISTICAL TESTS								
LIFE TABLE	P=0.276	P=0.092	P=0.513N	P=0.098	P=0.391N	P=0.461	P=0.551N	P=0.499N
POLY 3	P=0.365	P=0.175	P=0.360N	P=0.181	P=0.497N	P=0.465	P=0.432N	P=0.533
POLY 1.5	P=0.375	P=0.191	P=0.350N	P=0.194	P=0.513N	P=0.472	P=0.428N	P=0.520
POLY 6	P=0.347	P=0.152	P=0.382N	P=0.160	P=0.486N	P=0.471	P=0.435N	P=0.547
LOGISTIC REGRESSION	P=0.390	P=0.196	P=0.346N	P=0.206	P=0.502	P=0.503	P=0.392N	P=0.480
COCH-ARM / FISHERS	P=0.384	P=0.208	P=0.345N	P=0.208	P=0.527	P=0.500	P=0.419N	P=0.500
ORDER RESTRICTED	P=0.204	(e)	(e)	(e)	P=0.610N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Rats(FISCHER 344) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	Males 125 MG/L	Males 1000MG/L	Males 2000MG/L	Females 0 MG/L	Females 125 MG/L	Females 1000MG/L	Females 2000MG/L
All Organs Malignant and Benign Tumors								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	49/50 (98%)	50/50 (100%)	50/50 (100%)	50/50 (100%)	49/50 (98%)	48/50 (96%)	46/50 (92%)	48/50 (96%)
POLY-3 RATE (b)	49/49.20	50/50.00	50/50.00	50/50.00	49/50.00	48/49.21	46/49.17	48/49.41
POLY-3 PERCENT (g)	99.6%	100.0%	100.0%	100.0%	98.0%	97.5%	93.6%	97.1%
TERMINAL (d)	36/36 (100%)	27/27 (100%)	31/31 (100%)	28/28 (100%)	36/37 (97%)	35/36 (97%)	30/33 (91%)	40/41 (98%)
FIRST INCIDENCE	381	542	209	443	423	365	511	475
STATISTICAL TESTS								
LIFE TABLE	P=0.206	P=0.054	P=0.176	P=0.073	P=0.149N	P=0.551	P=0.467	P=0.168N
POLY 3	P=0.987	P=1.000	P=1.000	P=1.000	P=0.429N	P=0.706N	P=0.271N	P=0.652N
POLY 1.5	P=0.671	P=0.894	P=0.894	P=0.894	P=0.401N	P=0.639N	P=0.237N	P=0.589N
POLY 6	P=1.000	P=1.000	P=1.000	P=1.000	P=0.470N	P=0.746N	P=0.294N	P=0.716N
LOGISTIC REGRESSION	P=0.306	P=0.995	P=0.398	P=0.764	P=0.274N	P=0.536N	P=0.188N	P=0.444N
COCH-ARM / FISHERS	P=0.363	P=0.500	P=0.500	P=0.500	P=0.380N	P=0.500N	P=0.181N	P=0.500N
ORDER RESTRICTED	P=0.119	(e)	(e)	(e)	P=0.359N	(e)	(e)	(e)

(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Number of tumor-bearing animals / Poly-3 number
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(g) Poly-3 adjusted lifetime tumor incidence.
(I) Interim sacrifice
(T) Terminal sacrifice
Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FINAL#1/RATS

Facility: Southern Research Institute

Chemical CAS #: 7775-09-9

Lock Date: 10/16/01

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Natural Death	3	3	6	5
Moribund Sacrifice	10	11	11	4
Survivors				
Terminal Sacrifice	37	34	32	40
Natural Death			1	1
Moribund Sacrifice		2		
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Small, Duodenum	(50)	(49)	(45)	(49)
Amyloid Deposition		1 [2.0]		
Epithelium, Cyst				1 [1.0]
Liver	(50)	(50)	(50)	(50)
Angiectasis, Focal			2 [2.0]	
Basophilic Focus	42	44	41	42
Cholangiofibrosis	1 [4.0]		1 [4.0]	3 [4.0]
Clear Cell Focus	6	16	18	10
Congestion	6 [2.0]	2 [3.0]	2 [2.5]	1 [2.0]
Degeneration, Cystic, Focal	1 [2.0]		1 [2.0]	3 [2.0]
Eosinophilic Focus		1	1	2
Fibrosis, Focal				1 [1.0]
Hemorrhage	1 [2.0]			
Hepatodiaphragmatic Nodule	7	4	8	3
Hyperplasia, Focal, Histiocytic	20 [1.6]	19 [1.7]	16 [1.6]	23 [1.8]
Hyperplasia, Focal, Regenerative	1 [1.0]			1 [3.0]
Hyperplasia, Regenerative				2 [4.0]
Infarct, Multiple		1 [3.0]		
Infiltration Cellular, Focal, Polymorphonuclear			1 [2.0]	
Infiltration Cellular, Polymorphonuclear		1 [3.0]		
Infiltration Cellular, Mixed Cell	39 [1.9]	38 [1.9]	35 [1.9]	41 [2.0]
Mixed Cell Focus	12	6	7	8
Thrombosis		1 [3.0]		
Bile Duct, Cyst		1 [2.0]		
Bile Duct, Hyperplasia	29 [1.5]	24 [1.5]	34 [1.7]	26 [2.0]
Capsule, Cyst	1 [3.0]			
Hepatocyte, Karyomegaly		1 [3.0]		

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Hepatocyte, Necrosis, Focal		2 [1.5]		1 [2.0]
Hepatocyte, Vacuolization Cytoplasmic			2 [2.0]	
Hepatocyte, Vacuolization Cytoplasmic, Diffuse	1 [2.0]	2 [2.5]	1 [2.0]	2 [3.0]
Hepatocyte, Vacuolization Cytoplasmic, Focal	17 [1.5]	10 [1.7]	10 [1.8]	10 [1.4]
Hepatocyte, Periportal, Vacuolization Cytoplasmic		2 [2.0]		
Hepatocyte, Periportal, Centrilobular, Vacuolization Cytoplasmic			1 [2.0]	
Hepatocyte, Centrilobular, Necrosis	2 [2.0]	1 [4.0]	1 [3.0]	2 [2.5]
Hepatocyte, Centrilobular, Vacuolization Cytoplasmic	5 [3.0]	3 [3.0]	8 [3.4]	3 [2.3]
Hepatocyte, Midzonal, Vacuolization Cytoplasmic		2 [3.5]		
Mesentery	(18)	(10)	(13)	(16)
Inflammation, Chronic, Focal		1 [2.0]		
Fat, Necrosis	4 [2.5]	2 [2.0]	1 [3.0]	
Fat, Necrosis, Focal	12 [2.3]	5 [2.6]	9 [2.8]	13 [2.6]
Pancreas	(50)	(49)	(49)	(49)
Lipomatosis				1 [1.0]
Acinus, Atrophy, Diffuse				1 [4.0]
Acinus, Atrophy, Focal	15 [1.4]	8 [2.1]	9 [1.6]	16 [1.4]
Duct, Cyst, Focal	1 [1.0]	2 [1.0]	4 [1.0]	1 [2.0]
Duct, Cyst, Focal, Multiple	10 [1.4]	14 [1.8]	11 [1.5]	18 [1.6]
Duct, Hyperplasia, Focal				1 [1.0]
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy, Focal	2 [2.0]			
Stomach, Forestomach	(50)	(50)	(50)	(50)
Edema		1 [3.0]	1 [3.0]	1 [2.0]
Erosion		1 [2.0]		
Inflammation, Chronic		2 [2.5]	1 [3.0]	
Inflammation, Chronic, Focal			1 [2.0]	
Perforation			1 [3.0]	
Ulcer	2 [2.0]	7 [2.4]		1 [2.0]
Epithelium, Hyperplasia	2 [2.0]	4 [2.3]	6 [2.5]	1 [2.0]
Stomach, Glandular	(50)	(49)	(49)	(50)
Erosion	2 [2.0]		2 [1.5]	2 [1.5]
Erosion, Focal	1 [2.0]			
Inflammation, Chronic		1 [2.0]		
Necrosis, Focal		1 [2.0]		
Pigmentation, Focal	1 [2.0]			
Ulcer		1 [2.0]		
Tooth		(2)	(2)	(1)

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Malformation			1	
Dentine, Malformation		1 [3.0]		
Peridontal Tissue, Inflammation, Chronic		1 [3.0]	2 [3.0]	
Peridontal Tissue, Inflammation, Chronic, Focal				1 [3.0]
CARDIOVASCULAR SYSTEM				
Blood Vessel		(1)		(1)
Thrombosis		1 [3.0]		
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	4 [1.5]	2 [2.5]		2 [2.0]
Infiltration Cellular, Mixed Cell		1 [1.0]	1 [2.0]	4 [1.5]
Thrombosis	1 [3.0]			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	2 [1.0]	3 [1.3]	5 [1.0]	2 [1.0]
Angiectasis	2 [2.5]	1 [3.0]	1 [2.0]	2 [3.0]
Cytoplasmic Alteration, Focal	1 [2.0]	2 [2.0]	3 [2.0]	2 [1.5]
Degeneration, Cystic, Focal		1 [3.0]		1 [2.0]
Fibrosis, Focal			1 [2.0]	
Hematopoietic Cell Proliferation		1 [2.0]		
Hemorrhage	1 [3.0]	1 [3.0]		2 [2.5]
Infiltration Cellular, Mixed Cell		1 [2.0]		
Necrosis, Focal		1 [3.0]		
Vacuolization Cytoplasmic, Focal	7 [1.4]	13 [1.6]	7 [1.9]	8 [1.8]
Adrenal Medulla	(50)	(50)	(50)	(50)
Angiectasis				1 [3.0]
Hyperplasia, Focal	3 [1.0]	4 [1.3]	1 [1.0]	1 [1.0]
Infiltration Cellular, Focal, Lymphoid				1 [2.0]
Islets, Pancreatic	(50)	(49)	(49)	(50)
Hyperplasia, Focal			1 [2.0]	
Parathyroid Gland	(47)	(47)	(48)	(47)
Hyperplasia, Focal			1 [3.0]	
Pituitary Gland	(49)	(49)	(50)	(50)
Angiectasis	10 [2.5]	6 [2.8]	2 [3.5]	13 [2.6]
Pigmentation, Focal	1 [2.0]			
Pars Distalis, Angiectasis	1 [3.0]	2 [2.5]	2 [3.5]	
Pars Distalis, Cyst	2 [2.5]	2 [2.5]	1 [3.0]	2 [1.5]

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Pars Distalis, Cytoplasmic Alteration, Focal	3 [1.0]	1 [1.0]	2 [1.0]	3 [1.7]
Pars Distalis, Degeneration, Cystic, Focal	11 [1.9]	14 [1.8]	11 [2.4]	3 [2.0]
Pars Distalis, Hemorrhage, Focal	9 [2.9]	6 [2.8]	10 [2.5]	2 [3.0]
Pars Distalis, Hyperplasia, Focal	7 [2.3]	5 [2.4]	10 [2.8]	4 [1.8]
Pars Distalis, Infiltration Cellular, Focal			1 [2.0]	
Pars Nervosa, Hyperplasia, Atypical, Focal		1 [3.0]		
Rathke's Cleft, Cyst	1 [2.0]	2 [2.5]		
Rathke's Cleft, Hemorrhage	1 [2.0]	2 [2.5]	2 [2.5]	6 [2.8]
Rathke's Cleft, Hyperplasia, Cystic			1 [3.0]	
Thyroid Gland	(47)	(47)	(43)	(46)
Congestion				1 [1.0]
Ultimobranchial Cyst	1 [2.0]		1 [1.0]	
C-Cell, Hyperplasia	43 [2.2]	45 [2.1]	43 [2.5]	44 [2.3]
Follicle, Mineralization, Focal	25 [1.0]	26 [1.0]	40 [1.3]	44 [2.1]
Follicular Cell, Hyperplasia, Cystic, Focal	1 [2.0]			
Follicular Cell, Hypertrophy	3 [1.3]	7 [1.0]	27 [1.2]	42 [1.8]
GENERAL BODY SYSTEM				
Tissue NOS	(1)	(2)	(4)	(6)
Mediastinum, Cyst			1 [3.0]	
Mediastinum, Thrombosis				1 [3.0]
Oral, Foreign Body, Focal				1 [3.0]
Oral, Necrosis, Focal				1 [3.0]
GENITAL SYSTEM				
Clitoral Gland	(49)	(50)	(50)	(49)
Cyst	1 [4.0]			
Degeneration, Cystic	5 [3.0]	2 [3.0]	6 [2.8]	1 [3.0]
Hyperplasia				1 [3.0]
Hyperplasia, Cystic	1 [3.0]	4 [2.5]	3 [2.3]	1 [3.0]
Hyperplasia, Cystic, Focal		1 [2.0]		
Inflammation, Chronic	6 [2.8]	2 [1.5]	1 [3.0]	3 [2.3]
Duct, Inflammation, Chronic	1 [4.0]			
Ovary	(50)	(50)	(49)	(50)
Cyst	5 [2.2]	1 [3.0]	1 [3.0]	4 [1.8]
Corpus Luteum, Hyperplasia				1 [3.0]
Interstitial Cell, Hyperplasia		1 [2.0]	1 [3.0]	
Periovarian Tissue, Cyst	4 [3.0]	4 [3.0]	2 [3.5]	1 [3.0]
Uterus	(50)	(50)	(49)	(50)

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
GENITAL SYSTEM - CONT				
Hemorrhage		1 [3.0]		1 [3.0]
Hydrometra	1 [3.0]			
Inflammation, Chronic			1 [3.0]	
Inflammation, Focal, Suppurative				1 [3.0]
Inflammation, Suppurative		1 [3.0]		1 [3.0]
Ulcer, Chronic Active				1 [4.0]
Endometrium, Hyperplasia, Cystic	16 [1.8]	7 [1.4]	16 [1.9]	11 [1.8]
Vagina	(6)	(3)	(3)	(1)
Cyst	2 [3.0]	1 [3.0]	1 [3.0]	1 [3.0]
Inflammation, Chronic	1 [3.0]			
Inflammation, Suppurative		1 [3.0]	1 [3.0]	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(50)
Angiectasis			1 [3.0]	
Hemorrhage				1 [2.0]
Hyperplasia	2 [3.5]	1 [1.0]	1 [2.0]	
Hyperplasia, Focal, Histiocytic			2 [3.0]	2 [4.0]
Myeloid Cell, Hyperplasia	7 [2.4]	3 [2.7]	2 [2.5]	6 [2.7]
Myeloid Cell, Erythroid Cell, Hyperplasia		2 [3.0]	2 [3.0]	3 [3.0]
Lymph Node	(36)	(34)	(30)	(39)
Hyperplasia, Plasma Cell	1 [3.0]			
Pigmentation				1 [3.0]
Deep Cervical, Hemorrhage	1 [2.0]			
Deep Cervical, Hyperplasia, Lymphoid	1 [3.0]			
Deep Cervical, Hyperplasia, Plasma Cell				1 [3.0]
Mediastinal, Angiectasis			1 [3.0]	
Mediastinal, Congestion	1 [3.0]			
Mediastinal, Ectasia	2 [3.0]	4 [3.0]	2 [3.0]	4 [3.0]
Mediastinal, Hemorrhage	6 [3.0]	6 [3.0]	5 [3.0]	3 [2.7]
Mediastinal, Hyperplasia, Histiocytic	1 [3.0]	4 [3.0]	2 [3.0]	3 [3.0]
Mediastinal, Hyperplasia, Lymphoid	1 [3.0]	2 [2.5]	2 [3.0]	3 [3.0]
Mediastinal, Hyperplasia, Plasma Cell		1 [3.0]		
Mediastinal, Infiltration Cellular, Mixed Cell			1 [3.0]	
Mediastinal, Pigmentation			1 [3.0]	
Pancreatic, Angiectasis		1 [3.0]		
Pancreatic, Ectasia	1 [2.0]			1 [3.0]
Pancreatic, Hemorrhage	5 [3.0]	3 [3.0]		5 [2.6]
Pancreatic, Hyperplasia, Histiocytic	31 [1.8]	22 [2.2]	15 [2.5]	25 [2.4]
Pancreatic, Hyperplasia, Lymphoid			1 [1.0]	

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - CONT				
Pancreatic, Pigmentation	1 [2.0]	7 [1.6]	3 [2.0]	6 [1.7]
Lymph Node, Mandibular	(4)	(6)	(4)	(5)
Ectasia		1 [3.0]		
Lymph Node, Mesenteric	(50)	(49)	(49)	(50)
Hemorrhage				1 [3.0]
Hyperplasia, Focal, Histiocytic			1 [3.0]	
Hyperplasia, Histiocytic	2 [3.0]	4 [3.0]		4 [3.3]
Hyperplasia, Lymphoid	1 [3.0]			
Spleen	(50)	(50)	(50)	(50)
Angiectasis, Focal		1 [3.0]		1 [3.0]
Fibrosis, Focal		1 [3.0]		1 [3.0]
Hematopoietic Cell Proliferation	16 [2.4]	21 [2.4]	8 [2.4]	17 [2.4]
Hemorrhage	1 [2.0]	1 [2.0]	1 [3.0]	2 [2.5]
Hyperplasia, Focal, Histiocytic	2 [4.0]	4 [2.8]	2 [3.5]	5 [3.6]
Infarct				1 [3.0]
Pigmentation, Focal			1 [3.0]	
Red Pulp, Fibrosis, Diffuse				1 [3.0]
Thymus	(49)	(48)	(48)	(48)
Angiectasis	2 [2.5]	1 [2.0]		
Cyst		1 [2.0]		
Hemorrhage	1 [3.0]		2 [2.0]	1 [3.0]
Hyperplasia, Lymphoid	1 [2.0]			1 [3.0]
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Dilatation	37 [3.1]	39 [3.1]	34 [3.0]	38 [3.1]
Ectasia	4 [2.8]	1 [2.0]	3 [2.7]	2 [2.5]
Fibrosis	2 [2.5]	1 [3.0]	1 [2.0]	4 [2.8]
Fibrosis, Focal	1 [2.0]			
Hyperplasia	7 [2.4]	11 [2.2]	10 [2.4]	9 [2.3]
Hyperplasia, Focal	1 [3.0]			1 [4.0]
Inflammation, Chronic				1 [2.0]
Skin	(50)	(50)	(50)	(50)
Inflammation, Chronic, Focal		1 [1.0]		
Ulcer				1 [1.0]
Subcutaneous Tissue, Fibrosis, Focal	1 [2.0]			
MUSCULOSKELETAL SYSTEM				
None				

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
NERVOUS SYSTEM				
Brain	(49)	(50)	(50)	(50)
Compression, Focal	9 [2.7]	9 [2.9]	10 [2.9]	9 [3.0]
Hemorrhage, Focal		4 [2.3]	3 [1.7]	2 [1.5]
Necrosis, Focal		1 [3.0]		
Thalamus, Mineralization, Focal	1 [3.0]			
Thalamus, Necrosis, Focal	1 [3.0]			
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Congestion			2 [3.0]	1 [3.0]
Hemorrhage, Focal	1 [2.0]		1 [3.0]	2 [3.0]
Hyperplasia, Focal, Histiocytic	1 [2.0]	1 [2.0]		2 [3.0]
Hyperplasia, Histiocytic	4 [1.8]	6 [1.3]	5 [1.6]	2 [1.0]
Infiltration Cellular, Polymorphonuclear		1 [3.0]		
Infiltration Cellular, Mixed Cell	2 [2.5]	3 [2.0]	2 [2.0]	1 [3.0]
Inflammation, Chronic, Focal	2 [1.0]		4 [1.5]	2 [1.0]
Metaplasia, Focal, Osseous			1 [2.0]	
Alveolar Epithelium, Hyperplasia	1 [1.0]			
Alveolar Epithelium, Hyperplasia, Focal	4 [1.5]	2 [1.5]	3 [2.0]	2 [1.5]
Interstitium, Edema				1 [3.0]
Mediastinum, Edema			1 [3.0]	
Peribronchiolar, Hyperplasia, Lymphoid			1 [2.0]	
Nose	(50)	(50)	(50)	(50)
Inflammation, Suppurative	1 [2.0]	2 [2.0]		
Nasolacrimal Duct, Inflammation		1 [2.0]		1 [3.0]
Respiratory Epithelium, Metaplasia, Focal, Squamous				1 [2.0]
SPECIAL SENSES SYSTEM				
Eye	(50)	(49)	(47)	(50)
Atrophy	1 [3.0]			
Cataract	2 [2.5]	3 [2.3]	1 [3.0]	2 [3.0]
Hemorrhage		1 [3.0]		
Retinal Detachment	1 [3.0]			
Bilateral, Atrophy				1 [4.0]
Cornea, Inflammation, Chronic	1 [4.0]	1 [3.0]		
Cornea, Necrosis, Focal	1 [4.0]			

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS FEMALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
SPECIAL SENSES SYSTEM - CONT				
Retina, Degeneration	1 [4.0]	2 [3.0]	1 [3.0]	2 [2.5]
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia, Cystic, Focal	1 [2.0]			
Hyperplasia, Focal				1 [1.0]
Hyperplasia, Focal, Histiocytic	2 [2.5]		1 [1.0]	
Inflammation, Chronic, Focal		1 [3.0]	1 [1.0]	2 [1.0]
Metaplasia, Focal, Squamous			1 [3.0]	
Epithelium, Hyperplasia, Focal	1 [1.0]			
URINARY SYSTEM				
Kidney	(50)	(49)	(47)	(47)
Atrophy, Diffuse		1 [4.0]		
Atrophy, Focal	1 [3.0]			2 [3.0]
Cyst			1 [2.0]	1 [2.0]
Hyperplasia, Lymphoid			1 [2.0]	
Infarct		1 [3.0]	1 [3.0]	
Infiltration Cellular, Polymorphonuclear		1 [3.0]		
Inflammation, Chronic	1 [2.0]	2 [2.0]		
Inflammation, Chronic, Focal, Granulomatous				1 [3.0]
Nephropathy	43 [1.1]	41 [1.2]	37 [1.1]	38 [1.3]
Pelvis, Inflammation, Chronic		1 [3.0]		
Pelvis, Transitional Epithelium, Hyperplasia		1 [2.0]		
Renal Tubule, Accumulation, Hyaline Droplet	5 [2.6]	12 [2.0]	11 [2.2]	5 [2.0]
Renal Tubule, Pigmentation	2 [1.0]	1 [2.0]	4 [1.8]	4 [2.3]

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	10	13	11	14
Natural Death	3	10	8	8
Accidently Killed	1			
Survivors				
Terminal Sacrifice	36	27	31	28
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(48)	(47)	(44)	(49)
Edema				2 [3.0]
Intestine Large, Rectum	(48)	(47)	(47)	(50)
Congestion				1 [3.0]
Edema				1 [3.0]
Hemorrhage				1 [3.0]
Intestine Large, Cecum	(47)	(46)	(43)	(47)
Edema		1 [3.0]		1 [3.0]
Ulcer				1 [4.0]
Intestine Small, Duodenum	(49)	(46)	(46)	(47)
Ulcer		1 [3.0]		
Epithelium, Hyperplasia				1 [3.0]
Intestine Small, Jejunum	(47)	(46)	(42)	(44)
Epithelium, Necrosis			1 [2.0]	
Intestine Small, Ileum	(47)	(46)	(42)	(47)
Ulcer	1 [4.0]			
Liver	(50)	(50)	(48)	(50)
Angiectasis, Focal	2 [1.5]	1 [2.0]	1 [2.0]	3 [2.0]
Basophilic Focus	27	30	33	29
Cholangiofibrosis	2 [3.0]	1 [1.0]	1 [4.0]	1 [2.0]
Clear Cell Focus	21	18	29	15
Congestion		2 [3.0]		
Degeneration, Cystic, Focal	13 [1.4]	9 [1.7]	12 [2.0]	14 [1.9]
Eosinophilic Focus	2	3		2
Fibrosis, Focal		1 [3.0]		1 [2.0]
Hemorrhage, Focal	1 [3.0]			
Hepatodiaphragmatic Nodule	6 [2.7]	2 [3.0]	3 [3.0]	5 [3.0]
Hyperplasia, Focal, Histiocytic	6 [1.8]	2 [1.5]	8 [1.5]	5 [1.4]
Hyperplasia, Focal, Lymphoid			1 [3.0]	1 [2.0]

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Infarct	1 [3.0]			
Infiltration Cellular, Mixed Cell	36 [2.0]	29 [1.9]	33 [1.9]	28 [2.0]
Mixed Cell Focus	13	11	3	8
Bile Duct, Hyperplasia	48 [2.8]	49 [2.9]	46 [2.8]	50 [2.9]
Centrilobular, Congestion		1 [3.0]		
Hepatocyte, Necrosis, Focal		1 [2.0]		2 [2.5]
Hepatocyte, Vacuolization Cytoplasmic, Diffuse	3 [2.3]	3 [2.7]		4 [3.3]
Hepatocyte, Vacuolization Cytoplasmic, Focal	26 [1.8]	15 [1.7]	14 [1.9]	18 [1.7]
Hepatocyte, Periportal, Necrosis		1 [3.0]		
Hepatocyte, Periportal, Vacuolization Cytoplasmic		1 [2.0]	1 [2.0]	
Hepatocyte, Centrilobular, Atrophy				1 [3.0]
Hepatocyte, Centrilobular, Necrosis	1 [4.0]	3 [2.0]	6 [2.5]	4 [2.5]
Hepatocyte, Centrilobular, Vacuolization Cytoplasmic	4 [2.8]	9 [3.0]	12 [2.9]	11 [2.6]
Hepatocyte, Midzonal, Necrosis	1 [3.0]			
Hepatocyte, Midzonal, Vacuolization Cytoplasmic	6 [2.5]	1 [3.0]		1 [3.0]
Hepatocyte, Midzonal, Vacuolization Cytoplasmic, Focal		1 [3.0]		
Portal, Fibrosis		1 [3.0]		
Portal, Hemorrhage		1 [3.0]		
Mesentery	(19)	(20)	(19)	(23)
Angiectasis		1 [3.0]		
Hemorrhage	1 [4.0]		1 [3.0]	
Inflammation, Chronic			1 [3.0]	
Inflammation, Chronic, Focal				1 [3.0]
Fat, Necrosis	2 [3.0]		2 [3.0]	2 [2.0]
Fat, Necrosis, Focal	12 [2.8]	10 [2.7]	13 [2.5]	14 [2.5]
Pancreas	(49)	(49)	(49)	(50)
Inflammation, Chronic	1 [3.0]			
Acinus, Atrophy, Diffuse				1 [4.0]
Acinus, Atrophy, Focal	23 [1.8]	23 [2.1]	27 [1.9]	15 [1.7]
Acinus, Hyperplasia, Focal	1 [3.0]	1 [2.0]		
Duct, Cyst, Focal			1 [3.0]	1 [3.0]
Duct, Cyst, Focal, Multiple	15 [1.7]	13 [1.6]	18 [1.8]	15 [1.8]
Salivary Glands	(49)	(50)	(50)	(50)
Atrophy				1 [3.0]
Hyperplasia, Focal, Histiocytic				1 [3.0]
Stomach, Forestomach	(50)	(50)	(50)	(50)
Edema	1 [3.0]	1 [3.0]		4 [3.0]
Erosion			1 [3.0]	

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Inflammation, Chronic		4 [2.3]		1 [3.0]
Inflammation, Chronic, Focal			1 [3.0]	
Inflammation, Focal		1 [2.0]	1 [3.0]	
Ulcer	1 [2.0]	5 [2.4]	2 [1.5]	4 [2.8]
Epithelium, Cyst	1 [2.0]			
Epithelium, Hyperplasia	2 [2.0]	8 [2.4]	1 [3.0]	7 [2.3]
Epithelium, Hyperplasia, Focal			1 [3.0]	
Stomach, Glandular	(49)	(48)	(48)	(50)
Erosion	3 [1.3]	2 [2.0]	4 [1.8]	4 [1.5]
Perforation				1 [3.0]
Pigmentation, Focal		1 [2.0]	1 [1.0]	
Ulcer	1 [3.0]			3 [2.7]
Epithelium, Hyperplasia, Focal		1 [2.0]		
Tongue	(1)	(1)	(1)	(1)
Epithelium, Hyperplasia	1 [3.0]			
Tooth		(1)	(1)	
Malformation			1 [2.0]	
Peridontal Tissue, Hyperplasia, Squamous		1 [3.0]		
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	6 [1.5]	3 [2.0]	7 [1.7]	10 [1.8]
Infiltration Cellular, Mixed Cell	2 [1.5]	1 [2.0]		2 [2.0]
Inflammation, Chronic, Focal				1 [3.0]
Thrombosis	1 [3.0]	1 [4.0]	2 [3.0]	2 [3.0]
Artery, Inflammation, Chronic, Focal	1 [2.0]			
Endocardium, Valve, Inflammation, Chronic, Focal	1 [2.0]			
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule	1 [1.0]	7 [1.0]	4 [1.3]	3 [1.0]
Atrophy			1 [3.0]	
Cytoplasmic Alteration, Focal	3 [1.3]	3 [1.7]	2 [1.5]	4 [1.8]
Degeneration, Cystic, Focal			2 [3.0]	
Hyperplasia, Diffuse			1 [3.0]	
Infiltration Cellular, Mixed Cell				1 [2.0]
Necrosis, Focal			1 [2.0]	
Vacuolization Cytoplasmic, Diffuse		1 [3.0]		

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Vacuolization Cytoplasmic, Focal	12 [1.5]	8 [1.4]	7 [1.9]	6 [1.5]
Capsule, Fibrosis, Focal		1 [2.0]		
Adrenal Medulla	(49)	(49)	(50)	(50)
Hyperplasia, Focal	5 [1.6]	12 [1.4]	9 [1.6]	13 [1.8]
Islets, Pancreatic	(50)	(49)	(49)	(50)
Hyperplasia		2 [2.0]		
Hyperplasia, Focal	1 [2.0]	1 [2.0]		
Parathyroid Gland	(49)	(50)	(47)	(49)
Hyperplasia, Focal				1 [2.0]
Pituitary Gland	(48)	(50)	(49)	(50)
Angiectasis	2 [2.0]	4 [2.5]	1 [2.0]	3 [2.7]
Hemorrhage		1 [4.0]		
Hemorrhage, Focal				1 [2.0]
Pars Distalis, Cyst	2 [1.5]	1 [3.0]	1 [2.0]	1 [2.0]
Pars Distalis, Cytoplasmic Alteration, Focal	3 [1.3]	7 [1.4]	3 [1.0]	8 [1.4]
Pars Distalis, Degeneration, Cystic, Focal	2 [1.0]	2 [3.0]		
Pars Distalis, Hemorrhage, Focal	2 [3.0]	2 [2.5]	1 [2.0]	3 [2.7]
Pars Distalis, Hyperplasia, Focal	4 [2.3]	2 [3.5]	3 [2.3]	1 [2.0]
Pars Distalis, Pars Nervosa, Hemorrhage, Focal			1 [3.0]	
Pars Intermedia, Hemorrhage, Focal			1 [2.0]	
Rathke's Cleft, Cyst				1 [4.0]
Rathke's Cleft, Hemorrhage	1 [3.0]		2 [2.5]	2 [3.0]
Rathke's Cleft, Hyperplasia, Cystic		1 [2.0]		
Thyroid Gland	(47)	(44)	(43)	(47)
C-Cell, Hyperplasia	45 [1.8]	42 [2.0]	41 [2.0]	44 [1.8]
C-Cell, Hyperplasia, Focal			1 [2.0]	
Follicle, Cyst	1 [2.0]		1 [2.0]	2 [3.0]
Follicle, Degeneration, Cystic, Focal	2 [1.5]			
Follicle, Mineralization, Focal	45 [1.1]	43 [1.1]	42 [2.0]	42 [2.3]
Follicular Cell, Hypertrophy	4 [1.3]	13 [1.2]	33 [1.5]	40 [2.0]
Follicular Cell, Hypertrophy, Focal	1 [1.0]			
GENERAL BODY SYSTEM				
Tissue NOS	(5)	(6)	(2)	(7)
Abdominal, Fibrosis			1 [3.0]	
Mediastinum, Hemorrhage		1 [3.0]		
GENITAL SYSTEM				

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
GENITAL SYSTEM - CONT				
Epididymis	(50)	(50)	(50)	(50)
Fibrosis				1 [3.0]
Inflammation, Chronic	1 [2.0]	1 [3.0]		2 [2.5]
Penis		(2)		
Thrombosis		1 [2.0]		
Preputial Gland	(48)	(49)	(50)	(50)
Atrophy				1 [3.0]
Cyst		1 [2.0]	1 [2.0]	
Degeneration, Cystic		2 [3.0]	1 [3.0]	2 [3.0]
Hyperplasia, Cystic		1 [3.0]		1 [3.0]
Inflammation, Chronic	22 [1.7]	12 [1.8]	18 [1.8]	20 [1.3]
Necrosis				1 [3.0]
Prostate	(50)	(49)	(50)	(50)
Inflammation, Chronic	21 [1.9]	23 [2.0]	29 [2.2]	30 [1.8]
Mineralization, Focal	3 [2.0]	2 [2.5]	3 [2.0]	4 [2.3]
Epithelium, Hyperplasia, Focal	11 [1.3]	4 [1.3]	2 [2.0]	11 [1.2]
Testes	(50)	(50)	(50)	(50)
Atrophy	4 [3.0]	10 [2.9]	9 [2.9]	6 [3.2]
Bilateral, Atrophy		1 [3.0]		
Germinal Epithelium, Atrophy				1 [3.0]
Germinal Epithelium, Degeneration	1 [2.0]			
Interstitial Cell, Hyperplasia, Focal	1 [1.0]	1 [2.0]	1 [2.0]	3 [1.7]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(48)	(48)	(50)	(49)
Angiectasis		1 [2.0]		
Atrophy				1 [3.0]
Fibrosis	2 [3.0]			
Hyperplasia	28 [1.9]	35 [2.3]	41 [2.4]	40 [2.7]
Myeloid Cell, Erythroid Cell, Hyperplasia	2 [2.5]			
Lymph Node	(34)	(24)	(26)	(34)
Ectasia	1 [4.0]			
Hemorrhage				1 [3.0]
Deep Cervical, Hemorrhage			1 [3.0]	
Deep Cervical, Hyperplasia, Plasma Cell	1 [3.0]			
Mediastinal, Angiectasis			1 [3.0]	
Mediastinal, Ectasia	5 [2.6]	7 [3.0]	5 [3.0]	3 [3.3]
Mediastinal, Hemorrhage	3 [3.0]	2 [2.5]	2 [3.0]	1 [3.0]
Mediastinal, Hyperplasia, Histiocytic		3 [3.0]	2 [3.0]	1 [3.0]
Mediastinal, Hyperplasia, Lymphoid	1 [3.0]		1 [3.0]	3 [3.3]
Mediastinal, Hyperplasia, Plasma Cell	1 [3.0]		2 [3.0]	

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - CONT				
Mediastinal, Infiltration Cellular, Polymorphonuclear		1 [3.0]		
Mediastinal, Inflammation, Chronic Active				1 [3.0]
Mediastinal, Inflammation, Suppurative		1 [3.0]		
Pancreatic, Angiectasis	2 [3.0]			
Pancreatic, Ectasia	3 [2.7]	3 [3.0]	3 [3.0]	6 [2.8]
Pancreatic, Hemorrhage	5 [2.8]	3 [3.0]	1 [2.0]	1 [3.0]
Pancreatic, Hyperplasia, Histiocytic	8 [3.0]	5 [3.0]	9 [3.0]	6 [3.0]
Pancreatic, Hyperplasia, Lymphoid	1 [3.0]	1 [3.0]		
Pancreatic, Pigmentation	1 [2.0]	1 [2.0]	1 [3.0]	
Renal, Hemorrhage			1 [3.0]	
Renal, Hyperplasia, Focal, Histiocytic		1 [3.0]		
Renal, Hyperplasia, Lymphoid		1 [3.0]		
Lymph Node, Mesenteric	(49)	(50)	(49)	(50)
Amyloid Deposition				1 [4.0]
Ectasia	1 [3.0]	1 [3.0]	1 [3.0]	3 [3.7]
Hemorrhage		2 [2.5]	3 [3.0]	
Hyperplasia, Focal, Histiocytic	1 [2.0]			
Hyperplasia, Histiocytic	3 [3.0]	3 [3.0]		1 [3.0]
Hyperplasia, Lymphoid	2 [3.0]	1 [3.0]		1 [3.0]
Spleen	(48)	(49)	(49)	(50)
Amyloid Deposition		1 [3.0]		
Angiectasis, Focal		2 [3.0]	1 [3.0]	3 [2.3]
Atrophy				1 [2.0]
Congestion	1 [3.0]			1 [3.0]
Fibrosis, Focal		2 [3.0]	2 [3.0]	4 [2.8]
Hematopoietic Cell Proliferation	2 [2.5]	6 [2.3]	4 [2.5]	11 [2.5]
Hemorrhage	1 [3.0]	1 [2.0]		
Hyperplasia, Focal, Histiocytic	1 [3.0]	1 [2.0]	2 [2.0]	1 [3.0]
Infarct, Multiple				1 [3.0]
Metaplasia, Focal, Lipocyte			1 [2.0]	
Necrosis	1 [4.0]			
Pigmentation				1 [3.0]
Pigmentation, Focal			1 [3.0]	
Capsule, Accessory Spleen, Focal	1 [2.0]			
Capsule, Fibrosis, Focal				1 [2.0]
Lymphoid Follicle, Atrophy		1 [3.0]		
Thymus	(48)	(48)	(49)	(47)
Angiectasis			1 [3.0]	
Cyst		1 [2.0]		
Hemorrhage	1 [3.0]	2 [2.5]	3 [2.3]	
Hyperplasia, Lymphoid			2 [2.5]	1 [3.0]

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
INTEGUMENTARY SYSTEM				
Mammary Gland	(45)	(43)	(47)	(44)
Cyst				1 [3.0]
Dilatation	7 [2.7]	7 [2.7]	7 [2.1]	2 [2.5]
Hyperplasia		1 [2.0]	2 [2.5]	2 [3.0]
Inflammation, Chronic, Focal	1 [2.0]			1 [1.0]
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	3 [3.3]	1 [3.0]	3 [2.3]	1 [2.0]
Fibrosis, Focal		2 [3.0]		
Hyperkeratosis, Focal	1 [3.0]		1 [3.0]	
Inflammation, Chronic, Focal		2 [3.0]		
Ulcer		1 [3.0]		
Artery, Subcutaneous Tissue, Thrombosis		1 [3.0]		
Epidermis, Hyperplasia, Focal	1 [3.0]			
Lip, Inflammation, Chronic, Focal		1 [3.0]		
Subcutaneous Tissue, Cyst		1 [4.0]		
Subcutaneous Tissue, Cyst Epithelial Inclusion			1 [3.0]	
Subcutaneous Tissue, Hyperplasia, Focal, Histiocytic				1 [3.0]
Subcutaneous Tissue, Inflammation, Chronic, Focal		1 [3.0]		
Subcutaneous Tissue, Inflammation, Chronic, Focal, Suppurative			1 [3.0]	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Cranium, Hyperostosis		1 [2.0]		
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Compression, Focal	6 [3.2]	6 [2.8]	7 [3.0]	6 [3.0]
Hemorrhage, Focal	2 [2.5]	2 [3.5]	4 [1.3]	6 [2.7]
Cerebrum, Ventricle, Hydrocephalus		1 [2.0]		
RESPIRATORY SYSTEM				

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
RESPIRATORY SYSTEM - CONT				
Lung	(50)	(50)	(50)	(50)
Congestion	2 [2.0]	1 [3.0]	3 [3.0]	
Foreign Body, Focal	1 [2.0]			
Hemorrhage			1 [2.0]	
Hemorrhage, Focal	3 [1.3]	1 [2.0]	2 [2.0]	2 [2.0]
Hyperplasia, Focal, Histiocytic		1 [1.0]	1 [1.0]	
Hyperplasia, Histiocytic	2 [1.0]	1 [1.0]	1 [1.0]	2 [1.0]
Infiltration Cellular, Mixed Cell	1 [2.0]	3 [2.0]	1 [2.0]	2 [2.5]
Inflammation, Chronic, Focal	5 [2.2]	2 [1.0]	3 [1.3]	3 [1.7]
Inflammation, Focal, Suppurative		1 [3.0]		
Alveolar Epithelium, Hyperplasia, Focal	8 [1.9]	5 [1.6]	3 [2.0]	4 [2.8]
Alveolar Epithelium, Metaplasia, Squamous		1 [3.0]		
Alveolus, Edema, Focal			1 [2.0]	
Alveolus, Hyperplasia, Focal, Histiocytic	1 [3.0]			
Interstitium, Edema		1 [3.0]		1 [3.0]
Mediastinum, Edema		1 [3.0]	1 [3.0]	
Nose	(49)	(49)	(49)	(50)
Foreign Body		1 [2.0]	2 [2.0]	1 [2.0]
Inflammation, Chronic	1 [2.0]			
Inflammation, Suppurative	1 [2.0]	1 [3.0]	6 [2.0]	1 [2.0]
Nasolacrimal Duct, Inflammation	1 [1.0]	3 [2.0]		1 [2.0]
Olfactory Epithelium, Hyperplasia, Focal			1 [2.0]	
Respiratory Epithelium, Hyperplasia, Focal			1 [3.0]	
Trachea	(50)	(49)	(50)	(50)
Peritracheal Tissue, Edema		1 [3.0]		
SPECIAL SENSES SYSTEM				
Eye	(50)	(48)	(46)	(50)
Atrophy				2 [3.0]
Cataract		2 [2.5]	1 [3.0]	2 [2.5]
Exudate		1 [3.0]		
Cornea, Inflammation, Chronic			1 [3.0]	
Cornea, Retrobulbar, Inflammation, Chronic Active				1 [3.0]
Retina, Degeneration		2 [3.5]	1 [3.0]	2 [3.0]
Harderian Gland	(49)	(49)	(49)	(50)
Fibrosis, Focal				1 [2.0]
Hyperplasia, Focal, Histiocytic		1 [2.0]	1 [2.0]	1 [1.0]
Inflammation, Chronic, Focal		1 [3.0]	1 [1.0]	1 [2.0]
Inflammation, Chronic Active, Diffuse				1 [4.0]
Epithelium, Hyperplasia, Focal	1 [2.0]			

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FISCHER 344 RATS MALE	0 MG/L	125 MG/L	1000MG/L	2000MG/L
URINARY SYSTEM				
Kidney	(47)	(46)	(49)	(49)
Cyst			1 [2.0]	
Cyst, Multiple		1 [2.0]		
Hydronephrosis		1 [4.0]		
Infarct			1 [3.0]	
Infarct, Multiple	1 [4.0]	1 [3.0]		
Metaplasia, Focal, Lipocyte		1 [3.0]		
Nephropathy	45 [1.6]	44 [1.7]	48 [1.8]	47 [1.7]
Cortex, Medulla, Atrophy		1 [4.0]		
Pelvis, Infiltration Cellular, Mixed Cell				1 [2.0]
Pelvis, Transitional Epithelium, Hyperplasia		1 [2.0]	1 [2.0]	
Renal Tubule, Accumulation, Hyaline Droplet		1 [2.0]	4 [2.3]	2 [2.5]
Renal Tubule, Hyperplasia, Focal		1 [2.0]		
Renal Tubule, Pigmentation	4 [2.3]	4 [1.8]	1 [2.0]	4 [2.8]
Urinary Bladder	(48)	(49)	(47)	(50)
Calculus Micro Observation Only		1 [3.0]		
Edema				2 [3.0]
Hemorrhage			2 [2.0]	
Inflammation, Chronic			1 [4.0]	
Serosa, Inflammation, Focal				1 [2.0]
Transitional Epithelium, Hyperplasia, Diffuse		1 [2.0]		

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

END OF REPORT

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FINAL#1/MICE

Facility: Southern Research Institute

Chemical CAS #: 7775-09-9

Lock Date: 10/16/01

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Natural Death	10	10	12	7
Moribund Sacrifice	3	5	6	8
Accidently Killed	1			
Survivors				
Terminal Sacrifice	36	34	31	35
Moribund Sacrifice		1		
Other			1	
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(48)	(49)	(48)	(49)
Hemorrhage	1 (2%)			
Intestine Large, Cecum	(44)	(47)	(47)	(47)
Edema	4 (9%)	6 (13%)	6 (13%)	6 (13%)
Hemorrhage	1 (2%)			
Inflammation, Chronic			1 (2%)	
Ulcer			1 (2%)	
Intestine Small, Duodenum	(46)	(47)	(47)	(50)
Ulcer		1 (2%)	1 (2%)	
Epithelium, Hyperplasia			2 (4%)	
Intestine Small, Ileum	(42)	(45)	(46)	(47)
Inflammation, Chronic			1 (2%)	1 (2%)
Epithelium, Hyperplasia			1 (2%)	1 (2%)
Liver	(49)	(50)	(49)	(50)
Angiectasis	2 (4%)		2 (4%)	1 (2%)
Basophilic Focus	5 (10%)		4 (8%)	1 (2%)
Clear Cell Focus	3 (6%)		1 (2%)	
Eosinophilic Focus	9 (18%)	9 (18%)	13 (27%)	7 (14%)
Hematopoietic Cell Proliferation	7 (14%)	4 (8%)	3 (6%)	8 (16%)
Hemorrhage			1 (2%)	
Hepatodiaphragmatic Nodule		1 (2%)		
Hyperplasia, Lymphoid	4 (8%)	7 (14%)	3 (6%)	5 (10%)
Infarct		1 (2%)		
Infiltration Cellular, Mixed Cell	7 (14%)	7 (14%)	8 (16%)	7 (14%)
Mixed Cell Focus	7 (14%)	2 (4%)	3 (6%)	3 (6%)
Necrosis, Focal	5 (10%)	1 (2%)	4 (8%)	1 (2%)
Tension Lipidosis	2 (4%)	3 (6%)		1 (2%)

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Centrilobular, Necrosis	2 (4%)	2 (4%)	2 (4%)	2 (4%)
Hepatocyte, Karyomegaly				3 (6%)
Hepatocyte, Vacuolization Cytoplasmic	4 (8%)	3 (6%)	6 (12%)	4 (8%)
Kupffer Cell, Hyperplasia		1 (2%)	1 (2%)	2 (4%)
Kupffer Cell, Pigmentation	3 (6%)	4 (8%)	4 (8%)	7 (14%)
Mesentery	(30)	(32)	(27)	(24)
Angiectasis	1 (3%)			1 (4%)
Hemorrhage	1 (3%)			
Inflammation, Chronic				1 (4%)
Fat, Necrosis	21 (70%)	24 (75%)	20 (74%)	16 (67%)
Pancreas	(46)	(47)	(49)	(48)
Atrophy	2 (4%)	1 (2%)		1 (2%)
Cyst		1 (2%)	1 (2%)	
Acinus, Hyperplasia, Focal				1 (2%)
Salivary Glands	(48)	(47)	(49)	(50)
Hyperplasia, Lymphoid	16 (33%)	21 (45%)	15 (31%)	18 (36%)
Stomach, Forestomach	(49)	(50)	(50)	(49)
Diverticulum	2 (4%)	1 (2%)	1 (2%)	2 (4%)
Edema			3 (6%)	
Erosion		1 (2%)	2 (4%)	2 (4%)
Hyperplasia	1 (2%)			
Inflammation, Chronic Active			2 (4%)	2 (4%)
Ulcer	2 (4%)		3 (6%)	3 (6%)
Epithelium, Hyperplasia	3 (6%)	4 (8%)	9 (18%)	6 (12%)
Stomach, Glandular	(49)	(48)	(50)	(49)
Erosion		1 (2%)	2 (4%)	
Ulcer			1 (2%)	
CARDIOVASCULAR SYSTEM				
Blood Vessel	(1)	(3)		(1)
Aorta, Mineralization		1 (33%)		
Heart	(49)	(50)	(49)	(50)
Cardiomyopathy	1 (2%)	1 (2%)	1 (2%)	
Mineralization	1 (2%)		1 (2%)	2 (4%)
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(49)	(50)
Accessory Adrenal Cortical Nodule	4 (8%)	2 (4%)	7 (14%)	7 (14%)
Hyperplasia, Focal			1 (2%)	

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Capsule, Hyperplasia			1 (2%)	2 (4%)
Zona Reticularis, Vacuolization Cytoplasmic			1 (2%)	1 (2%)
Adrenal Medulla	(50)	(49)	(49)	(50)
Hyperplasia	2 (4%)		2 (4%)	1 (2%)
Islets, Pancreatic	(46)	(47)	(49)	(49)
Hyperplasia	9 (20%)	6 (13%)	4 (8%)	3 (6%)
Parathyroid Gland	(45)	(47)	(48)	(47)
Cyst	1 (2%)	1 (2%)	2 (4%)	2 (4%)
Pituitary Gland	(46)	(45)	(48)	(50)
Pars Distalis, Angiectasis	1 (2%)	2 (4%)	2 (4%)	
Pars Distalis, Cyst				1 (2%)
Pars Distalis, Hyperplasia, Focal	3 (7%)	3 (7%)	3 (6%)	1 (2%)
Thyroid Gland	(48)	(50)	(49)	(50)
Degeneration, Cystic	25 (52%)	28 (56%)	34 (69%)	32 (64%)
Follicle, Cyst	1 (2%)	1 (2%)		1 (2%)
Follicular Cell, Cyst				2 (4%)
Follicular Cell, Hypertrophy	3 (6%)	2 (4%)	5 (10%)	14 (28%)
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(47)	(47)	(47)	(49)
Inflammation, Chronic		2 (4%)		4 (8%)
Ovary	(45)	(45)	(47)	(50)
Angiectasis	3 (7%)	2 (4%)	4 (9%)	3 (6%)
Cyst	9 (20%)	14 (31%)	14 (30%)	13 (26%)
Cyst, Hemorrhagic	1 (2%)			
Hemorrhage	1 (2%)			
Thrombosis	3 (7%)	1 (2%)	1 (2%)	
Bilateral, Cyst		1 (2%)		
Follicle, Hemorrhage	1 (2%)	4 (9%)	4 (9%)	9 (18%)
Granulosa Cell, Hyperplasia			3 (6%)	7 (14%)
Uterus	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)		2 (4%)	1 (2%)
Hyperplasia, Atypical		1 (2%)		
Hyperplasia, Cystic	45 (90%)	45 (90%)	40 (80%)	41 (82%)
Inflammation, Chronic			2 (4%)	
Inflammation, Suppurative	1 (2%)			

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
GENITAL SYSTEM - CONT				
Metaplasia, Squamous		2 (4%)	1 (2%)	
Endometrium, Hyperplasia, Atypical		1 (2%)		
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	14 (28%)	28 (56%)	29 (58%)	31 (62%)
Myelofibrosis	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Lymph Node	(7)	(5)	(11)	(9)
Iliac, Hemorrhage			1 (9%)	
Iliac, Hyperplasia, Lymphoid	1 (14%)			1 (11%)
Mediastinal, Hyperplasia, Lymphoid	1 (14%)	1 (20%)	2 (18%)	
Mediastinal, Pigmentation	1 (14%)			
Pancreatic, Hemorrhage				1 (11%)
Renal, Hemorrhage	1 (14%)			1 (11%)
Lymph Node, Mandibular	(46)	(46)	(49)	(49)
Atrophy		1 (2%)		1 (2%)
Hematopoietic Cell Proliferation		1 (2%)	1 (2%)	1 (2%)
Hyperplasia, Lymphoid	12 (26%)	7 (15%)	7 (14%)	10 (20%)
Pigmentation	18 (39%)	16 (35%)	18 (37%)	15 (31%)
Lymph Node, Mesenteric	(47)	(49)	(49)	(49)
Atrophy	1 (2%)	1 (2%)		2 (4%)
Ectasia	2 (4%)			1 (2%)
Hematopoietic Cell Proliferation	2 (4%)	2 (4%)	1 (2%)	2 (4%)
Hemorrhage	4 (9%)	2 (4%)		1 (2%)
Hyperplasia, Lymphoid	10 (21%)	8 (16%)	11 (22%)	6 (12%)
Pigmentation	1 (2%)	2 (4%)		
Spleen	(49)	(48)	(49)	(50)
Accessory Spleen				1 (2%)
Hematopoietic Cell Proliferation	39 (80%)	39 (81%)	35 (71%)	39 (78%)
Hyperplasia, Lymphoid	11 (22%)	10 (21%)	5 (10%)	9 (18%)
Pigmentation	28 (57%)	30 (63%)	28 (57%)	27 (54%)
Lymphoid Follicle, Atrophy	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Thymus	(48)	(44)	(48)	(48)
Atrophy	5 (10%)	7 (16%)	5 (10%)	9 (19%)
Cyst	3 (6%)		1 (2%)	1 (2%)
Hyperplasia, Lymphoid	5 (10%)	3 (7%)	4 (8%)	2 (4%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
INTEGUMENTARY SYSTEM - CONT				
Hyperplasia	5 (10%)	11 (22%)	8 (16%)	10 (20%)
Skin	(48)	(50)	(50)	(50)
Edema		1 (2%)		1 (2%)
Epidermis, Hyperplasia	1 (2%)			1 (2%)
Subcutaneous Tissue, Edema			1 (2%)	2 (4%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Callus	1 (2%)			
Fracture			1 (2%)	1 (2%)
Hyperostosis	1 (2%)	1 (2%)	4 (8%)	3 (6%)
Cranium, Osteopetrosis			1 (2%)	
Femur, Osteopetrosis		1 (2%)	1 (2%)	
Skeletal Muscle		(2)	(4)	(6)
Angiectasis				1 (17%)
Atrophy				1 (17%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Compression	1 (2%)		1 (2%)	1 (2%)
Inflammation, Chronic				1 (2%)
Necrosis			1 (2%)	1 (2%)
Peripheral Nerve			(2)	(2)
Atrophy			1 (50%)	2 (100%)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(49)	(50)
Edema	5 (10%)	8 (16%)	3 (6%)	5 (10%)
Foreign Body	2 (4%)			
Hemorrhage	5 (10%)	8 (16%)	6 (12%)	4 (8%)
Hyperplasia, Lymphoid	10 (20%)	8 (16%)	3 (6%)	9 (18%)
Infiltration Cellular, Polymorphonuclear		1 (2%)		
Infiltration Cellular, Histiocyte	1 (2%)	1 (2%)	3 (6%)	5 (10%)
Metaplasia, Osseous		1 (2%)	2 (4%)	
Thrombosis	1 (2%)	4 (8%)	1 (2%)	
Alveolar Epithelium, Hyperplasia	2 (4%)	2 (4%)	1 (2%)	2 (4%)

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
SPECIAL SENSES SYSTEM				
Eye	(50)	(48)	(50)	(50)
Inflammation, Chronic	3 (6%)	3 (6%)		
Cornea, Hyperplasia	2 (4%)	1 (2%)		
Harderian Gland	(50)	(50)	(50)	(49)
Cyst				1 (2%)
Hyperplasia, Focal	1 (2%)	1 (2%)		1 (2%)
URINARY SYSTEM				
Kidney	(50)	(49)	(49)	(50)
Hydronephrosis			1 (2%)	1 (2%)
Hyperplasia, Lymphoid	8 (16%)	9 (18%)	6 (12%)	8 (16%)
Infarct	3 (6%)	2 (4%)	4 (8%)	5 (10%)
Metaplasia, Osseous		1 (2%)	3 (6%)	2 (4%)
Nephropathy	14 (28%)	11 (22%)	14 (29%)	12 (24%)
Renal Tubule, Accumulation, Hyaline Droplet	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Renal Tubule, Dilatation	1 (2%)			1 (2%)
Renal Tubule, Necrosis	1 (2%)			1 (2%)
Renal Tubule, Pigmentation	3 (6%)	1 (2%)		1 (2%)
Transitional Epithelium, Hyperplasia	1 (2%)			
Urinary Bladder	(49)	(50)	(50)	(50)
Hyperplasia, Lymphoid	4 (8%)	12 (24%)	4 (8%)	5 (10%)
Transitional Epithelium, Hyperplasia			1 (2%)	

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Natural Death	7	4	5	7
Moribund Sacrifice	5	5	4	10
Survivors				
Terminal Sacrifice	38	41	41	33
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Cecum	(47)	(49)	(49)	(48)
Edema	1 (2%)	3 (6%)	4 (8%)	2 (4%)
Inflammation, Chronic		1 (2%)		1 (2%)
Intestine Small, Duodenum	(48)	(50)	(49)	(49)
Ulcer		1 (2%)	1 (2%)	
Epithelium, Hyperplasia			1 (2%)	1 (2%)
Intestine Small, Jejunum	(47)	(49)	(50)	(50)
Epithelium, Hyperplasia				2 (4%)
Intestine Small, Ileum	(47)	(49)	(49)	(49)
Cyst		1 (2%)		
Liver	(48)	(50)	(50)	(50)
Angiectasis	2 (4%)	2 (4%)		
Basophilic Focus		2 (4%)	3 (6%)	4 (8%)
Clear Cell Focus	12 (25%)	19 (38%)	19 (38%)	13 (26%)
Cyst			1 (2%)	1 (2%)
Eosinophilic Focus	11 (23%)	10 (20%)	5 (10%)	11 (22%)
Hematopoietic Cell Proliferation	1 (2%)			4 (8%)
Hemorrhage	1 (2%)	1 (2%)		
Hyperplasia, Lymphoid		1 (2%)	1 (2%)	
Infarct			1 (2%)	
Infiltration Cellular, Mixed Cell	2 (4%)	1 (2%)	1 (2%)	
Mixed Cell Focus	2 (4%)	9 (18%)	8 (16%)	7 (14%)
Necrosis, Focal	4 (8%)	6 (12%)	7 (14%)	6 (12%)
Regeneration, Focal			1 (2%)	
Tension Lipidosis	1 (2%)		1 (2%)	
Bile Duct, Hyperplasia				2 (4%)
Centrilobular, Necrosis	1 (2%)			2 (4%)
Hepatocyte, Karyomegaly			1 (2%)	1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	2 (4%)			3 (6%)
Kupffer Cell, Pigmentation	2 (4%)		1 (2%)	

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Mesentery	(9)	(10)	(10)	(8)
Infarct			1 (10%)	
Inflammation, Chronic	1 (11%)			2 (25%)
Fat, Necrosis	3 (33%)	8 (80%)	6 (60%)	5 (63%)
Pancreas	(48)	(50)	(50)	(50)
Cyst				2 (4%)
Acinus, Cytoplasmic Alteration			1 (2%)	1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	2 (4%)
Hyperplasia, Lymphoid	7 (14%)	3 (6%)	6 (12%)	4 (8%)
Stomach, Forestomach	(49)	(50)	(50)	(50)
Cyst	2 (4%)			
Diverticulum	1 (2%)	1 (2%)		2 (4%)
Erosion		1 (2%)		
Inflammation, Chronic Active	2 (4%)	2 (4%)	4 (8%)	2 (4%)
Ulcer	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Epithelium, Hyperplasia	3 (6%)	7 (14%)	2 (4%)	4 (8%)
Stomach, Glandular	(48)	(50)	(50)	(50)
Cyst	1 (2%)	2 (4%)	1 (2%)	
Ulcer				1 (2%)
Tooth	(2)	(4)	(1)	(3)
Malformation	2 (100%)	4 (100%)		2 (67%)
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy				2 (4%)
Inflammation, Chronic	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Mineralization	1 (2%)			2 (4%)
Thrombosis			1 (2%)	1 (2%)
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	6 (12%)	5 (10%)	3 (6%)	5 (10%)
Degeneration, Fatty	1 (2%)	1 (2%)		2 (4%)
Hyperplasia, Focal	4 (8%)	6 (12%)	7 (14%)	9 (18%)
Hypertrophy	1 (2%)			
Hypertrophy, Focal	9 (18%)	16 (32%)	11 (22%)	11 (22%)
Capsule, Hyperplasia	5 (10%)	3 (6%)	1 (2%)	8 (16%)
Adrenal Medulla	(49)	(48)	(49)	(49)

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Hyperplasia	1 (2%)	1 (2%)	1 (2%)	
Islets, Pancreatic	(48)	(50)	(50)	(50)
Hyperplasia	31 (65%)	25 (50%)	28 (56%)	23 (46%)
Parathyroid Gland	(46)	(48)	(47)	(49)
Cyst		1 (2%)	2 (4%)	1 (2%)
Pituitary Gland	(47)	(47)	(45)	(49)
Pars Distalis, Cyst	1 (2%)	1 (2%)	2 (4%)	5 (10%)
Pars Intermedia, Cyst	1 (2%)			
Thyroid Gland	(48)	(50)	(48)	(50)
Degeneration, Cystic	13 (27%)	17 (34%)	14 (29%)	15 (30%)
Follicular Cell, Hypertrophy	2 (4%)		1 (2%)	2 (4%)
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Atypia Cellular	1 (2%)	6 (12%)	4 (8%)	3 (6%)
Granuloma Sperm		1 (2%)		1 (2%)
Inflammation, Chronic		1 (2%)	1 (2%)	1 (2%)
Preputial Gland	(50)	(50)	(50)	(50)
Cyst	22 (44%)	26 (52%)	15 (30%)	29 (58%)
Inflammation, Chronic	28 (56%)	27 (54%)	18 (36%)	21 (42%)
Prostate	(50)	(50)	(50)	(50)
Inflammation, Chronic	1 (2%)	4 (8%)	3 (6%)	5 (10%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Degeneration		1 (2%)		2 (4%)
Dilatation			1 (2%)	
Inflammation, Chronic	3 (6%)		1 (2%)	
Testes	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)			1 (2%)
Atrophy		1 (2%)	1 (2%)	1 (2%)
Necrosis				1 (2%)
Germinal Epithelium, Atrophy	1 (2%)	5 (10%)	3 (6%)	4 (8%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(50)	(50)

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - CONT				
Hyperplasia	21 (43%)	12 (24%)	13 (26%)	15 (30%)
Lymph Node	(3)		(1)	(3)
Mediastinal, Hemorrhage				1 (33%)
Lymph Node, Mandibular	(49)	(48)	(45)	(49)
Atrophy	1 (2%)			1 (2%)
Hyperplasia, Lymphoid	14 (29%)	14 (29%)	16 (36%)	16 (33%)
Pigmentation	7 (14%)	10 (21%)	9 (20%)	9 (18%)
Lymph Node, Mesenteric	(47)	(50)	(50)	(50)
Atrophy	2 (4%)	1 (2%)		1 (2%)
Hematopoietic Cell Proliferation	2 (4%)		4 (8%)	1 (2%)
Hemorrhage	4 (9%)	6 (12%)	2 (4%)	4 (8%)
Hyperplasia, Lymphoid	11 (23%)	6 (12%)	6 (12%)	9 (18%)
Spleen	(48)	(50)	(50)	(50)
Depletion Lymphoid				1 (2%)
Hematopoietic Cell Proliferation	21 (44%)	17 (34%)	18 (36%)	21 (42%)
Hyperplasia, Lymphoid	8 (17%)	9 (18%)	10 (20%)	8 (16%)
Pigmentation		3 (6%)	1 (2%)	1 (2%)
Lymphoid Follicle, Atrophy	1 (2%)		1 (2%)	3 (6%)
Thymus	(43)	(43)	(40)	(44)
Atrophy	11 (26%)	13 (30%)	4 (10%)	13 (30%)
Cyst	1 (2%)	3 (7%)	4 (10%)	4 (9%)
Hyperplasia, Lymphoid	2 (5%)	1 (2%)		
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	1 (2%)			
Edema				3 (6%)
Inflammation, Chronic			1 (2%)	1 (2%)
Ulcer	2 (4%)			
Epidermis, Hyperplasia	1 (2%)			1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fracture	1 (2%)	1 (2%)		2 (4%)
Hyperostosis	1 (2%)	1 (2%)		
Skeletal Muscle	(3)	(1)	(3)	(2)
Atrophy		1 (100%)		
Infiltration Cellular, Lipocyte	1 (33%)			

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
NERVOUS SYSTEM				
Peripheral Nerve		(1)	(2)	(1)
Atrophy		1 (100%)		
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Edema	6 (12%)	11 (22%)	7 (14%)	8 (16%)
Foreign Body	1 (2%)			1 (2%)
Hemorrhage	5 (10%)	3 (6%)	4 (8%)	5 (10%)
Hyperplasia, Lymphoid	4 (8%)	5 (10%)	7 (14%)	6 (12%)
Infiltration Cellular, Histiocyte	8 (16%)	5 (10%)	9 (18%)	10 (20%)
Metaplasia, Osseous		2 (4%)		
Alveolar Epithelium, Hyperplasia	2 (4%)	3 (6%)	1 (2%)	5 (10%)
Nose	(50)	(50)	(50)	(50)
Foreign Body	1 (2%)	1 (2%)		2 (4%)
Inflammation, Chronic	1 (2%)	2 (4%)	1 (2%)	5 (10%)
Respiratory Epithelium, Hyperplasia	1 (2%)	1 (2%)		
SPECIAL SENSES SYSTEM				
Eye	(49)	(50)	(50)	(50)
Cataract		1 (2%)		
Inflammation, Chronic			3 (6%)	
Harderian Gland	(50)	(50)	(50)	(49)
Hyperplasia, Focal	1 (2%)			1 (2%)
Inflammation, Chronic	1 (2%)	3 (6%)	3 (6%)	2 (4%)
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Cyst	14 (29%)	10 (20%)	9 (18%)	10 (20%)
Hydronephrosis	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Hyperplasia, Lymphoid	8 (16%)	6 (12%)	4 (8%)	11 (22%)
Infarct	5 (10%)	1 (2%)	4 (8%)	5 (10%)
Inflammation, Chronic		1 (2%)		1 (2%)
Metaplasia, Osseous	7 (14%)	5 (10%)	3 (6%)	4 (8%)
Nephropathy	37 (76%)	42 (84%)	43 (86%)	36 (72%)
Renal Tubule, Accumulation, Hyaline Droplet		1 (2%)	1 (2%)	

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
URINARY SYSTEM - CONT				
Renal Tubule, Dilatation	1 (2%)	2 (4%)		3 (6%)
Renal Tubule, Hyperplasia	1 (2%)	1 (2%)		1 (2%)
Renal Tubule, Necrosis	1 (2%)			2 (4%)
Renal Tubule, Pigmentation		2 (4%)	1 (2%)	1 (2%)
Urethra			(1)	
Angiectasis			1 (100%)	
Urinary Bladder	(49)	(50)	(50)	(50)
Edema	1 (2%)			1 (2%)
Hyperplasia, Lymphoid		1 (2%)	1 (2%)	
Inflammation, Chronic				1 (2%)
Transitional Epithelium, Hyperplasia		2 (4%)		1 (2%)

a Number of animals examined microscopically at site and number of animals with lesion

END OF REPORT

FINAL#1/MICE

Facility: Southern Research Institute

Chemical CAS #: 7775-09-9

Lock Date: 10/16/01

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially in Study	50	50	50	50
Early Deaths				
Natural Death	10	10	12	7
Moribund Sacrifice	3	5	6	8
Accidently Killed	1			
Survivors				
Terminal Sacrifice	36	34	31	35
Moribund Sacrifice		1		
Other			1	
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(49)	(50)	(50)	(50)
Gallbladder	(40)	(44)	(44)	(48)
Intestine Large, Cecum	(44)	(47)	(47)	(47)
Hemangioma			1 (2%)	
Intestine Small, Duodenum	(46)	(47)	(47)	(50)
Adenoma		1 (2%)		
Polyp Adenomatous				1 (2%)
Intestine Small, Jejunum	(45)	(47)	(47)	(47)
Histiocytic Sarcoma			1 (2%)	
Intestine Small, Ileum	(42)	(45)	(46)	(47)
Liver	(49)	(50)	(49)	(50)
Hemangioma	2 (4%)			
Hemangiosarcoma	1 (2%)	2 (4%)		
Hemangiosarcoma, Metastatic, Spleen		1 (2%)		
Hepatoblastoma	1 (2%)			
Hepatocellular Carcinoma	2 (4%)	6 (12%)	11 (22%)	6 (12%)
Hepatocellular Carcinoma, Multiple	1 (2%)	7 (14%)	4 (8%)	3 (6%)
Hepatocellular Adenoma	15 (31%)	9 (18%)	14 (29%)	8 (16%)
Hepatocellular Adenoma, Multiple	15 (31%)	10 (20%)	12 (24%)	15 (30%)
Histiocytic Sarcoma			1 (2%)	1 (2%)
Mesentery	(30)	(32)	(27)	(24)
Fibrosarcoma			1 (4%)	
Fibrous Histiocytoma	1 (3%)			
Hemangiosarcoma				1 (4%)
Hepatocellular Carcinoma, Metastatic, Liver			1 (4%)	
Histiocytic Sarcoma			1 (4%)	

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - cont				
Sarcoma, Metastatic, Skin				1 (4%)
Schwannoma Malignant, Metastatic, Skin	1 (3%)			
Oral Mucosa	(2)			(1)
Squamous Cell Carcinoma	1 (50%)			
Squamous Cell Papilloma				1 (100%)
Pancreas	(46)	(47)	(49)	(48)
Fibrosarcoma, Metastatic, Mesentery			1 (2%)	
Histiocytic Sarcoma			1 (2%)	
Sarcoma, Metastatic, Skin				1 (2%)
Acinus, Sarcoma			1 (2%)	
Salivary Glands	(48)	(47)	(49)	(50)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Histiocytic Sarcoma			1 (2%)	
Stomach, Forestomach	(49)	(50)	(50)	(49)
Squamous Cell Carcinoma		1 (2%)	1 (2%)	
Squamous Cell Papilloma			1 (2%)	1 (2%)
Squamous Cell Papilloma, Multiple			1 (2%)	
Stomach, Glandular	(49)	(48)	(50)	(49)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Tongue			(2)	
CARDIOVASCULAR SYSTEM				
Heart	(49)	(50)	(49)	(50)
Hemangiosarcoma, Metastatic, Spleen		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(49)	(50)
Histiocytic Sarcoma			1 (2%)	
Osteosarcoma, Metastatic, Bone			1 (2%)	
Subcapsular, Adenoma	1 (2%)			
Adrenal Medulla	(50)	(49)	(49)	(50)
Pheochromocytoma Malignant	2 (4%)			
Pheochromocytoma Complex				1 (2%)
Pheochromocytoma Benign	1 (2%)			1 (2%)
Islets, Pancreatic	(46)	(47)	(49)	(49)
Adenoma		2 (4%)	2 (4%)	3 (6%)
Carcinoma				1 (2%)
Pituitary Gland	(46)	(45)	(48)	(50)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - cont				
Histiocytic Sarcoma			1 (2%)	
Pars Distalis, Adenoma	3 (7%)	2 (4%)	4 (8%)	4 (8%)
Thyroid Gland	(48)	(50)	(49)	(50)
Follicular Cell, Adenoma	1 (2%)			
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(47)	(47)	(47)	(49)
Ovary	(45)	(45)	(47)	(50)
Choriocarcinoma			2 (4%)	
Cystadenoma	1 (2%)	4 (9%)	1 (2%)	1 (2%)
Granulosa Cell Tumor Malignant				1 (2%)
Granulosa Cell Tumor Benign	1 (2%)	1 (2%)	1 (2%)	5 (10%)
Histiocytic Sarcoma			2 (4%)	1 (2%)
Luteoma	3 (7%)		1 (2%)	
Yolk Sac Carcinoma				1 (2%)
Uterus	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Histiocytic Sarcoma			2 (4%)	1 (2%)
Leiomyosarcoma			1 (2%)	
Polyp Stromal	1 (2%)			3 (6%)
Yolk Sac Carcinoma, Metastatic, Ovary				1 (2%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)	2 (4%)	
Histiocytic Sarcoma				1 (2%)
Lymph Node	(7)	(5)	(11)	(9)
Histiocytic Sarcoma			1 (9%)	
Liposarcoma, Metastatic, Skin		1 (20%)		
Iliac, Histiocytic Sarcoma			2 (18%)	
Iliac, Liposarcoma, Metastatic, Skin		1 (20%)		
Mediastinal, Sarcoma, Metastatic, Pancreas			1 (9%)	
Pancreatic, Histiocytic Sarcoma			1 (9%)	
Renal, Histiocytic Sarcoma			1 (9%)	1 (11%)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - cont				
Lymph Node, Mandibular	(46)	(46)	(49)	(49)
Histiocytic Sarcoma			2 (4%)	
Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
Lymph Node, Mesenteric	(47)	(49)	(49)	(49)
Histiocytic Sarcoma		1 (2%)	2 (4%)	
Histiocytic Sarcoma, Metastatic, Mesentery			1 (2%)	
Yolk Sac Carcinoma, Metastatic, Ovary				1 (2%)
Spleen	(49)	(48)	(49)	(50)
Hemangiosarcoma	2 (4%)	1 (2%)	1 (2%)	
Histiocytic Sarcoma			2 (4%)	
Sarcoma, Metastatic, Skin				1 (2%)
Thymus	(48)	(44)	(48)	(48)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Histiocytic Sarcoma			1 (2%)	1 (2%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Adenoma			1 (2%)	
Carcinoma		1 (2%)		
Skin	(48)	(50)	(50)	(50)
Hemangioma		1 (2%)		
Squamous Cell Carcinoma			1 (2%)	
Subcutaneous Tissue, Fibrosarcoma		1 (2%)		2 (4%)
Subcutaneous Tissue, Hemangioma				1 (2%)
Subcutaneous Tissue, Hemangiosarcoma			1 (2%)	
Subcutaneous Tissue, Liposarcoma		1 (2%)		
Subcutaneous Tissue, Sarcoma				1 (2%)
Subcutaneous Tissue, Schwannoma Malignant	3 (6%)	1 (2%)		1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma		1 (2%)	1 (2%)	2 (4%)
Sarcoma			1 (2%)	
Skeletal Muscle		(2)	(4)	(6)
Histiocytic Sarcoma, Metastatic, Mesentery			1 (25%)	
Rhabdomyosarcoma		1 (50%)	1 (25%)	2 (33%)
Sarcoma, Metastatic, Pancreas			1 (25%)	
Sarcoma, Metastatic, Skin				1 (17%)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
MUSCULOSKELETAL SYSTEM - cont				
Yolk Sac Carcinoma, Metastatic, Ovary				1 (17%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Osteosarcoma, Metastatic, Bone			1 (2%)	
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Adenoma	3 (6%)	1 (2%)		3 (6%)
Alveolar/Bronchiolar Carcinoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	3 (6%)	5 (10%)	2 (4%)
Histiocytic Sarcoma			1 (2%)	1 (2%)
Liposarcoma, Metastatic, Skin		1 (2%)		
Osteosarcoma, Metastatic, Bone			1 (2%)	
Sarcoma, Metastatic, Skin				1 (2%)
Nose	(50)	(50)	(50)	(50)
Carcinoma	1 (2%)			
Histiocytic Sarcoma			1 (2%)	
SPECIAL SENSES SYSTEM				
Eye	(50)	(48)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(49)
Adenoma	11 (22%)	9 (18%)	5 (10%)	6 (12%)
Carcinoma	1 (2%)	1 (2%)		
Histiocytic Sarcoma			1 (2%)	
URINARY SYSTEM				
Kidney	(50)	(49)	(49)	(50)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Histiocytic Sarcoma			1 (2%)	
Osteosarcoma, Metastatic, Bone			1 (2%)	
Urinary Bladder	(49)	(50)	(50)	(50)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		1 (2%)	4 (8%)	2 (4%)
Leukemia Granulocytic			1 (2%)	
Lymphoma Malignant	23 (46%)	19 (38%)	28 (56%)	27 (54%)

* Number of animals with any tissue examined microscopically

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
TUMOR SUMMARY				
Total Animals with Primary Neoplasms (b)	47	45	46	47
Total Primary Neoplasms	99	87	108	105
Total Animals with Benign Neoplasms	38	27	33	31
Total Benign Neoplasms	58	40	44	53
Total Animals with Malignant Neoplasms	33	38	41	41
Total Malignant Neoplasms	41	47	64	52
Total Animals with Metastatic Neoplasms	2	5	10	5
Total Metastatic Neoplasm	2	8	20	11
Total Animals with Malignant Neoplasms Uncertain Primary Site				1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially in Study	50	50	50	50
Early Deaths				
Natural Death	7	4	5	7
Moribund Sacrifice	5	5	4	10
Survivors				
Terminal Sacrifice	38	41	41	33
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(48)	(50)	(50)	(50)
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Intestine Large, Cecum	(47)	(49)	(49)	(48)
Carcinoma				1 (2%)
Histiocytic Sarcoma				1 (2%)
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Intestine Small, Duodenum	(48)	(50)	(49)	(49)
Adenoma	1 (2%)			
Carcinoma				1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic				1 (2%)
Polyp Adenomatous			2 (4%)	
Intestine Small, Jejunum	(47)	(49)	(50)	(50)
Adenoma			1 (2%)	1 (2%)
Carcinoma	2 (4%)	2 (4%)		2 (4%)
Liver	(48)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic				1 (2%)
Cholangiocarcinoma	1 (2%)		1 (2%)	
Hemangioma			1 (2%)	
Hemangiosarcoma	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Hepatoblastoma	5 (10%)	3 (6%)	1 (2%)	3 (6%)
Hepatoblastoma, Multiple	1 (2%)			
Hepatocellular Carcinoma	14 (29%)	13 (26%)	14 (28%)	12 (24%)
Hepatocellular Carcinoma, Multiple	6 (13%)	1 (2%)	5 (10%)	1 (2%)
Hepatocellular Adenoma	16 (33%)	15 (30%)	13 (26%)	14 (28%)
Hepatocellular Adenoma, Multiple	14 (29%)	17 (34%)	23 (46%)	16 (32%)
Histiocytic Sarcoma	1 (2%)		2 (4%)	2 (4%)
Ito Cell Tumor Malignant		1 (2%)		
Leiomyosarcoma, Metastatic, Mesentery	1 (2%)			

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - cont				
Mesentery	(9)	(10)	(10)	(8)
Cholangiocarcinoma, Metastatic, Liver	1 (11%)			
Hepatocellular Carcinoma, Metastatic, Liver			1 (10%)	1 (13%)
Histiocytic Sarcoma				2 (25%)
Histiocytic Sarcoma, Metastatic, Liver	1 (11%)			
Ito Cell Tumor Malignant, Metastatic, Liver		1 (10%)		
Leiomyosarcoma	1 (11%)			
Liposarcoma			1 (10%)	
Pancreas	(48)	(50)	(50)	(50)
Cholangiocarcinoma, Metastatic, Liver	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)		1 (2%)	
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)
Histiocytic Sarcoma				1 (2%)
Stomach, Forestomach	(49)	(50)	(50)	(50)
Leiomyosarcoma, Metastatic, Mesentery	1 (2%)			
Squamous Cell Papilloma			2 (4%)	2 (4%)
Stomach, Glandular	(48)	(50)	(50)	(50)
Adenoma		2 (4%)		
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Leiomyosarcoma, Metastatic, Mesentery	1 (2%)			
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cholangiocarcinoma, Metastatic, Liver	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Adenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Bilateral, Subcapsular, Adenoma	1 (2%)			
Subcapsular, Adenoma	1 (2%)	3 (6%)	4 (8%)	2 (4%)
Islets, Pancreatic	(48)	(50)	(50)	(50)
Adenoma	1 (2%)			1 (2%)
Carcinoma				1 (2%)
Pituitary Gland	(47)	(47)	(45)	(49)
Pars Distalis, Adenoma		1 (2%)		

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Cholangiocarcinoma, Metastatic, Liver			1 (2%)	
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Prostate	(50)	(50)	(50)	(50)
Seminal Vesicle	(50)	(50)	(50)	(50)
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma				2 (4%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(50)	(50)
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Histiocytic Sarcoma				1 (2%)
Lymph Node	(3)		(1)	(3)
Mediastinal, Carcinoma, Metastatic, Harderian Gland				1 (33%)
Mediastinal, Hepatocellular Carcinoma, Metastatic, Liver			1 (100%)	1 (33%)
Mediastinal, Histiocytic Sarcoma, Metastatic, Liver	1 (33%)			
Mediastinal, Leiomyosarcoma, Metastatic, Mesentery	1 (33%)			
Pancreatic, Hepatocellular Carcinoma, Metastatic, Liver			1 (100%)	
Pancreatic, Histiocytic Sarcoma, Metastatic, Liver	1 (33%)			
Renal, Hepatocellular Carcinoma, Metastatic, Liver			1 (100%)	
Renal, Histiocytic Sarcoma, Metastatic, Liver	1 (33%)			
Renal, Leiomyosarcoma, Metastatic, Mesentery	1 (33%)			
Lymph Node, Mandibular	(49)	(48)	(45)	(49)
Histiocytic Sarcoma				1 (2%)
Lymph Node, Mesenteric	(47)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - cont				
Histiocytic Sarcoma				1 (2%)
Leiomyosarcoma, Metastatic, Mesentery	1 (2%)			
Spleen	(48)	(50)	(50)	(50)
Hemangiosarcoma			1 (2%)	
Histiocytic Sarcoma			1 (2%)	1 (2%)
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Leiomyosarcoma, Metastatic, Mesentery	1 (2%)			
Thymus	(43)	(43)	(40)	(44)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (3%)	
Hepatocellular Carcinoma, Metastatic, Liver			1 (3%)	
Leiomyosarcoma, Metastatic, Mesentery	1 (2%)			
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Subcutaneous Tissue, Fibrous Histiocytoma			1 (2%)	
Subcutaneous Tissue, Lipoma			1 (2%)	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
Skeletal Muscle	(3)	(1)	(3)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			2 (67%)	
Hepatocellular Carcinoma, Metastatic, Liver				1 (50%)
Histiocytic Sarcoma, Metastatic, Liver	1 (33%)			
Leiomyosarcoma, Metastatic, Mesentery	1 (33%)			
Rhabdomyosarcoma				1 (50%)
NERVOUS SYSTEM				
None				

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	6 (12%)	4 (8%)	7 (14%)	6 (12%)
Alveolar/Bronchiolar Carcinoma	4 (8%)	5 (10%)	6 (12%)	4 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)	
Carcinoma, Metastatic, Harderian Gland				1 (2%)
Carcinoma, Metastatic, Kidney			1 (2%)	
Hemangiosarcoma				1 (2%)
Hepatoblastoma, Metastatic, Liver	1 (2%)	2 (4%)		
Hepatocellular Carcinoma, Metastatic, Liver	9 (18%)	2 (4%)	4 (8%)	6 (12%)
Histiocytic Sarcoma			1 (2%)	1 (2%)
Histiocytic Sarcoma, Metastatic, Liver	1 (2%)			
Leiomyosarcoma, Metastatic, Mesentery	1 (2%)			
SPECIAL SENSES SYSTEM				
Harderian Gland	(50)	(50)	(50)	(49)
Adenoma	6 (12%)	4 (8%)	4 (8%)	6 (12%)
Carcinoma			1 (2%)	1 (2%)
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Renal Tubule, Adenoma		1 (2%)		
Renal Tubule, Carcinoma			1 (2%)	
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)		2 (4%)	3 (6%)
Lymphoma Malignant	3 (6%)	1 (2%)		3 (6%)

* Number of animals with any tissue examined microscopically

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
TUMOR SUMMARY				
Total Animals with Primary Neoplasms (b)	45	45	47	45
Total Primary Neoplasms	86	76	95	87
Total Animals with Benign Neoplasms	34	38	37	34
Total Benign Neoplasms	47	48	59	51
Total Animals with Malignant Neoplasms	29	22	30	27
Total Malignant Neoplasms	39	28	36	36
Total Animals with Metastatic Neoplasms	12	5	9	8
Total Metastatic Neoplasm	38	5	20	14
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors

END OF REPORT

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

FINAL#1/MICE

Facility: Southern Research Institute

Chemical CAS #: 7775-09-9

Lock Date: 10/16/01

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Natural Death	10	10	12	7
Moribund Sacrifice	3	5	6	8
Accidently Killed	1			
Survivors				
Terminal Sacrifice	36	34	31	35
Moribund Sacrifice		1		
Other			1	
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Colon	(48)	(49)	(48)	(49)
Hemorrhage	1 [3.0]			
Intestine Large, Cecum	(44)	(47)	(47)	(47)
Edema	4 [2.0]	6 [2.0]	6 [2.2]	6 [1.8]
Hemorrhage	1 [4.0]			
Inflammation, Chronic			1 [3.0]	
Ulcer			1 [3.0]	
Intestine Small, Duodenum	(46)	(47)	(47)	(50)
Ulcer		1 [4.0]	1 [2.0]	
Epithelium, Hyperplasia			2 [2.5]	
Intestine Small, Ileum	(42)	(45)	(46)	(47)
Inflammation, Chronic			1 [2.0]	1 [3.0]
Epithelium, Hyperplasia			1 [2.0]	1 [2.0]
Liver	(49)	(50)	(49)	(50)
Angiectasis	2 [2.0]		2 [3.5]	1 [3.0]
Basophilic Focus	5		4	1
Clear Cell Focus	3		1	
Eosinophilic Focus	9	9	13	7
Hematopoietic Cell Proliferation	7 [2.1]	4 [2.5]	3 [2.7]	8 [2.3]
Hemorrhage			1 [2.0]	
Hepatodiaphragmatic Nodule		1		
Hyperplasia, Lymphoid	4 [2.0]	7 [2.1]	3 [2.0]	5 [2.0]
Infarct		1 [3.0]		
Infiltration Cellular, Mixed Cell	7 [1.9]	7 [1.6]	8 [1.9]	7 [2.1]
Mixed Cell Focus	7	2	3	3
Necrosis, Focal	5 [1.8]	1 [1.0]	4 [2.0]	1 [3.0]
Tension Lipidosis	2	3		1

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Centrilobular, Necrosis	2 [2.5]	2 [3.5]	2 [2.5]	2 [3.0]
Hepatocyte, Karyomegaly				3 [2.3]
Hepatocyte, Vacuolization Cytoplasmic	4 [3.3]	3 [3.3]	6 [3.0]	4 [3.5]
Kupffer Cell, Hyperplasia		1 [3.0]	1 [2.0]	2 [3.0]
Kupffer Cell, Pigmentation	3 [2.0]	4 [2.3]	4 [1.8]	7 [2.3]
Mesentery	(30)	(32)	(27)	(24)
Angiectasis	1 [3.0]			1 [3.0]
Hemorrhage	1 [4.0]			
Inflammation, Chronic				1 [3.0]
Fat, Necrosis	21 [3.0]	24 [3.1]	20 [3.6]	16 [3.3]
Pancreas	(46)	(47)	(49)	(48)
Atrophy	2 [2.5]	1 [4.0]		1 [1.0]
Cyst		1 [3.0]	1 [3.0]	
Acinus, Hyperplasia, Focal				1 [2.0]
Salivary Glands	(48)	(47)	(49)	(50)
Hyperplasia, Lymphoid	16 [2.3]	21 [2.2]	15 [2.4]	18 [2.3]
Stomach, Forestomach	(49)	(50)	(50)	(49)
Diverticulum	2	1	1	2
Edema			3 [2.7]	
Erosion		1 [2.0]	2 [2.5]	2 [1.5]
Hyperplasia	1 [1.0]			
Inflammation, Chronic Active			2 [1.5]	2 [2.0]
Ulcer	2 [2.5]		3 [2.3]	3 [2.3]
Epithelium, Hyperplasia	3 [2.3]	4 [2.0]	9 [2.4]	6 [2.2]
Stomach, Glandular	(49)	(48)	(50)	(49)
Erosion		1 [3.0]	2 [2.5]	
Ulcer			1 [3.0]	
CARDIOVASCULAR SYSTEM				
Blood Vessel	(1)	(3)		(1)
Aorta, Mineralization		1 [4.0]		
Heart	(49)	(50)	(49)	(50)
Cardiomyopathy	1 [2.0]	1 [2.0]	1 [2.0]	
Mineralization	1 [2.0]		1 [2.0]	2 [3.5]
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(49)	(50)
Accessory Adrenal Cortical Nodule	4 [3.0]	2 [3.0]	7 [3.0]	7 [3.0]
Hyperplasia, Focal			1 [2.0]	

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Capsule, Hyperplasia			1 [2.0]	2 [2.0]
Zona Reticularis, Vacuolization Cytoplasmic			1 [3.0]	1 [3.0]
Adrenal Medulla	(50)	(49)	(49)	(50)
Hyperplasia	2 [1.0]		2 [1.5]	1 [1.0]
Islets, Pancreatic	(46)	(47)	(49)	(49)
Hyperplasia	9 [1.7]	6 [2.0]	4 [2.3]	3 [2.0]
Parathyroid Gland	(45)	(47)	(48)	(47)
Cyst	1 [2.0]	1 [3.0]	2 [2.5]	2 [3.0]
Pituitary Gland	(46)	(45)	(48)	(50)
Pars Distalis, Angiectasis	1 [1.0]	2 [2.5]	2 [1.5]	
Pars Distalis, Cyst				1 [3.0]
Pars Distalis, Hyperplasia, Focal	3 [1.7]	3 [2.3]	3 [2.7]	1 [3.0]
Thyroid Gland	(48)	(50)	(49)	(50)
Degeneration, Cystic	25 [2.3]	28 [2.1]	34 [2.5]	32 [2.3]
Follicle, Cyst	1	1		1
Follicular Cell, Cyst				2
Follicular Cell, Hypertrophy	3 [1.3]	2 [2.0]	5 [1.0]	14 [1.4]
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(47)	(47)	(47)	(49)
Inflammation, Chronic		2 [2.0]		4 [2.3]
Ovary	(45)	(45)	(47)	(50)
Angiectasis	3 [3.0]	2 [3.0]	4 [2.5]	3 [2.7]
Cyst	9	14	14	13
Cyst, Hemorrhagic	1			
Hemorrhage	1 [2.0]			
Thrombosis	3	1	1	
Bilateral, Cyst		1		
Follicle, Hemorrhage	1 [2.0]	4 [3.0]	4 [2.3]	9 [2.2]
Granulosa Cell, Hyperplasia			3 [2.7]	7 [2.6]
Uterus	(50)	(50)	(50)	(50)
Angiectasis	1 [2.0]		2 [3.5]	1 [4.0]
Hyperplasia, Atypical		1 [3.0]		
Hyperplasia, Cystic	45 [3.1]	45 [3.2]	40 [3.1]	41 [3.1]
Inflammation, Chronic			2 [2.5]	
Inflammation, Suppurative	1 [4.0]			

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
GENITAL SYSTEM - CONT				
Metaplasia, Squamous		2 [2.5]	1 [2.0]	
Endometrium, Hyperplasia, Atypical		1 [2.0]		
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	14 [2.4]	28 [2.6]	29 [2.9]	31 [2.7]
Myelofibrosis	1 [3.0]	2 [3.5]	1 [4.0]	2 [2.0]
Lymph Node	(7)	(5)	(11)	(9)
Iliac, Hemorrhage			1 [3.0]	
Iliac, Hyperplasia, Lymphoid	1 [3.0]			1 [3.0]
Mediastinal, Hyperplasia, Lymphoid	1 [3.0]	1 [3.0]	2 [3.5]	
Mediastinal, Pigmentation	1 [2.0]			
Pancreatic, Hemorrhage				1 [4.0]
Renal, Hemorrhage	1 [4.0]			1 [3.0]
Lymph Node, Mandibular	(46)	(46)	(49)	(49)
Atrophy		1 [3.0]		1 [3.0]
Hematopoietic Cell Proliferation		1 [2.0]	1 [2.0]	1 [2.0]
Hyperplasia, Lymphoid	12 [2.7]	7 [2.4]	7 [2.3]	10 [2.8]
Pigmentation	18 [2.4]	16 [2.6]	18 [2.2]	15 [2.3]
Lymph Node, Mesenteric	(47)	(49)	(49)	(49)
Atrophy	1 [3.0]	1 [3.0]		2 [2.5]
Ectasia	2 [3.0]			1 [3.0]
Hematopoietic Cell Proliferation	2 [2.0]	2 [2.5]	1 [2.0]	2 [2.0]
Hemorrhage	4 [3.3]	2 [4.0]		1 [2.0]
Hyperplasia, Lymphoid	10 [2.6]	8 [2.1]	11 [2.8]	6 [2.5]
Pigmentation	1 [2.0]	2 [2.5]		
Spleen	(49)	(48)	(49)	(50)
Accessory Spleen				1
Hematopoietic Cell Proliferation	39 [2.5]	39 [2.8]	35 [2.8]	39 [2.8]
Hyperplasia, Lymphoid	11 [2.6]	10 [2.3]	5 [3.0]	9 [2.4]
Pigmentation	28 [2.4]	30 [2.6]	28 [2.6]	27 [2.6]
Lymphoid Follicle, Atrophy	1 [3.0]	2 [2.5]	1 [3.0]	2 [3.0]
Thymus	(48)	(44)	(48)	(48)
Atrophy	5 [3.0]	7 [2.9]	5 [3.0]	9 [2.9]
Cyst	3 [3.0]		1 [3.0]	1 [3.0]
Hyperplasia, Lymphoid	5 [2.8]	3 [2.7]	4 [3.0]	2 [2.0]
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
INTEGUMENTARY SYSTEM - CONT				
Hyperplasia	5 [1.4]	11 [1.5]	8 [1.9]	10 [1.4]
Skin	(48)	(50)	(50)	(50)
Edema		1 [3.0]		1 [3.0]
Epidermis, Hyperplasia	1 [2.0]			1 [4.0]
Subcutaneous Tissue, Edema			1 [4.0]	2 [2.0]
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Callus	1 [4.0]			
Fracture			1	1
Hyperostosis	1 [3.0]	1 [2.0]	4 [2.0]	3 [2.0]
Cranium, Osteopetrosis			1 [3.0]	
Femur, Osteopetrosis		1 [2.0]	1 [3.0]	
Skeletal Muscle		(2)	(4)	(6)
Angiectasis				1 [3.0]
Atrophy				1 [1.0]
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Compression	1 [4.0]		1 [3.0]	1 [4.0]
Inflammation, Chronic				1 [2.0]
Necrosis			1 [2.0]	1 [3.0]
Peripheral Nerve			(2)	(2)
Atrophy			1 [2.0]	2 [1.5]
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(49)	(50)
Edema	5 [2.0]	8 [2.1]	3 [2.0]	5 [2.0]
Foreign Body	2			
Hemorrhage	5 [1.4]	8 [1.8]	6 [2.0]	4 [2.3]
Hyperplasia, Lymphoid	10 [2.0]	8 [2.1]	3 [2.3]	9 [2.1]
Infiltration Cellular, Polymorphonuclear		1 [3.0]		
Infiltration Cellular, Histiocyte	1 [2.0]	1 [4.0]	3 [2.3]	5 [2.0]
Metaplasia, Osseous		1 [1.0]	2 [1.0]	
Thrombosis	1 [2.0]	4 [2.3]	1 [3.0]	
Alveolar Epithelium, Hyperplasia	2 [2.0]	2 [1.5]	1 [1.0]	2 [1.0]

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

B6C3F1 MICE FEMALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
SPECIAL SENSES SYSTEM				
Eye	(50)	(48)	(50)	(50)
Inflammation, Chronic	3 [2.3]	3 [2.3]		
Cornea, Hyperplasia	2 [3.0]	1 [2.0]		
Harderian Gland	(50)	(50)	(50)	(49)
Cyst				1 [3.0]
Hyperplasia, Focal	1 [2.0]	1 [1.0]		1 [2.0]
URINARY SYSTEM				
Kidney	(50)	(49)	(49)	(50)
Hydronephrosis			1 [3.0]	1 [3.0]
Hyperplasia, Lymphoid	8 [2.1]	9 [2.1]	6 [2.2]	8 [2.1]
Infarct	3 [2.0]	2 [2.5]	4 [1.8]	5 [1.8]
Metaplasia, Osseous		1 [1.0]	3 [1.3]	2 [1.5]
Nephropathy	14 [1.3]	11 [1.4]	14 [1.6]	12 [1.4]
Renal Tubule, Accumulation, Hyaline Droplet	2 [2.5]	1 [2.0]	2 [2.5]	1 [3.0]
Renal Tubule, Dilatation	1 [3.0]			1 [3.0]
Renal Tubule, Necrosis	1 [3.0]			1 [3.0]
Renal Tubule, Pigmentation	3 [2.3]	1 [2.0]		1 [2.0]
Transitional Epithelium, Hyperplasia	1 [1.0]			
Urinary Bladder	(49)	(50)	(50)	(50)
Hyperplasia, Lymphoid	4 [2.0]	12 [2.4]	4 [2.0]	5 [2.0]
Transitional Epithelium, Hyperplasia			1 [3.0]	

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
DISPOSITION SUMMARY				
Animals Initially In Study	50	50	50	50
Early Deaths				
Natural Death	7	4	5	7
Moribund Sacrifice	5	5	4	10
Survivors				
Terminal Sacrifice	38	41	41	33
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Intestine Large, Cecum	(47)	(49)	(49)	(48)
Edema	1 [2.0]	3 [2.0]	4 [2.0]	2 [2.0]
Inflammation, Chronic		1 [3.0]		1 [2.0]
Intestine Small, Duodenum	(48)	(50)	(49)	(49)
Ulcer		1 [2.0]	1 [4.0]	
Epithelium, Hyperplasia			1 [2.0]	1 [3.0]
Intestine Small, Jejunum	(47)	(49)	(50)	(50)
Epithelium, Hyperplasia				2 [2.5]
Intestine Small, Ileum	(47)	(49)	(49)	(49)
Cyst		1 [3.0]		
Liver	(48)	(50)	(50)	(50)
Angiectasis	2 [2.5]	2 [1.5]		
Basophilic Focus		2	3	4
Clear Cell Focus	12	19	19	13
Cyst			1 [2.5]	1 [3.0]
Eosinophilic Focus	11	10	5	11
Hematopoietic Cell Proliferation	1 [3.0]			4 [2.0]
Hemorrhage	1 [3.0]	1 [2.0]		
Hyperplasia, Lymphoid		1 [2.0]	1 [2.0]	
Infarct			1 [2.0]	
Infiltration Cellular, Mixed Cell	2 [1.5]	1 [2.0]	1 [1.0]	
Mixed Cell Focus	2	9	8	7
Necrosis, Focal	4 [2.3]	6 [2.8]	7 [2.3]	6 [3.2]
Regeneration, Focal			1 [2.0]	
Tension Lipidosis	1		1	
Bile Duct, Hyperplasia				2 [2.0]
Centrilobular, Necrosis	1 [3.0]			2 [3.0]
Hepatocyte, Karyomegaly			1 [2.0]	1 [2.0]
Hepatocyte, Vacuolization Cytoplasmic	2 [3.0]			3 [2.7]
Kupffer Cell, Pigmentation	2 [4.0]		1 [4.0]	

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ALIMENTARY SYSTEM - CONT				
Mesentery	(9)	(10)	(10)	(8)
Infarct			1	
Inflammation, Chronic	1 [3.0]			2 [4.0]
Fat, Necrosis	3 [3.7]	8 [3.1]	6 [3.2]	5 [3.2]
Pancreas	(48)	(50)	(50)	(50)
Cyst				2 [3.0]
Acinus, Cytoplasmic Alteration			1 [3.0]	1 [3.0]
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy			1 [2.0]	2 [2.0]
Hyperplasia, Lymphoid	7 [2.3]	3 [2.0]	6 [2.0]	4 [2.0]
Stomach, Forestomach	(49)	(50)	(50)	(50)
Cyst	2			
Diverticulum	1	1		2
Erosion		1 [2.0]		
Inflammation, Chronic Active	2 [3.0]	2 [2.5]	4 [1.8]	2 [2.0]
Ulcer	1 [3.0]	1 [2.0]	2 [2.0]	1 [2.0]
Epithelium, Hyperplasia	3 [3.0]	7 [2.3]	2 [2.5]	4 [2.0]
Stomach, Glandular	(48)	(50)	(50)	(50)
Cyst	1 [3.0]	2 [3.0]	1 [3.0]	
Ulcer				1 [3.0]
Tooth	(2)	(4)	(1)	(3)
Malformation	2	4		2
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy				2 [2.5]
Inflammation, Chronic	2 [2.0]	1 [3.0]	1 [1.0]	1 [3.0]
Mineralization	1 [3.0]			2 [2.0]
Thrombosis			1 [4.0]	1 [4.0]
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	6 [3.0]	5 [3.0]	3 [3.0]	5 [3.0]
Degeneration, Fatty	1 [1.0]	1 [2.0]		2 [1.0]
Hyperplasia, Focal	4 [1.5]	6 [1.7]	7 [1.7]	9 [1.4]
Hypertrophy	1 [2.0]			
Hypertrophy, Focal	9 [1.7]	16 [1.8]	11 [1.7]	11 [1.9]
Capsule, Hyperplasia	5 [2.0]	3 [2.0]	1 [3.0]	8 [2.4]
Adrenal Medulla	(49)	(48)	(49)	(49)

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
ENDOCRINE SYSTEM - CONT				
Hyperplasia	1 [1.0]	1 [2.0]	1 [2.0]	
Islets, Pancreatic	(48)	(50)	(50)	(50)
Hyperplasia	31 [2.4]	25 [2.3]	28 [2.5]	23 [2.3]
Parathyroid Gland	(46)	(48)	(47)	(49)
Cyst		1 [3.0]	2 [3.0]	1 [3.0]
Pituitary Gland	(47)	(47)	(45)	(49)
Pars Distalis, Cyst	1 [3.0]	1 [3.0]	2 [3.0]	5 [3.0]
Pars Intermedia, Cyst	1 [3.0]			
Thyroid Gland	(48)	(50)	(48)	(50)
Degeneration, Cystic	13 [1.8]	17 [2.0]	14 [1.9]	15 [1.7]
Follicular Cell, Hypertrophy	2 [1.0]		1 [1.0]	2 [1.5]
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Atypia Cellular	1 [2.0]	6 [2.2]	4 [2.3]	3 [2.3]
Granuloma Sperm		1 [4.0]		1 [4.0]
Inflammation, Chronic		1 [3.0]	1 [2.0]	1 [3.0]
Preputial Gland	(50)	(50)	(50)	(50)
Cyst	22 [3.0]	26 [3.0]	15 [3.0]	29 [3.0]
Inflammation, Chronic	28 [2.4]	27 [2.4]	18 [2.2]	21 [2.2]
Prostate	(50)	(50)	(50)	(50)
Inflammation, Chronic	1 [2.0]	4 [2.0]	3 [2.7]	5 [2.4]
Seminal Vesicle	(50)	(50)	(50)	(50)
Degeneration		1 [3.0]		2 [3.0]
Dilatation			1 [3.0]	
Inflammation, Chronic	3 [2.3]		1 [4.0]	
Testes	(50)	(50)	(50)	(50)
Angiectasis	1 [3.0]			1 [4.0]
Atrophy		1 [2.0]	1 [3.0]	1 [3.0]
Necrosis				1 [3.0]
Germinal Epithelium, Atrophy	1 [1.0]	5 [2.0]	3 [1.7]	4 [1.8]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(50)	(50)

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
HEMATOPOIETIC SYSTEM - CONT				
Hyperplasia	21 [2.2]	12 [2.6]	13 [2.2]	15 [2.6]
Lymph Node	(3)		(1)	(3)
Mediastinal, Hemorrhage				1 [3.0]
Lymph Node, Mandibular	(49)	(48)	(45)	(49)
Atrophy	1 [3.0]			1 [2.0]
Hyperplasia, Lymphoid	14 [2.4]	14 [2.3]	16 [2.2]	16 [2.3]
Pigmentation	7 [2.0]	10 [2.2]	9 [2.1]	9 [2.1]
Lymph Node, Mesenteric	(47)	(50)	(50)	(50)
Atrophy	2 [2.5]	1 [2.0]		1 [3.0]
Hematopoietic Cell Proliferation	2 [2.5]		4 [2.5]	1 [2.0]
Hemorrhage	4 [1.8]	6 [2.3]	2 [2.0]	4 [2.5]
Hyperplasia, Lymphoid	11 [2.7]	6 [2.8]	6 [2.8]	9 [2.6]
Spleen	(48)	(50)	(50)	(50)
Depletion Lymphoid				1 [3.0]
Hematopoietic Cell Proliferation	21 [2.8]	17 [2.6]	18 [2.8]	21 [3.3]
Hyperplasia, Lymphoid	8 [2.3]	9 [2.0]	10 [2.2]	8 [2.1]
Pigmentation		3 [2.0]	1 [2.0]	1 [3.0]
Lymphoid Follicle, Atrophy	1 [3.0]		1 [2.0]	3 [3.0]
Thymus	(43)	(43)	(40)	(44)
Atrophy	11 [2.6]	13 [2.6]	4 [2.5]	13 [2.5]
Cyst	1 [3.0]	3 [3.0]	4 [3.0]	4 [3.0]
Hyperplasia, Lymphoid	2 [3.0]	1 [2.0]		
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	1			
Edema				3 [3.0]
Inflammation, Chronic			1 [3.0]	1 [3.0]
Ulcer	2 [3.5]			
Epidermis, Hyperplasia	1 [3.0]			1 [3.0]
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fracture	1	1		2
Hyperostosis	1 [3.0]	1 [3.0]		
Skeletal Muscle	(3)	(1)	(3)	(2)
Atrophy		1 [2.0]		
Infiltration Cellular, Lipocyte	1 [3.0]			

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
NERVOUS SYSTEM				
Peripheral Nerve		(1)	(2)	(1)
Atrophy		1 [3.0]		
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Edema	6 [2.2]	11 [2.1]	7 [2.0]	8 [2.0]
Foreign Body	1			1
Hemorrhage	5 [1.6]	3 [2.0]	4 [1.3]	5 [2.0]
Hyperplasia, Lymphoid	4 [2.0]	5 [2.0]	7 [2.0]	6 [2.0]
Infiltration Cellular, Histiocyte	8 [2.6]	5 [3.0]	9 [3.1]	10 [2.5]
Metaplasia, Osseous		2 [1.0]		
Alveolar Epithelium, Hyperplasia	2 [1.0]	3 [1.7]	1 [1.0]	5 [1.6]
Nose	(50)	(50)	(50)	(50)
Foreign Body	1	1		2
Inflammation, Chronic	1 [1.0]	2 [2.5]	1 [1.0]	5 [2.8]
Respiratory Epithelium, Hyperplasia	1 [1.0]	1 [2.0]		
SPECIAL SENSES SYSTEM				
Eye	(49)	(50)	(50)	(50)
Cataract		1 [2.0]		
Inflammation, Chronic			3 [2.0]	
Harderian Gland	(50)	(50)	(50)	(49)
Hyperplasia, Focal	1 [2.0]			1 [2.0]
Inflammation, Chronic	1 [2.0]	3 [2.3]	3 [2.0]	2 [3.0]
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Cyst	14 [3.0]	10 [3.0]	9 [3.0]	10 [2.9]
Hydronephrosis	1 [2.0]	2 [2.0]	2 [2.0]	1 [3.0]
Hyperplasia, Lymphoid	8 [2.3]	6 [2.5]	4 [2.3]	11 [2.3]
Infarct	5 [1.8]	1 [1.0]	4 [1.3]	5 [2.2]
Inflammation, Chronic		1 [3.0]		1 [2.0]
Metaplasia, Osseous	7 [1.4]	5 [2.0]	3 [2.7]	4 [2.5]
Nephropathy	37 [1.3]	42 [1.7]	43 [1.5]	36 [1.6]
Renal Tubule, Accumulation, Hyaline Droplet		1 [3.0]	1 [3.0]	

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

B6C3F1 MICE MALE	0 MG/L	500 MG/L	1000MG/L	2000MG/L
URINARY SYSTEM - CONT				
Renal Tubule, Dilatation	1 [2.0]	2 [2.5]		3 [2.3]
Renal Tubule, Hyperplasia	1 [1.0]	1 [1.0]		1 [1.0]
Renal Tubule, Necrosis	1 [2.0]			2 [3.5]
Renal Tubule, Pigmentation		2 [4.0]	1 [2.0]	1 [2.0]
Urethra			(1)	
Angiectasis			1 [4.0]	
Urinary Bladder	(49)	(50)	(50)	(50)
Edema	1 [3.0]			1 [4.0]
Hyperplasia, Lymphoid		1 [2.0]	1 [2.0]	
Inflammation, Chronic				1 [3.0]
Transitional Epithelium, Hyperplasia		2 [2.0]		1 [3.0]

a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)

END OF REPORT

FINAL#1/MICE

REASONS FOR REMOVAL: ALL

REMOVAL DATE RANGE: ALL

TREATMENT GROUPS: INCLUDE ALL

NTP
LAB: Southern Research Inst
EXPERIMENT: 96010 TEST: 04
TEST TYPE: CHRONIC
CONT: N01-ES-85420
PATHOLOGIST: HEATH, JAMES E.
Mice(B6C3F1)

STATISTICAL ANALYSIS OF PRIMARY TUMORS
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

CAGES FROM 0000 TO LAST CAGE
ROUTE: DOSED WATER

REPORT: PEIRPT08
DATE: 03/26/03
TIME: 10:41:04

NTP C#: 96010A
CAS: 7775-09-9

FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.

Adrenal Cortex
Adrenal Medulla
Bone Marrow
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Pituitary Gland
Spleen
Testes
Thyroid Gland

NTP
LAB: Southern Research Inst
EXPERIMENT: 96010 TEST: 04
TEST TYPE: CHRONIC
CONT: N01-ES-85420
PATHOLOGIST: HEATH, JAMES E.

STATISTICAL ANALYSIS OF PRIMARY TUMORS
WATER DISINFECTION BYPRODUCTS (SODIUM CHLORATE)

CAGES FROM 0000 TO LAST CAGE
ROUTE: DOSED WATER

REPORT: PEIRPT08
DATE: 03/26/03
TIME: 10:41:04

NTP C#: 96010A
CAS: 7775-09-9

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF WATER DISINFECTION BYPRODUCTS (SODIUM

Male Mice

Organ	Morphology
Liver	Hepatoblastoma
Testes	Adenoma

Female Mice

Organ	Morphology
Adrenal Medulla	Pheochromocytoma Malignant
Islets, Pancreatic	Carcinoma or Adenoma
Liver	Hemangioma
	Hepatocellular Adenoma
	Hepatocellular Carcinoma
	Hepatocellular Carcinoma or Hepatoblastoma
Ovary	Granulosa Cell Tumor Benign
	Granulosa Cell Tumor: Benign, Malignant, NOS
	Luteoma
Skin	Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma
	Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma
Uterus	Polyp Stromal
All Organs	Benign Tumors
	Malignant Tumors

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Adrenal Cortex Adenoma								
TUMOR RATES								
OVERALL (a)	3/50 (6%)	4/50 (8%)	5/50 (10%)	3/50 (6%)	1/50 (2%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/44.60	4/47.28	5/46.48	3/43.80	1/43.63	0/44.35	0/42.00	0/43.40
POLY-3 PERCENT (g)	6.7%	8.5%	10.8%	6.9%	2.3%	0.0%	0.0%	0.0%
TERMINAL (d)	3/38 (8%)	4/41 (10%)	5/41 (12%)	3/33 (9%)	1/36 (3%)	0/34 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.500	P=0.542	P=0.398	P=0.597	P=0.313N	P=0.511N	P=0.530N	P=0.506N
POLY 3	P=0.566	P=0.532	P=0.379	P=0.654	P=0.310N	P=0.497N	P=0.508N	P=0.501N
POLY 1.5	P=0.566N	P=0.519	P=0.372	P=0.658	P=0.309N	P=0.499N	P=0.509N	P=0.502N
POLY 6	P=0.550	P=0.547	P=0.387	P=0.648	P=0.313N	P=0.493N	P=0.507N	P=0.500N
LOGISTIC REGRESSION	P=0.500	P=0.542	P=0.398	P=0.597	P=0.313N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.554N	P=0.500	P=0.357	P=0.661N	P=0.306N	P=0.505N	P=0.505N	P=0.500N
ORDER RESTRICTED	P=0.564	(e)	(e)	(e)	P=0.121N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Adrenal Medulla Pheochromocytoma Malignant								
TUMOR RATES								
OVERALL (a)	0/49 (0%)	0/48 (0%)	0/49 (0%)	0/49 (0%)	2/50 (4%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.98	0/45.28	0/45.48	0/42.80	2/43.88	0/44.35	0/42.00	0/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	4.6%	0.0%	0.0%	0.0%
TERMINAL (d)	0/38 (0%)	0/39 (0%)	0/40 (0%)	0/32 (0%)	1/36 (3%)	0/34 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---	660	---	---	---
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.119N	P=0.233N	P=0.256N	P=0.237N
POLY 3	(e)	(e)	(e)	(e)	P=0.117N	P=0.235N	P=0.247N	P=0.239N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.116N	P=0.237N	P=0.248N	P=0.240N
POLY 6	(e)	(e)	(e)	(e)	P=0.118N	P=0.232N	P=0.247N	P=0.239N
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.116N	P=0.241N	P=0.245N	P=0.238N
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.115N	P=0.253N	P=0.253N	P=0.247N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.030N*	(e)	(e)	(e)

Dose	Males 0 MG/L	Males 500 MG/L	Males 1000MG/L	Males 2000MG/L	Females 0 MG/L	Females 500 MG/L	Females 1000MG/L	Females 2000MG/L
Adrenal Medulla								
Pheochromocytoma: Benign, Complex, Malignant, NOS								
TUMOR RATES								
OVERALL (a)	0/49 (0%)	0/48 (0%)	0/49 (0%)	0/49 (0%)	3/50 (6%)	0/49 (0%)	0/49 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.98	0/45.28	0/45.48	0/42.80	3/43.88	0/44.35	0/42.00	2/43.58
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	6.8%	0.0%	0.0%	4.6%
TERMINAL (d)	0/38 (0%)	0/39 (0%)	0/40 (0%)	0/32 (0%)	2/36 (6%)	0/34 (0%)	0/31 (0%)	1/35 (3%)
FIRST INCIDENCE	---	---	---	---	660	---	---	681
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.532N	P=0.122N	P=0.141N	P=0.496N
POLY 3	(e)	(e)	(e)	(e)	P=0.538N	P=0.117N	P=0.126N	P=0.503N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.536N	P=0.119N	P=0.127N	P=0.504N
POLY 6	(e)	(e)	(e)	(e)	P=0.541N	P=0.114N	P=0.127N	P=0.501N
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.535N	P=0.119N	P=0.127N	P=0.502N
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.529N	P=0.125N	P=0.125N	P=0.500N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.102N	(e)	(e)	(e)

Dose	Males 0 MG/L	Males 500 MG/L	Males 1000MG/L	Males 2000MG/L	Females 0 MG/L	Females 500 MG/L	Females 1000MG/L	Females 2000MG/L
Bone								
Osteosarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.60	0/47.28	0/46.48	0/43.80	0/43.63	1/45.39	1/42.71	2/44.56
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	2.3%	4.5%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---	---	719	622	447
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.154	P=0.505	P=0.495	P=0.247
POLY 3	(e)	(e)	(e)	(e)	P=0.156	P=0.508	P=0.496	P=0.242
POLY 1.5	(e)	(e)	(e)	(e)	P=0.154	P=0.505	P=0.495	P=0.239
POLY 6	(e)	(e)	(e)	(e)	P=0.159	P=0.512	P=0.496	P=0.246
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.167	P=0.511	P=0.520	P=0.273
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.153	P=0.500	P=0.500	P=0.247
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.122	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Bone Marrow								
Hemangiosarcoma								
TUMOR RATES								
OVERALL (a)	0/49 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/44.53	0/47.28	0/46.48	0/43.80	1/44.05	1/45.35	2/42.58	0/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	2.3%	2.2%	4.7%	0.0%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	1/35 (3%)	1/31 (3%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---	606	729 (T)	662	---
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.371N	P=0.758N	P=0.483	P=0.495N
POLY 3	(e)	(e)	(e)	(e)	P=0.376N	P=0.754N	P=0.488	P=0.503N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.374N	P=0.756N	P=0.489	P=0.503N
POLY 6	(e)	(e)	(e)	(e)	P=0.377N	P=0.752N	P=0.487	P=0.503N
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.366N	P=0.752	P=0.506	P=0.482N
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.366N	P=0.753N	P=0.500	P=0.500N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.274N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Harderian Gland								
Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	6/50 (12%)	4/50 (8%)	4/50 (8%)	6/50 (12%)	11/50 (22%)	9/50 (18%)	5/50 (10%)	6/50 (12%)
POLY-3 RATE (b)	6/45.47	4/47.40	4/47.28	6/44.51	11/44.13	9/45.61	5/42.40	6/43.85
POLY-3 PERCENT (g)	13.2%	8.4%	8.5%	13.5%	24.9%	19.7%	11.8%	13.7%
TERMINAL (d)	4/38 (11%)	3/41 (7%)	2/41 (5%)	3/33 (9%)	10/36 (28%)	7/35 (20%)	4/31 (13%)	5/35 (14%)
FIRST INCIDENCE	562	698	543	605	576	673	712	597
STATISTICAL TESTS								
LIFE TABLE	P=0.422	P=0.323N	P=0.333N	P=0.556	P=0.104N	P=0.420N	P=0.142N	P=0.157N
POLY 3	P=0.478	P=0.344N	P=0.345N	P=0.606	P=0.093N	P=0.368N	P=0.095N	P=0.142N
POLY 1.5	P=0.487	P=0.353N	P=0.353N	P=0.612	P=0.093N	P=0.380N	P=0.095N	P=0.145N
POLY 6	P=0.466	P=0.332N	P=0.338N	P=0.596	P=0.092N	P=0.351N	P=0.097N	P=0.137N
LOGISTIC REGRESSION	P=0.511	P=0.375N	P=0.417N	P=0.621N	P=0.093N	P=0.348N	P=0.095N	P=0.143N
COCH-ARM / FISHERS	P=0.500	P=0.370N	P=0.370N	P=0.620N	P=0.088N	P=0.402N	P=0.086N	P=0.143N
ORDER RESTRICTED	P=0.473	(e)	(e)	(e)	P=0.100N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Harderian Gland Carcinoma or Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	6/50 (12%)	4/50 (8%)	5/50 (10%)	7/50 (14%)	12/50 (24%)	10/50 (20%)	5/50 (10%)	6/50 (12%)
POLY-3 RATE (b)	6/45.47	4/47.40	5/47.28	7/44.97	12/44.13	10/46.13	5/42.40	6/43.85
POLY-3 PERCENT (g)	13.2%	8.4%	10.6%	15.6%	27.2%	21.7%	11.8%	13.7%
TERMINAL (d)	4/38 (11%)	3/41 (7%)	3/41 (7%)	3/33 (9%)	11/36 (31%)	7/35 (20%)	4/31 (13%)	5/35 (14%)
FIRST INCIDENCE	562	698	543	595	576	568	712	597
STATISTICAL TESTS								
LIFE TABLE	P=0.281	P=0.323N	P=0.453N	P=0.442	P=0.063N	P=0.426N	P=0.097N	P=0.107N
POLY 3	P=0.335	P=0.344N	P=0.473N	P=0.491	P=0.053N	P=0.358N	P=0.060N	P=0.094N
POLY 1.5	P=0.342	P=0.353N	P=0.481N	P=0.495	P=0.053N	P=0.375N	P=0.061N	P=0.096N
POLY 6	P=0.326	P=0.332N	P=0.465N	P=0.485	P=0.054N	P=0.334N	P=0.061N	P=0.090N
LOGISTIC REGRESSION	P=0.366	P=0.375N	P=0.543N	P=0.504	P=0.054N	P=0.365N	P=0.060N	P=0.095N
COCH-ARM / FISHERS	P=0.351	P=0.370N	P=0.500N	P=0.500	P=0.050N	P=0.405N	P=0.054N	P=0.096N
ORDER RESTRICTED	P=0.383	(e)	(e)	(e)	P=0.059N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Intestine Small: Duodenum Polyp Adenomatous								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.60	0/47.28	2/46.48	0/43.80	0/43.63	0/45.35	0/42.33	1/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	4.3%	0.0%	0.0%	0.0%	0.0%	2.3%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	2/41 (5%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	1/35 (3%)
FIRST INCIDENCE	---	---	729 (T)	---	---	---	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.566	(e)	P=0.255	(e)	P=0.199	(e)	(e)	P=0.494
POLY 3	P=0.573	(e)	P=0.246	(e)	P=0.196	(e)	(e)	P=0.499
POLY 1.5	P=0.582	(e)	P=0.243	(e)	P=0.196	(e)	(e)	P=0.498
POLY 6	P=0.558	(e)	P=0.250	(e)	P=0.196	(e)	(e)	P=0.500
LOGISTIC REGRESSION	(e)	(e)	P=0.255	(e)	(e)	(e)	(e)	P=0.494
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)	P=0.198	(e)	(e)	P=0.500
ORDER RESTRICTED	P=0.255	(e)	(e)	(e)	P=0.119	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Intestine Small: Jejunum Carcinoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.60	2/47.28	0/46.48	2/44.39	0/43.63	0/45.35	0/42.33	0/43.40
POLY-3 PERCENT (g)	4.5%	4.2%	0.0%	4.5%	0.0%	0.0%	0.0%	0.0%
TERMINAL (d)	2/38 (5%)	2/41 (5%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	570	---	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.599N	P=0.667N	P=0.222N	P=0.666	(e)	(e)	(e)	(e)
POLY 3	P=0.557N	P=0.673N	P=0.228N	P=0.692	(e)	(e)	(e)	(e)
POLY 1.5	P=0.556N	P=0.681N	P=0.231N	P=0.693	(e)	(e)	(e)	(e)
POLY 6	P=0.559N	P=0.663N	P=0.225N	P=0.690	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	P=0.555N	P=0.667N	(e)	P=0.694N	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.556N	P=0.691N	P=0.247N	P=0.691N	(e)	(e)	(e)	(e)
ORDER RESTRICTED	P=0.437N	(e)	(e)	(e)	(e)	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Intestine Small: Site Unspecified Carcinoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	0/50 (0%)	3/50 (6%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.60	2/47.28	0/46.48	3/44.39	0/43.63	0/45.35	0/42.33	0/43.40
POLY-3 PERCENT (g)	4.5%	4.2%	0.0%	6.8%	0.0%	0.0%	0.0%	0.0%
TERMINAL (d)	2/38 (5%)	2/41 (5%)	0/41 (0%)	1/33 (3%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	570	---	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.373	P=0.667N	P=0.222N	P=0.461	(e)	(e)	(e)	(e)
POLY 3	P=0.418	P=0.673N	P=0.228N	P=0.498	(e)	(e)	(e)	(e)
POLY 1.5	P=0.420	P=0.681N	P=0.231N	P=0.499	(e)	(e)	(e)	(e)
POLY 6	P=0.414	P=0.663N	P=0.225N	P=0.495	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	P=0.420	P=0.667N	(e)	P=0.499	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.423	P=0.691N	P=0.247N	P=0.500	(e)	(e)	(e)	(e)
ORDER RESTRICTED	P=0.277	(e)	(e)	(e)	(e)	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Intestine Small: Site Unspecified Carcinoma or Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	3/50 (6%)	2/50 (4%)	1/50 (2%)	4/50 (8%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/44.60	2/47.28	1/46.48	4/44.39	0/43.63	1/45.45	0/42.33	0/43.40
POLY-3 PERCENT (g)	6.7%	4.2%	2.2%	9.0%	0.0%	2.2%	0.0%	0.0%
TERMINAL (d)	3/38 (8%)	2/41 (5%)	1/41 (2%)	2/33 (6%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	570	---	706	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.309	P=0.465N	P=0.278N	P=0.445	P=0.582N	P=0.520	(e)	(e)
POLY 3	P=0.362	P=0.473N	P=0.291N	P=0.497	P=0.565N	P=0.508	(e)	(e)
POLY 1.5	P=0.366	P=0.484N	P=0.296N	P=0.499	P=0.567N	P=0.505	(e)	(e)
POLY 6	P=0.356	P=0.461N	P=0.286N	P=0.494	P=0.563N	P=0.512	(e)	(e)
LOGISTIC REGRESSION	P=0.358	P=0.465N	P=0.278N	P=0.494	P=0.570N	P=0.505	(e)	(e)
COCH-ARM / FISHERS	P=0.371	P=0.500N	P=0.309N	P=0.500	P=0.567N	P=0.500	(e)	(e)
ORDER RESTRICTED	P=0.270	(e)	(e)	(e)	P=0.389N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Intestine Small: Site Unspecified Polyp Adenomatous								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.60	0/47.28	2/46.48	0/43.80	0/43.63	0/45.35	0/42.33	1/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	4.3%	0.0%	0.0%	0.0%	0.0%	2.3%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	2/41 (5%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	1/35 (3%)
FIRST INCIDENCE	---	---	729 (T)	---	---	---	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.566	(e)	P=0.255	(e)	P=0.199	(e)	(e)	P=0.494
POLY 3	P=0.573	(e)	P=0.246	(e)	P=0.196	(e)	(e)	P=0.499
POLY 1.5	P=0.582	(e)	P=0.243	(e)	P=0.196	(e)	(e)	P=0.498
POLY 6	P=0.558	(e)	P=0.250	(e)	P=0.196	(e)	(e)	P=0.500
LOGISTIC REGRESSION	(e)	(e)	P=0.255	(e)	(e)	(e)	(e)	P=0.494
COCH-ARM / FISHERS	P=0.595	(e)	P=0.247	(e)	P=0.198	(e)	(e)	P=0.500
ORDER RESTRICTED	P=0.255	(e)	(e)	(e)	P=0.119	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Islets, Pancreatic Adenoma								
TUMOR RATES								
OVERALL (a)	1/48 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/46 (0%)	2/47 (4%)	2/49 (4%)	3/49 (6%)
POLY-3 RATE (b)	1/43.91	0/47.28	0/46.48	1/43.84	0/42.28	2/44.36	2/42.00	3/43.88
POLY-3 PERCENT (g)	2.3%	0.0%	0.0%	2.3%	0.0%	4.5%	4.8%	6.8%
TERMINAL (d)	1/38 (3%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	1/35 (3%)	2/31 (7%)	1/35 (3%)
FIRST INCIDENCE	729 (T)	---	---	719	---	706	729 (T)	475
STATISTICAL TESTS								
LIFE TABLE	P=0.570	P=0.485N	P=0.485N	P=0.735	P=0.106	P=0.248	P=0.206	P=0.126
POLY 3	P=0.591	P=0.485N	P=0.489N	P=0.760	P=0.112	P=0.248	P=0.235	P=0.125
POLY 1.5	P=0.595	P=0.488N	P=0.490N	P=0.758N	P=0.113	P=0.245	P=0.238	P=0.125
POLY 6	P=0.585	P=0.481N	P=0.487N	P=0.756	P=0.112	P=0.252	P=0.232	P=0.126
LOGISTIC REGRESSION	P=0.583	(e)	(e)	P=0.752	P=0.127	P=0.248	P=0.206	P=0.171
COCH-ARM / FISHERS	P=0.602	P=0.490N	P=0.490N	P=0.742N	P=0.121	P=0.253	P=0.263	P=0.133
ORDER RESTRICTED	P=0.393	(e)	(e)	(e)	P=0.082	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Islets, Pancreatic Carcinoma or Adenoma								
TUMOR RATES								
OVERALL (a)	1/48 (2%)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/46 (0%)	2/47 (4%)	2/49 (4%)	4/49 (8%)
POLY-3 RATE (b)	1/43.91	0/47.28	0/46.48	2/43.84	0/42.28	2/44.36	2/42.00	4/43.88
POLY-3 PERCENT (g)	2.3%	0.0%	0.0%	4.6%	0.0%	4.5%	4.8%	9.1%
TERMINAL (d)	1/38 (3%)	0/41 (0%)	0/41 (0%)	1/33 (3%)	0/36 (0%)	1/35 (3%)	2/31 (7%)	2/35 (6%)
FIRST INCIDENCE	729 (T)	---	---	719	---	706	729 (T)	475
STATISTICAL TESTS								
LIFE TABLE	P=0.210	P=0.485N	P=0.485N	P=0.458	P=0.043 *	P=0.248	P=0.206	P=0.066
POLY 3	P=0.243	P=0.485N	P=0.489N	P=0.499	P=0.045 *	P=0.248	P=0.235	P=0.065
POLY 1.5	P=0.246	P=0.488N	P=0.490N	P=0.505	P=0.046 *	P=0.245	P=0.238	P=0.065
POLY 6	P=0.238	P=0.481N	P=0.487N	P=0.492	P=0.045 *	P=0.252	P=0.232	P=0.065
LOGISTIC REGRESSION	P=0.222	(e)	(e)	P=0.479	P=0.052	P=0.248	P=0.206	P=0.087
COCH-ARM / FISHERS	P=0.252	P=0.490N	P=0.490N	P=0.515	P=0.051	P=0.253	P=0.263	P=0.067
ORDER RESTRICTED	P=0.128	(e)	(e)	(e)	P=0.030 *	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Liver Hemangioma								
TUMOR RATES								
OVERALL (a)	0/48 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/49 (4%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.91	0/47.28	1/46.48	0/43.80	2/43.57	0/45.35	0/42.00	0/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	2.2%	0.0%	4.6%	0.0%	0.0%	0.0%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	1/41 (2%)	0/33 (0%)	2/36 (6%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	729 (T)	---	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.681	(e)	P=0.515	(e)	P=0.123N	P=0.244N	P=0.272N	P=0.244N
POLY 3	P=0.675	(e)	P=0.511	(e)	P=0.114N	P=0.228N	P=0.245N	P=0.238N
POLY 1.5	P=0.684	(e)	P=0.510	(e)	P=0.114N	P=0.231N	P=0.246N	P=0.238N
POLY 6	P=0.662	(e)	P=0.513	(e)	P=0.116N	P=0.224N	P=0.245N	P=0.237N
LOGISTIC REGRESSION	(e)	(e)	P=0.515	(e)	P=0.123N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.699	(e)	P=0.510	(e)	P=0.114N	P=0.242N	P=0.247N	P=0.242N
ORDER RESTRICTED	P=0.391	(e)	(e)	(e)	P=0.030N*	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Liver Hemangiosarcoma								
TUMOR RATES								
OVERALL (a)	1/48 (2%)	2/50 (4%)	1/50 (2%)	2/50 (4%)	1/49 (2%)	2/50 (4%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.91	2/47.28	1/46.48	2/43.80	1/43.57	2/45.35	0/42.00	0/43.40
POLY-3 PERCENT (g)	2.3%	4.2%	2.2%	4.6%	2.3%	4.4%	0.0%	0.0%
TERMINAL (d)	1/38 (3%)	2/41 (5%)	1/41 (2%)	2/33 (6%)	1/36 (3%)	2/35 (6%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)	729 (T)	729 (T)	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.385	P=0.527	P=0.745N	P=0.451	P=0.198N	P=0.490	P=0.530N	P=0.506N
POLY 3	P=0.437	P=0.526	P=0.748N	P=0.499	P=0.190N	P=0.514	P=0.507N	P=0.501N
POLY 1.5	P=0.444	P=0.520	P=0.749N	P=0.505	P=0.190N	P=0.510	P=0.508N	P=0.501N
POLY 6	P=0.428	P=0.533	P=0.746N	P=0.492	P=0.189N	P=0.520	P=0.507N	P=0.500N
LOGISTIC REGRESSION	P=0.385	P=0.527	P=0.745N	P=0.451	P=0.198N	P=0.490	(e)	(e)
COCH-ARM / FISHERS	P=0.456	P=0.515	P=0.742N	P=0.515	P=0.186N	P=0.508	P=0.500N	P=0.495N
ORDER RESTRICTED	P=0.442	(e)	(e)	(e)	P=0.175N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Liver Hepatoblastoma								
TUMOR RATES								
OVERALL (a)	6/48 (13%)	3/50 (6%)	1/50 (2%)	3/50 (6%)	1/49 (2%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	6/44.45	3/47.85	1/46.71	3/43.84	1/43.57	0/45.35	0/42.00	0/43.40
POLY-3 PERCENT (g)	13.5%	6.3%	2.1%	6.8%	2.3%	0.0%	0.0%	0.0%
TERMINAL (d)	5/38 (13%)	1/41 (2%)	0/41 (0%)	2/33 (6%)	1/36 (3%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	561	577	668	719	729 (T)	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.222N	P=0.212N	P=0.051N	P=0.307N	P=0.313N	P=0.506N	P=0.530N	P=0.506N
POLY 3	P=0.179N	P=0.207N	P=0.048N*	P=0.248N	P=0.306N	P=0.492N	P=0.507N	P=0.501N
POLY 1.5	P=0.174N	P=0.214N	P=0.049N*	P=0.239N	P=0.305N	P=0.494N	P=0.508N	P=0.501N
POLY 6	P=0.186N	P=0.197N	P=0.047N*	P=0.261N	P=0.308N	P=0.489N	P=0.507N	P=0.500N
LOGISTIC REGRESSION	P=0.158N	P=0.238N	P=0.054N	P=0.239N	P=0.313N	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.166N	P=0.223N	P=0.050N	P=0.223N	P=0.304N	P=0.495N	P=0.500N	P=0.495N
ORDER RESTRICTED	P=0.076N	(e)	(e)	(e)	P=0.121N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Liver Hepatocellular Adenoma								
TUMOR RATES								
OVERALL (a)	30/48 (63%)	32/50 (64%)	36/50 (72%)	30/50 (60%)	30/49 (61%)	19/50 (38%)	26/49 (53%)	23/50 (46%)
POLY-3 RATE (b)	30/46.51	32/47.31	36/48.04	30/45.77	30/45.42	19/45.74	26/43.41	23/44.75
POLY-3 PERCENT (g)	64.5%	67.6%	74.9%	65.5%	66.1%	41.5%	59.9%	51.4%
TERMINAL (d)	25/38 (66%)	31/41 (76%)	32/41 (78%)	24/33 (73%)	26/36 (72%)	17/35 (49%)	19/31 (61%)	20/35 (57%)
FIRST INCIDENCE	484	722	543	535	524	674	602	475
STATISTICAL TESTS								
LIFE TABLE	P=0.185	P=0.563N	P=0.300	P=0.310	P=0.289N	P=0.023N*	P=0.537N	P=0.132N
POLY 3	P=0.478	P=0.459	P=0.184	P=0.546	P=0.252N	P=0.013N*	P=0.348N	P=0.108N
POLY 1.5	P=0.533	P=0.482	P=0.197	P=0.577N	P=0.248N	P=0.014N*	P=0.350N	P=0.108N
POLY 6	P=0.417	P=0.438	P=0.172	P=0.492	P=0.252N	P=0.011N*	P=0.339N	P=0.104N
LOGISTIC REGRESSION	P=0.500	P=0.584N	P=0.228	P=0.549N	P=0.263N	P=0.010N*	P=0.331N	P=0.108N
COCH-ARM / FISHERS	P=0.449N	P=0.522	P=0.216	P=0.482N	P=0.214N	P=0.017N*	P=0.270N	P=0.094N
ORDER RESTRICTED	P=0.427	(e)	(e)	(e)	P=0.100N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Mice(B6C3F1) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	Males 500 MG/L	Males 1000MG/L	Males 2000MG/L	Females 0 MG/L	Females 500 MG/L	Females 1000MG/L	Females 2000MG/L
Liver								
Hepatocellular Carcinoma								
TUMOR RATES								
OVERALL (a)	20/48 (42%)	14/50 (28%)	19/50 (38%)	13/50 (26%)	3/49 (6%)	13/50 (26%)	15/49 (31%)	9/50 (18%)
POLY-3 RATE (b)	20/46.21	14/48.93	19/48.53	13/45.80	3/43.65	13/45.65	15/42.18	9/44.29
POLY-3 PERCENT (g)	43.3%	28.6%	39.2%	28.4%	6.9%	28.5%	35.6%	20.3%
TERMINAL (d)	14/38 (37%)	10/41 (24%)	14/41 (34%)	5/33 (15%)	2/36 (6%)	9/35 (26%)	12/31 (39%)	7/35 (20%)
FIRST INCIDENCE	484	431	558	570	710	682	711	475
STATISTICAL TESTS								
LIFE TABLE	P=0.276N	P=0.110N	P=0.400N	P=0.200N	P=0.154	P=0.009 **	P<0.001 **	P=0.060
POLY 3	P=0.159N	P=0.099N	P=0.421N	P=0.100N	P=0.158	P=0.007 **	P<0.001 **	P=0.061
POLY 1.5	P=0.144N	P=0.105N	P=0.427N	P=0.091N	P=0.157	P=0.007 **	P<0.001 **	P=0.061
POLY 6	P=0.176N	P=0.093N	P=0.416N	P=0.109N	P=0.164	P=0.008 **	P<0.001 **	P=0.063
LOGISTIC REGRESSION	P=0.084N	P=0.142N	P=0.462N	P=0.068N	P=0.150	P=0.009 **	P<0.001 **	P=0.062
COCH-ARM / FISHERS	P=0.117N	P=0.113N	P=0.435N	P=0.077N	P=0.179	P=0.007 **	P=0.002 **	P=0.065
ORDER RESTRICTED	P=0.104N	(e)	(e)	(e)	P=0.010 *	(e)	(e)	(e)

Dose	Males 0 MG/L	Males 500 MG/L	Males 1000MG/L	Males 2000MG/L	Females 0 MG/L	Females 500 MG/L	Females 1000MG/L	Females 2000MG/L
Liver								
Hepatocellular Carcinoma or Hepatoblastoma								
TUMOR RATES								
OVERALL (a)	23/48 (48%)	16/50 (32%)	20/50 (40%)	16/50 (32%)	4/49 (8%)	13/50 (26%)	15/49 (31%)	9/50 (18%)
POLY-3 RATE (b)	23/46.76	16/49.00	20/48.76	16/45.84	4/43.65	13/45.65	15/42.18	9/44.29
POLY-3 PERCENT (g)	49.2%	32.7%	41.0%	34.9%	9.2%	28.5%	35.6%	20.3%
TERMINAL (d)	16/38 (42%)	11/41 (27%)	14/41 (34%)	7/33 (21%)	3/36 (8%)	9/35 (26%)	12/31 (39%)	7/35 (20%)
FIRST INCIDENCE	484	431	558	570	710	682	711	475
STATISTICAL TESTS								
LIFE TABLE	P=0.313N	P=0.084N	P=0.267N	P=0.232N	P=0.208	P=0.020 *	P=0.002 **	P=0.112
POLY 3	P=0.180N	P=0.074N	P=0.276N	P=0.117N	P=0.219	P=0.018 *	P=0.002 **	P=0.119
POLY 1.5	P=0.160N	P=0.076N	P=0.278N	P=0.102N	P=0.217	P=0.017 *	P=0.003 **	P=0.118
POLY 6	P=0.203N	P=0.070N	P=0.272N	P=0.133N	P=0.226	P=0.020 *	P=0.002 **	P=0.123
LOGISTIC REGRESSION	P=0.091N	P=0.106N	P=0.306N	P=0.073N	P=0.207	P=0.022 *	P=0.003 **	P=0.116
COCH-ARM / FISHERS	P=0.125N	P=0.080N	P=0.279N	P=0.080N	P=0.241	P=0.017 *	P=0.005 **	P=0.125
ORDER RESTRICTED	P=0.126N	(e)	(e)	(e)	P=0.022 *	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
Liver Hepatocellular Carcinoma or Hepatocellular Adenoma								
TUMOR RATES								
OVERALL (a)	41/48 (85%)	42/50 (84%)	44/50 (88%)	40/50 (80%)	31/49 (63%)	26/50 (52%)	31/49 (63%)	26/50 (52%)
POLY-3 RATE (b)	41/47.67	42/48.96	44/49.35	40/47.50	31/45.50	26/45.86	31/43.48	26/44.92
POLY-3 PERCENT (g)	86.0%	85.8%	89.2%	84.2%	68.1%	56.7%	71.3%	57.9%
TERMINAL (d)	32/38 (84%)	37/41 (90%)	37/41 (90%)	27/33 (82%)	26/36 (72%)	21/35 (60%)	23/31 (74%)	22/35 (63%)
FIRST INCIDENCE	484	431	543	535	524	674	602	475
STATISTICAL TESTS								
LIFE TABLE	P=0.197	P=0.404N	P=0.576N	P=0.333	P=0.340N	P=0.239N	P=0.292	P=0.249N
POLY 3	P=0.477N	P=0.604N	P=0.434	P=0.517N	P=0.287N	P=0.174N	P=0.461	P=0.207N
POLY 1.5	P=0.416N	P=0.574N	P=0.450	P=0.455N	P=0.283N	P=0.176N	P=0.467	P=0.206N
POLY 6	P=0.525N	P=0.597	P=0.411	P=0.571N	P=0.286N	P=0.164N	P=0.464	P=0.202N
LOGISTIC REGRESSION	P=0.371N	P=0.523N	P=0.466	P=0.394N	P=0.297N	P=0.123N	P=0.493	P=0.204N
COCH-ARM / FISHERS	P=0.289N	P=0.535N	P=0.468	P=0.330N	P=0.237N	P=0.176N	P=0.583N	P=0.176N
ORDER RESTRICTED	P=0.539N	(e)	(e)	(e)	P=0.233N	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
Liver Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma								
TUMOR RATES								
OVERALL (a)	41/48 (85%)	43/50 (86%)	45/50 (90%)	40/50 (80%)	31/49 (63%)	26/50 (52%)	31/49 (63%)	26/50 (52%)
POLY-3 RATE (b)	41/47.67	43/49.02	45/49.58	40/47.50	31/45.50	26/45.86	31/43.48	26/44.92
POLY-3 PERCENT (g)	86.0%	87.7%	90.8%	84.2%	68.1%	56.7%	71.3%	57.9%
TERMINAL (d)	32/38 (84%)	37/41 (90%)	37/41 (90%)	27/33 (82%)	26/36 (72%)	21/35 (60%)	23/31 (74%)	22/35 (63%)
FIRST INCIDENCE	484	431	543	535	524	674	602	475
STATISTICAL TESTS								
LIFE TABLE	P=0.212	P=0.481N	P=0.508	P=0.333	P=0.340N	P=0.239N	P=0.292	P=0.249N
POLY 3	P=0.448N	P=0.522	P=0.337	P=0.517N	P=0.287N	P=0.174N	P=0.461	P=0.207N
POLY 1.5	P=0.387N	P=0.547	P=0.342	P=0.455N	P=0.283N	P=0.176N	P=0.467	P=0.206N
POLY 6	P=0.498N	P=0.490	P=0.332	P=0.571N	P=0.286N	P=0.164N	P=0.464	P=0.202N
LOGISTIC REGRESSION	P=0.338N	P=0.594	P=0.344	P=0.394N	P=0.297N	P=0.123N	P=0.493	P=0.204N
COCH-ARM / FISHERS	P=0.259N	P=0.581	P=0.351	P=0.330N	P=0.237N	P=0.176N	P=0.583N	P=0.176N
ORDER RESTRICTED	P=0.440N	(e)	(e)	(e)	P=0.233N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Mice(B6C3F1) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Lung Alveolar/Bronchiolar Adenoma								
TUMOR RATES								
OVERALL (a)	6/50 (12%)	4/50 (8%)	7/50 (14%)	6/50 (12%)	3/50 (6%)	1/50 (2%)	0/49 (0%)	3/50 (6%)
POLY-3 RATE (b)	6/44.60	4/47.71	7/47.00	6/43.91	3/43.98	1/45.35	0/41.33	3/43.40
POLY-3 PERCENT (g)	13.5%	8.4%	14.9%	13.7%	6.8%	2.2%	0.0%	6.9%
TERMINAL (d)	6/38 (16%)	3/41 (7%)	6/41 (15%)	4/33 (12%)	2/36 (6%)	1/35 (3%)	0/30 (0%)	3/35 (9%)
FIRST INCIDENCE	729 (T)	604	570	711	630	729 (T)	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.354	P=0.324N	P=0.556	P=0.528	P=0.512	P=0.308N	P=0.148N	P=0.653
POLY 3	P=0.423	P=0.328N	P=0.540	P=0.610	P=0.513	P=0.294N	P=0.130N	P=0.657
POLY 1.5	P=0.437	P=0.344N	P=0.526	P=0.615	P=0.515	P=0.298N	P=0.129N	P=0.657
POLY 6	P=0.403	P=0.308N	P=0.556	P=0.602	P=0.509	P=0.290N	P=0.132N	P=0.657
LOGISTIC REGRESSION	P=0.427	P=0.333N	P=0.535	P=0.573	P=0.516	P=0.296N	P=0.128N	P=0.662
COCH-ARM / FISHERS	P=0.455	P=0.370N	P=0.500	P=0.620N	P=0.525	P=0.309N	P=0.125N	P=0.661N
ORDER RESTRICTED	P=0.496	(e)	(e)	(e)	P=0.284	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Lung Alveolar/Bronchiolar Carcinoma								
TUMOR RATES								
OVERALL (a)	4/50 (8%)	5/50 (10%)	7/50 (14%)	4/50 (8%)	1/50 (2%)	1/50 (2%)	2/49 (4%)	1/50 (2%)
POLY-3 RATE (b)	4/45.19	5/47.28	7/47.72	4/44.15	1/43.63	1/45.35	2/41.40	1/43.40
POLY-3 PERCENT (g)	8.9%	10.6%	14.7%	9.1%	2.3%	2.2%	4.8%	2.3%
TERMINAL (d)	2/38 (5%)	5/41 (12%)	4/41 (10%)	2/33 (6%)	1/36 (3%)	1/35 (3%)	1/30 (3%)	1/35 (3%)
FIRST INCIDENCE	638	729 (T)	543	640	729 (T)	729 (T)	712	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.481	P=0.550	P=0.314	P=0.590	P=0.575	P=0.756	P=0.455	P=0.756
POLY 3	P=0.534	P=0.528	P=0.293	P=0.631	P=0.581	P=0.752N	P=0.482	P=0.760
POLY 1.5	P=0.547	P=0.518	P=0.282	P=0.636	P=0.582	P=0.755N	P=0.482	P=0.759
POLY 6	P=0.516	P=0.539	P=0.305	P=0.621	P=0.581	P=0.748N	P=0.481	P=0.761N
LOGISTIC REGRESSION	P=0.559N	P=0.522	P=0.219	P=0.641	P=0.580	P=0.756	P=0.477	P=0.756
COCH-ARM / FISHERS	P=0.563	P=0.500	P=0.262	P=0.643N	P=0.590	P=0.753N	P=0.492	P=0.753N
ORDER RESTRICTED	P=0.505	(e)	(e)	(e)	P=0.563	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Mice(B6C3F1) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Lung								
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma								
TUMOR RATES								
OVERALL (a)	10/50 (20%)	8/50 (16%)	13/50 (26%)	9/50 (18%)	4/50 (8%)	2/50 (4%)	2/49 (4%)	4/50 (8%)
POLY-3 RATE (b)	10/45.19	8/47.71	13/48.25	9/44.27	4/43.98	2/45.35	2/41.40	4/43.40
POLY-3 PERCENT (g)	22.1%	16.8%	27.0%	20.3%	9.1%	4.4%	4.8%	9.2%
TERMINAL (d)	8/38 (21%)	7/41 (17%)	9/41 (22%)	5/33 (15%)	3/36 (8%)	2/35 (6%)	1/30 (3%)	4/35 (11%)
FIRST INCIDENCE	638	604	543	640	630	729 (T)	712	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.418	P=0.331N	P=0.398	P=0.590	P=0.479	P=0.343N	P=0.402N	P=0.631
POLY 3	P=0.505	P=0.349N	P=0.383	P=0.520N	P=0.482	P=0.323N	P=0.365N	P=0.636
POLY 1.5	P=0.523	P=0.367N	P=0.359	P=0.511N	P=0.486	P=0.328N	P=0.363N	P=0.637
POLY 6	P=0.480	P=0.328N	P=0.408	P=0.536N	P=0.478	P=0.317N	P=0.369N	P=0.636
LOGISTIC REGRESSION	P=0.537	P=0.358N	P=0.310	P=0.524N	P=0.486	P=0.318N	P=0.362N	P=0.644
COCH-ARM / FISHERS	P=0.548	P=0.398N	P=0.318	P=0.500N	P=0.499	P=0.339N	P=0.349N	P=0.643N
ORDER RESTRICTED	P=0.488	(e)	(e)	(e)	P=0.449	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Ovary								
Choriocarcinoma								
TUMOR RATES								
OVERALL (a)					0/45 (0%)	0/45 (0%)	2/47 (4%)	0/50 (0%)
POLY-3 RATE (b)					0/39.57	0/41.72	2/40.43	0/43.40
POLY-3 PERCENT (g)					0.0%	0.0%	5.0%	0.0%
TERMINAL (d)					0/32 (0%)	0/34 (0%)	1/30 (3%)	0/35 (0%)
FIRST INCIDENCE					---	---	683	---
STATISTICAL TESTS								
LIFE TABLE					P=0.602	(e)	P=0.233	(e)
POLY 3					P=0.604	(e)	P=0.241	(e)
POLY 1.5					P=0.606	(e)	P=0.240	(e)
POLY 6					P=0.604	(e)	P=0.244	(e)
LOGISTIC REGRESSION					P=0.612	(e)	P=0.241	(e)
COCH-ARM / FISHERS					P=0.617	(e)	P=0.258	(e)
ORDER RESTRICTED					P=0.252	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Ovary Cystadenoma								
TUMOR RATES								
OVERALL (a)					1/45 (2%)	4/45 (9%)	1/47 (2%)	1/50 (2%)
POLY-3 RATE (b)					1/39.57	4/41.90	1/40.25	1/43.40
POLY-3 PERCENT (g)					2.5%	9.6%	2.5%	2.3%
TERMINAL (d)					1/32 (3%)	3/34 (9%)	1/30 (3%)	1/35 (3%)
FIRST INCIDENCE					729 (T)	682	729 (T)	729 (T)
STATISTICAL TESTS								
LIFE TABLE					P=0.353N	P=0.204	P=0.748	P=0.742N
POLY 3					P=0.336N	P=0.196	P=0.757N	P=0.740N
POLY 1.5					P=0.338N	P=0.188	P=0.758N	P=0.741N
POLY 6					P=0.330N	P=0.208	P=0.755N	P=0.738N
LOGISTIC REGRESSION					P=0.343N	P=0.204	P=0.748	P=0.742N
COCH-ARM / FISHERS					P=0.332N	P=0.180	P=0.742N	P=0.726N
ORDER RESTRICTED					P=0.305N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Ovary Granulosa Cell Tumor Benign								
TUMOR RATES								
OVERALL (a)					1/45 (2%)	1/45 (2%)	1/47 (2%)	5/50 (10%)
POLY-3 RATE (b)					1/39.57	1/41.72	1/40.25	5/43.40
POLY-3 PERCENT (g)					2.5%	2.4%	2.5%	11.5%
TERMINAL (d)					1/32 (3%)	1/34 (3%)	1/30 (3%)	5/35 (14%)
FIRST INCIDENCE					729 (T)	729 (T)	729 (T)	729 (T)
STATISTICAL TESTS								
LIFE TABLE					P=0.031 *	P=0.748N	P=0.748	P=0.123
POLY 3					P=0.031 *	P=0.749N	P=0.757N	P=0.123
POLY 1.5					P=0.032 *	P=0.754N	P=0.758N	P=0.122
POLY 6					P=0.030 *	P=0.741N	P=0.755N	P=0.125
LOGISTIC REGRESSION					P=0.031 *	P=0.748N	P=0.748	P=0.123
COCH-ARM / FISHERS					P=0.035 *	P=0.753N	P=0.742N	P=0.128
ORDER RESTRICTED					P=0.036 *	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Mice(B6C3F1) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Ovary								
Granulosa Cell Tumor: Benign, Malignant, NOS								
TUMOR RATES								
OVERALL (a)					1/45 (2%)	1/45 (2%)	1/47 (2%)	6/50 (12%)
POLY-3 RATE (b)					1/39.57	1/41.72	1/40.25	6/44.39
POLY-3 PERCENT (g)					2.5%	2.4%	2.5%	13.5%
TERMINAL (d)					1/32 (3%)	1/34 (3%)	1/30 (3%)	5/35 (14%)
FIRST INCIDENCE					729 (T)	729 (T)	729 (T)	142
STATISTICAL TESTS								
LIFE TABLE					P=0.012 *	P=0.748N	P=0.748	P=0.073
POLY 3					P=0.012 *	P=0.749N	P=0.757N	P=0.075
POLY 1.5					P=0.012 *	P=0.754N	P=0.758N	P=0.075
POLY 6					P=0.011 *	P=0.741N	P=0.755N	P=0.077
LOGISTIC REGRESSION					P=0.015 *	P=0.748N	P=0.748	P=0.089
COCH-ARM / FISHERS					P=0.013 *	P=0.753N	P=0.742N	P=0.074
ORDER RESTRICTED					P=0.015 *	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Ovary								
Luteoma								
TUMOR RATES								
OVERALL (a)					3/45 (7%)	0/45 (0%)	1/47 (2%)	0/50 (0%)
POLY-3 RATE (b)					3/39.78	0/41.72	1/40.25	0/43.40
POLY-3 PERCENT (g)					7.5%	0.0%	2.5%	0.0%
TERMINAL (d)					2/32 (6%)	0/34 (0%)	1/30 (3%)	0/35 (0%)
FIRST INCIDENCE					674	---	729 (T)	---
STATISTICAL TESTS								
LIFE TABLE					P=0.084N	P=0.109N	P=0.326N	P=0.110N
POLY 3					P=0.079N	P=0.110N	P=0.300N	P=0.103N
POLY 1.5					P=0.078N	P=0.114N	P=0.302N	P=0.103N
POLY 6					P=0.082N	P=0.105N	P=0.298N	P=0.101N
LOGISTIC REGRESSION					P=0.078N	P=0.111N	P=0.295N	P=0.104N
COCH-ARM / FISHERS					P=0.075N	P=0.121N	P=0.292N	P=0.103N
ORDER RESTRICTED					P=0.016N*	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
Pituitary Gland: Pars Distalis or Unspecified Site								
Adenoma								
TUMOR RATES								
OVERALL (a)	0/47 (0%)	1/47 (2%)	0/45 (0%)	0/49 (0%)	3/46 (7%)	2/45 (4%)	4/48 (8%)	4/50 (8%)
POLY-3 RATE (b)	0/42.10	1/44.28	0/42.54	0/42.80	3/41.52	2/41.26	4/40.71	4/43.56
POLY-3 PERCENT (g)	0.0%	2.3%	0.0%	0.0%	7.2%	4.9%	9.8%	9.2%
TERMINAL (d)	0/37 (0%)	1/38 (3%)	0/38 (0%)	0/32 (0%)	3/35 (9%)	2/32 (6%)	4/30 (13%)	3/35 (9%)
FIRST INCIDENCE	---	729 (T)	---	---	729 (T)	729 (T)	729 (T)	688
STATISTICAL TESTS								
LIFE TABLE	P=0.591N	P=0.505	(e)	(e)	P=0.339	P=0.541N	P=0.415	P=0.500
POLY 3	P=0.553N	P=0.510	(e)	(e)	P=0.356	P=0.503N	P=0.489	P=0.526
POLY 1.5	P=0.556N	P=0.506	(e)	(e)	P=0.362	P=0.506N	P=0.494	P=0.530
POLY 6	P=0.550N	P=0.514	(e)	(e)	P=0.352	P=0.497N	P=0.484	P=0.526
LOGISTIC REGRESSION	(e)	P=0.505	(e)	(e)	P=0.340	P=0.541N	P=0.415	P=0.520
COCH-ARM / FISHERS	P=0.561N	P=0.500	(e)	(e)	P=0.383	P=0.511N	P=0.524	P=0.547
ORDER RESTRICTED	P=0.387N	(e)	(e)	(e)	P=0.436	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
Skeletal Muscle								
Rhabdomyosarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.60	0/47.28	0/46.48	1/44.40	0/43.63	1/46.10	1/42.33	2/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	2.3%	0.0%	2.2%	2.4%	4.6%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	1/31 (3%)	2/35 (6%)
FIRST INCIDENCE	---	---	---	535	---	461	729 (T)	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.197	(e)	(e)	P=0.500	P=0.150	P=0.508	P=0.470	P=0.232
POLY 3	P=0.195	(e)	(e)	P=0.499	P=0.149	P=0.511	P=0.494	P=0.236
POLY 1.5	P=0.197	(e)	(e)	P=0.500	P=0.150	P=0.507	P=0.494	P=0.235
POLY 6	P=0.192	(e)	(e)	P=0.498	P=0.149	P=0.516	P=0.493	P=0.237
LOGISTIC REGRESSION	P=0.246	(e)	(e)	P=0.513	P=0.156	P=0.312	P=0.470	P=0.232
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500	P=0.153	P=0.500	P=0.500	P=0.247
ORDER RESTRICTED	P=0.119	(e)	(e)	(e)	P=0.116	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Mice(B6C3F1) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Skin Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	0/44.60	0/47.28	1/46.48	0/43.80	0/43.63	1/46.01	0/42.33	3/43.50
POLY-3 PERCENT (g)	0.0%	0.0%	2.2%	0.0%	0.0%	2.2%	0.0%	6.9%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	1/41 (2%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	2/35 (6%)
FIRST INCIDENCE	---	---	729 (T)	---	---	513	---	705
STATISTICAL TESTS								
LIFE TABLE	P=0.681	(e)	P=0.515	(e)	P=0.043 *	P=0.500	(e)	P=0.118
POLY 3	P=0.677	(e)	P=0.508	(e)	P=0.041 *	P=0.511	(e)	P=0.118
POLY 1.5	P=0.684	(e)	P=0.506	(e)	P=0.042 *	P=0.507	(e)	P=0.117
POLY 6	P=0.666	(e)	P=0.511	(e)	P=0.041 *	P=0.515	(e)	P=0.119
LOGISTIC REGRESSION	(e)	(e)	P=0.515	(e)	P=0.045 *	P=0.371	(e)	P=0.120
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)	P=0.044 *	P=0.500	(e)	P=0.121
ORDER RESTRICTED	P=0.389	(e)	(e)	(e)	P=0.020 *	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Skin Fibrosarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/44.60	0/47.28	0/46.48	0/43.80	0/43.63	1/46.01	0/42.33	2/43.50
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	0.0%	4.6%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	1/35 (3%)
FIRST INCIDENCE	---	---	---	---	---	513	---	705
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.135	P=0.500	(e)	P=0.234
POLY 3	(e)	(e)	(e)	(e)	P=0.137	P=0.511	(e)	P=0.236
POLY 1.5	(e)	(e)	(e)	(e)	P=0.137	P=0.507	(e)	P=0.236
POLY 6	(e)	(e)	(e)	(e)	P=0.138	P=0.515	(e)	P=0.238
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.144	P=0.371	(e)	P=0.237
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.140	P=0.500	(e)	P=0.247
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.074	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Skin — Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	0/44.60	0/47.28	1/46.48	0/43.80	0/43.63	1/46.01	0/42.33	3/43.50
POLY-3 PERCENT (g)	0.0%	0.0%	2.2%	0.0%	0.0%	2.2%	0.0%	6.9%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	1/41 (2%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	2/35 (6%)
FIRST INCIDENCE	---	---	729 (T)	---	---	513	---	705
STATISTICAL TESTS								
LIFE TABLE	P=0.681	(e)	P=0.515	(e)	P=0.043 *	P=0.500	(e)	P=0.118
POLY 3	P=0.677	(e)	P=0.508	(e)	P=0.041 *	P=0.511	(e)	P=0.118
POLY 1.5	P=0.684	(e)	P=0.506	(e)	P=0.042 *	P=0.507	(e)	P=0.117
POLY 6	P=0.666	(e)	P=0.511	(e)	P=0.041 *	P=0.515	(e)	P=0.119
LOGISTIC REGRESSION	(e)	(e)	P=0.515	(e)	P=0.045 *	P=0.371	(e)	P=0.120
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)	P=0.044 *	P=0.500	(e)	P=0.121
ORDER RESTRICTED	P=0.389	(e)	(e)	(e)	P=0.020 *	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Skin — Schwannoma Malignant								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	3/50 (6%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.60	0/47.28	0/46.48	0/43.80	3/44.09	1/45.90	0/42.33	1/43.57
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	6.8%	2.2%	0.0%	2.3%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	2/36 (6%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---	591	561	---	685
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.211N	P=0.317N	P=0.144N	P=0.310N
POLY 3	(e)	(e)	(e)	(e)	P=0.207N	P=0.291N	P=0.126N	P=0.309N
POLY 1.5	(e)	(e)	(e)	(e)	P=0.206N	P=0.296N	P=0.125N	P=0.309N
POLY 6	(e)	(e)	(e)	(e)	P=0.210N	P=0.285N	P=0.127N	P=0.308N
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.192N	P=0.337N	P=0.121N	P=0.305N
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.200N	P=0.309N	P=0.121N	P=0.309N
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.085N	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
Spleen								
Hemangiosarcoma								
TUMOR RATES								
OVERALL (a)	0/48 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/49 (4%)	1/48 (2%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.91	0/47.28	1/46.72	0/43.80	2/44.00	1/44.82	1/42.00	0/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	2.1%	0.0%	4.6%	2.2%	2.4%	0.0%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	1/36 (3%)	0/35 (0%)	1/31 (3%)	0/35 (0%)
FIRST INCIDENCE	---	---	667	---	606	674	729 (T)	---
STATISTICAL TESTS								
LIFE TABLE	P=0.690	(e)	P=0.529	(e)	P=0.159N	P=0.484N	P=0.535N	P=0.240N
POLY 3	P=0.675	(e)	P=0.512	(e)	P=0.159N	P=0.494N	P=0.516N	P=0.240N
POLY 1.5	P=0.684	(e)	P=0.511	(e)	P=0.157N	P=0.500N	P=0.515N	P=0.239N
POLY 6	P=0.662	(e)	P=0.515	(e)	P=0.161N	P=0.485N	P=0.518N	P=0.240N
LOGISTIC REGRESSION	P=0.721	(e)	P=0.492	(e)	P=0.147N	P=0.535N	P=0.504N	P=0.221N
COCH-ARM / FISHERS	P=0.699	(e)	P=0.510	(e)	P=0.149N	P=0.508N	P=0.500N	P=0.242N
ORDER RESTRICTED	P=0.392	(e)	(e)	(e)	P=0.120N	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
Stomach, Forestomach								
Squamous Cell Carcinoma or Papilloma Squamous								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	2/50 (4%)	0/50 (0%)	1/50 (2%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	0/44.60	0/47.28	2/46.48	2/44.19	0/43.63	1/45.35	3/42.84	1/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	4.3%	4.5%	0.0%	2.2%	7.0%	2.3%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	2/41 (5%)	1/33 (3%)	0/36 (0%)	1/35 (3%)	2/31 (7%)	1/35 (3%)
FIRST INCIDENCE	---	---	729 (T)	618	---	729 (T)	574	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.067	(e)	P=0.255	P=0.222	P=0.341	P=0.494	P=0.102	P=0.494
POLY 3	P=0.080	(e)	P=0.246	P=0.235	P=0.343	P=0.508	P=0.115	P=0.499
POLY 1.5	P=0.082	(e)	P=0.243	P=0.236	P=0.344	P=0.505	P=0.114	P=0.498
POLY 6	P=0.076	(e)	P=0.250	P=0.233	P=0.344	P=0.511	P=0.116	P=0.500
LOGISTIC REGRESSION	P=0.085	(e)	P=0.255	P=0.240	P=0.347	P=0.494	P=0.120	P=0.494
COCH-ARM / FISHERS	P=0.086	(e)	P=0.247	P=0.247	P=0.351	P=0.500	P=0.121	P=0.500
ORDER RESTRICTED	P=0.114	(e)	(e)	(e)	P=0.150	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Stomach, Forestomach								
Squamous Cell Papilloma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/44.60	0/47.28	2/46.48	2/44.19	0/43.63	0/45.35	2/42.84	1/43.40
POLY-3 PERCENT (g)	0.0%	0.0%	4.3%	4.5%	0.0%	0.0%	4.7%	2.3%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	2/41 (5%)	1/33 (3%)	0/36 (0%)	0/35 (0%)	1/31 (3%)	1/35 (3%)
FIRST INCIDENCE	---	---	729 (T)	618	---	---	574	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.067	(e)	P=0.255	P=0.222	P=0.241	(e)	P=0.216	P=0.494
POLY 3	P=0.080	(e)	P=0.246	P=0.235	P=0.239	(e)	P=0.233	P=0.499
POLY 1.5	P=0.082	(e)	P=0.243	P=0.236	P=0.240	(e)	P=0.232	P=0.498
POLY 6	P=0.076	(e)	P=0.250	P=0.233	P=0.239	(e)	P=0.234	P=0.500
LOGISTIC REGRESSION	P=0.085	(e)	P=0.255	P=0.240	P=0.247	(e)	P=0.244	P=0.494
COCH-ARM / FISHERS	P=0.086	(e)	P=0.247	P=0.247	P=0.246	(e)	P=0.247	P=0.500
ORDER RESTRICTED	P=0.114	(e)	(e)	(e)	P=0.164	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Stomach, Glandular								
Adenoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.60	2/47.28	0/46.48	0/43.80	0/43.63	0/45.35	0/42.33	0/43.40
POLY-3 PERCENT (g)	0.0%	4.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
TERMINAL (d)	0/38 (0%)	2/41 (5%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	---	729 (T)	---	---	---	---	---	---
STATISTICAL TESTS								
LIFE TABLE	P=0.434N	P=0.255	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	P=0.396N	P=0.250	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	P=0.399N	P=0.245	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	P=0.394N	P=0.257	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	P=0.255	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	P=0.262N	(e)	(e)	(e)	(e)	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Testes								
Adenoma								
TUMOR RATES								
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)				
POLY-3 RATE (b)	0/44.60	0/47.28	0/46.48	2/43.80				
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	4.6%				
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	2/33 (6%)				
FIRST INCIDENCE	---	---	---	729 (T)				
STATISTICAL TESTS								
LIFE TABLE	P=0.033 *	(e)	(e)	P=0.208				
POLY 3	P=0.043 *	(e)	(e)	P=0.233				
POLY 1.5	P=0.044 *	(e)	(e)	P=0.235				
POLY 6	P=0.042 *	(e)	(e)	P=0.230				
LOGISTIC REGRESSION	(e)	(e)	(e)	P=0.208				
COCH-ARM / FISHERS	P=0.046 *	(e)	(e)	P=0.247				
ORDER RESTRICTED	P=0.028 *	(e)	(e)	(e)				

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
Uterus								
Polyp Stromal								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)					1/50 (2%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)					1/43.63	0/45.35	0/42.33	3/43.40
POLY-3 PERCENT (g)					2.3%	0.0%	0.0%	6.9%
TERMINAL (d)					1/36 (3%)	0/35 (0%)	0/31 (0%)	3/35 (9%)
FIRST INCIDENCE					729 (T)	---	---	729 (T)
STATISTICAL TESTS								
LIFE TABLE					P=0.085	P=0.506N	P=0.530N	P=0.295
POLY 3					P=0.081	P=0.492N	P=0.506N	P=0.303
POLY 1.5					P=0.082	P=0.495N	P=0.506N	P=0.302
POLY 6					P=0.080	P=0.489N	P=0.507N	P=0.305
LOGISTIC REGRESSION					P=0.085	(e)	(e)	P=0.295
COCH-ARM / FISHERS					P=0.086	P=0.500N	P=0.500N	P=0.309
ORDER RESTRICTED					P=0.037 *	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs Hemangioma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/44.60	0/47.28	1/46.48	0/43.80	2/43.63	1/45.35	1/42.33	1/43.79
POLY-3 PERCENT (g)	0.0%	0.0%	2.2%	0.0%	4.6%	2.2%	2.4%	2.3%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	1/41 (2%)	0/33 (0%)	2/36 (6%)	1/35 (3%)	1/31 (3%)	0/35 (0%)
FIRST INCIDENCE	---	---	729 (T)	---	729 (T)	729 (T)	729 (T)	618
STATISTICAL TESTS								
LIFE TABLE	P=0.681	(e)	P=0.515	(e)	P=0.418N	P=0.510N	P=0.552N	P=0.501N
POLY 3	P=0.677	(e)	P=0.508	(e)	P=0.416N	P=0.486N	P=0.511N	P=0.499N
POLY 1.5	P=0.684	(e)	P=0.506	(e)	P=0.416N	P=0.491N	P=0.511N	P=0.501N
POLY 6	P=0.666	(e)	P=0.511	(e)	P=0.416N	P=0.480N	P=0.512N	P=0.495N
LOGISTIC REGRESSION	(e)	(e)	P=0.515	(e)	P=0.415N	P=0.510N	P=0.552N	P=0.501N
COCH-ARM / FISHERS	P=0.694	(e)	P=0.500	(e)	P=0.409N	P=0.500N	P=0.500N	P=0.500N
ORDER RESTRICTED	P=0.389	(e)	(e)	(e)	P=0.412N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs Hemangiosarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	2/50 (4%)	3/50 (6%)	4/50 (8%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/44.60	2/47.28	2/46.72	2/43.80	3/44.05	4/45.56	2/42.58	1/43.40
POLY-3 PERCENT (g)	2.2%	4.2%	4.3%	4.6%	6.8%	8.8%	4.7%	2.3%
TERMINAL (d)	1/38 (3%)	2/41 (5%)	1/41 (2%)	2/33 (6%)	2/36 (6%)	3/35 (9%)	1/31 (3%)	1/35 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	667	729 (T)	606	674	662	729 (T)
STATISTICAL TESTS								
LIFE TABLE	P=0.363	P=0.527	P=0.534	P=0.451	P=0.173N	P=0.502	P=0.540N	P=0.312N
POLY 3	P=0.409	P=0.520	P=0.516	P=0.494	P=0.170N	P=0.518	P=0.515N	P=0.310N
POLY 1.5	P=0.415	P=0.512	P=0.511	P=0.497	P=0.169N	P=0.512	P=0.515N	P=0.310N
POLY 6	P=0.399	P=0.530	P=0.522	P=0.489	P=0.171N	P=0.527	P=0.517N	P=0.310N
LOGISTIC REGRESSION	P=0.399	P=0.527	P=0.508	P=0.451	P=0.167N	P=0.512	P=0.508N	P=0.307N
COCH-ARM / FISHERS	P=0.423	P=0.500	P=0.500	P=0.500	P=0.162N	P=0.500	P=0.500N	P=0.309N
ORDER RESTRICTED	P=0.457	(e)	(e)	(e)	P=0.211N	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Mice(B6C3F1) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs Hemangiosarcoma or Hemangioma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	2/50 (4%)	5/50 (10%)	5/50 (10%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/44.60	2/47.28	3/46.72	2/43.80	5/44.05	5/45.56	3/42.58	2/43.79
POLY-3 PERCENT (g)	2.2%	4.2%	6.4%	4.6%	11.4%	11.0%	7.1%	4.6%
TERMINAL (d)	1/38 (3%)	2/41 (5%)	2/41 (5%)	2/33 (6%)	4/36 (11%)	4/35 (11%)	2/31 (7%)	1/35 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	667	729 (T)	606	674	662	618
STATISTICAL TESTS								
LIFE TABLE	P=0.339	P=0.527	P=0.340	P=0.451	P=0.141N	P=0.626	P=0.420N	P=0.224N
POLY 3	P=0.386	P=0.520	P=0.322	P=0.494	P=0.134N	P=0.609N	P=0.375N	P=0.218N
POLY 1.5	P=0.394	P=0.512	P=0.316	P=0.497	P=0.134N	P=0.616N	P=0.374N	P=0.219N
POLY 6	P=0.374	P=0.530	P=0.329	P=0.489	P=0.134N	P=0.599N	P=0.377N	P=0.215N
LOGISTIC REGRESSION	P=0.376	P=0.527	P=0.318	P=0.451	P=0.134N	P=0.607N	P=0.372N	P=0.218N
COCH-ARM / FISHERS	P=0.404	P=0.500	P=0.309	P=0.500	P=0.128N	P=0.630N	P=0.357N	P=0.218N
ORDER RESTRICTED	P=0.365	(e)	(e)	(e)	P=0.201N	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs Histiocytic Sarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	3/50 (6%)	0/50 (0%)	1/50 (2%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	1/44.86	0/47.28	2/46.48	3/44.39	0/43.63	1/45.35	4/43.11	2/44.00
POLY-3 PERCENT (g)	2.2%	0.0%	4.3%	6.8%	0.0%	2.2%	9.3%	4.6%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	2/41 (5%)	1/33 (3%)	0/36 (0%)	1/35 (3%)	1/31 (3%)	1/35 (3%)
FIRST INCIDENCE	661	---	729 (T)	595	---	729 (T)	503	535
STATISTICAL TESTS								
LIFE TABLE	P=0.083	P=0.477N	P=0.528	P=0.287	P=0.159	P=0.494	P=0.059	P=0.234
POLY 3	P=0.097	P=0.489N	P=0.512	P=0.301	P=0.163	P=0.508	P=0.058	P=0.239
POLY 1.5	P=0.099	P=0.493N	P=0.509	P=0.303	P=0.161	P=0.505	P=0.058	P=0.237
POLY 6	P=0.093	P=0.485N	P=0.516	P=0.298	P=0.165	P=0.511	P=0.059	P=0.242
LOGISTIC REGRESSION	P=0.109	P=0.531N	P=0.506	P=0.309	P=0.169	P=0.494	P=0.064	P=0.247
COCH-ARM / FISHERS	P=0.104	P=0.500N	P=0.500	P=0.309	P=0.165	P=0.500	P=0.059	P=0.247
ORDER RESTRICTED	P=0.104	(e)	(e)	(e)	P=0.073	(e)	(e)	(e)

Statistical Analysis of Primary Tumors in Mice(B6C3F1) - WATER DISINFECTION BYPRODUCTS (SODIUM
Terminal Sacrifice at 105 weeks

Dose	Males 0 MG/L	Males 500 MG/L	Males 1000MG/L	Males 2000MG/L	Females 0 MG/L	Females 500 MG/L	Females 1000MG/L	Females 2000MG/L
All Organs Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	3/50 (6%)	1/50 (2%)	0/50 (0%)	3/50 (6%)	23/50 (46%)	19/50 (38%)	28/50 (56%)	27/50 (54%)
POLY-3 RATE (b)	3/45.53	1/47.28	0/46.48	3/44.19	23/45.56	19/46.35	28/43.89	27/45.42
POLY-3 PERCENT (g)	6.6%	2.1%	0.0%	6.8%	50.5%	41.0%	63.8%	59.5%
TERMINAL (d)	2/38 (5%)	1/41 (2%)	0/41 (0%)	2/33 (6%)	19/36 (53%)	16/35 (46%)	23/31 (74%)	22/35 (63%)
FIRST INCIDENCE	301	729 (T)	---	616	440	492	503	447
STATISTICAL TESTS								
LIFE TABLE	P=0.480	P=0.287N	P=0.114N	P=0.616	P=0.094	P=0.296N	P=0.073	P=0.250
POLY 3	P=0.514	P=0.292N	P=0.115N	P=0.649	P=0.089	P=0.238N	P=0.138	P=0.254
POLY 1.5	P=0.519	P=0.298N	P=0.117N	P=0.653	P=0.093	P=0.249N	P=0.149	P=0.253
POLY 6	P=0.508	P=0.283N	P=0.113N	P=0.644	P=0.089	P=0.224N	P=0.126	P=0.264
LOGISTIC REGRESSION	P=0.555	P=0.406N	P=0.196N	P=0.653N	P=0.095	P=0.232N	P=0.161	P=0.259
COCH-ARM / FISHERS	P=0.526	P=0.309N	P=0.121N	P=0.661N	P=0.121	P=0.272N	P=0.212	P=0.274
ORDER RESTRICTED	P=0.268	(e)	(e)	(e)	P=0.089	(e)	(e)	(e)

Dose	Males 0 MG/L	Males 500 MG/L	Males 1000MG/L	Males 2000MG/L	Females 0 MG/L	Females 500 MG/L	Females 1000MG/L	Females 2000MG/L
All Organs Osteosarcoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.60	0/47.28	0/46.48	0/43.80	0/43.63	1/45.39	1/42.71	2/44.56
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	2.3%	4.5%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---	---	719	622	447
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.154	P=0.505	P=0.495	P=0.247
POLY 3	(e)	(e)	(e)	(e)	P=0.156	P=0.508	P=0.496	P=0.242
POLY 1.5	(e)	(e)	(e)	(e)	P=0.154	P=0.505	P=0.495	P=0.239
POLY 6	(e)	(e)	(e)	(e)	P=0.159	P=0.512	P=0.496	P=0.246
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.167	P=0.511	P=0.520	P=0.273
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.153	P=0.500	P=0.500	P=0.247
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.122	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs Osteosarcoma or Osteoma								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/44.60	0/47.28	0/46.48	0/43.80	0/43.63	1/45.39	1/42.71	2/44.56
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	2.3%	4.5%
TERMINAL (d)	0/38 (0%)	0/41 (0%)	0/41 (0%)	0/33 (0%)	0/36 (0%)	0/35 (0%)	0/31 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---	---	719	622	447
STATISTICAL TESTS								
LIFE TABLE	(e)	(e)	(e)	(e)	P=0.154	P=0.505	P=0.495	P=0.247
POLY 3	(e)	(e)	(e)	(e)	P=0.156	P=0.508	P=0.496	P=0.242
POLY 1.5	(e)	(e)	(e)	(e)	P=0.154	P=0.505	P=0.495	P=0.239
POLY 6	(e)	(e)	(e)	(e)	P=0.159	P=0.512	P=0.496	P=0.246
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.167	P=0.511	P=0.520	P=0.273
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	P=0.153	P=0.500	P=0.500	P=0.247
ORDER RESTRICTED	(e)	(e)	(e)	(e)	P=0.122	(e)	(e)	(e)

Dose	Males 0 MG/L	500 MG/L	1000MG/L	2000MG/L	Females 0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs Benign Tumors								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	34/50 (68%)	38/50 (76%)	37/50 (74%)	34/50 (68%)	38/50 (76%)	27/50 (54%)	33/50 (66%)	31/50 (62%)
POLY-3 RATE (b)	34/48.07	38/47.86	37/48.25	34/46.91	38/46.54	27/46.09	33/44.32	31/45.66
POLY-3 PERCENT (g)	70.7%	79.4%	76.7%	72.5%	81.6%	58.6%	74.5%	67.9%
TERMINAL (d)	27/38 (71%)	35/41 (85%)	32/41 (78%)	24/33 (73%)	31/36 (86%)	22/35 (63%)	24/31 (77%)	25/35 (71%)
FIRST INCIDENCE	484	604	543	535	524	673	574	475
STATISTICAL TESTS								
LIFE TABLE	P=0.243	P=0.472	P=0.541	P=0.314	P=0.307N	P=0.028N*	P=0.527N	P=0.144N
POLY 3	P=0.528N	P=0.223	P=0.330	P=0.515	P=0.234N	P=0.010N*	P=0.273N	P=0.090N
POLY 1.5	P=0.499N	P=0.239	P=0.339	P=0.541	P=0.238N	P=0.011N*	P=0.263N	P=0.094N
POLY 6	P=0.538	P=0.207	P=0.317	P=0.492	P=0.231N	P=0.009N**	P=0.293N	P=0.085N
LOGISTIC REGRESSION	P=0.509N	P=0.343	P=0.382	P=0.569	P=0.253N	P=0.006N**	P=0.234N	P=0.094N
COCH-ARM / FISHERS	P=0.447N	P=0.252	P=0.330	P=0.585N	P=0.219N	P=0.018N*	P=0.189N	P=0.097N
ORDER RESTRICTED	P=0.419	(e)	(e)	(e)	P=0.075N	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs								
Malignant Tumors								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	29/50 (58%)	22/50 (44%)	30/50 (60%)	27/50 (54%)	33/50 (66%)	38/50 (76%)	41/50 (82%)	41/50 (82%)
POLY-3 RATE (b)	29/49.08	22/49.00	30/50.00	27/47.63	33/47.24	38/49.43	41/46.20	41/48.78
POLY-3 PERCENT (g)	59.1%	44.9%	60.0%	56.7%	69.9%	76.9%	88.8%	84.1%
TERMINAL (d)	19/38 (50%)	17/41 (42%)	21/41 (51%)	14/33 (42%)	24/36 (67%)	24/35 (69%)	27/31 (87%)	29/35 (83%)
FIRST INCIDENCE	301	431	543	535	440	461	503	142
STATISTICAL TESTS								
LIFE TABLE	P=0.290	P=0.088N	P=0.496N	P=0.526	P=0.081	P=0.253	P=0.031 *	P=0.097
POLY 3	P=0.435	P=0.113N	P=0.544	P=0.487N	P=0.041 *	P=0.289	P=0.018 *	P=0.073
POLY 1.5	P=0.451	P=0.114N	P=0.526	P=0.470N	P=0.040 *	P=0.252	P=0.019 *	P=0.066
POLY 6	P=0.428	P=0.113N	P=0.568	P=0.498N	P=0.043 *	P=0.334	P=0.018 *	P=0.081
LOGISTIC REGRESSION	P=0.525N	P=0.175N	P=0.400	P=0.405N	P=0.033 *	P=0.197	P=0.028 *	P=0.053
COCH-ARM / FISHERS	P=0.500	P=0.115N	P=0.500	P=0.420N	P=0.043 *	P=0.189	P=0.055	P=0.055
ORDER RESTRICTED	P=0.419	(e)	(e)	(e)	P=0.025 *	(e)	(e)	(e)

	Males				Females			
Dose	0 MG/L	500 MG/L	1000MG/L	2000MG/L	0 MG/L	500 MG/L	1000MG/L	2000MG/L
All Organs								
Malignant and Benign Tumors								
TUMOR RATES	#	#	#	#	#	#	#	#
OVERALL (a)	45/50 (90%)	45/50 (90%)	47/50 (94%)	45/50 (90%)	47/50 (94%)	45/50 (90%)	46/50 (92%)	47/50 (94%)
POLY-3 RATE (b)	45/49.62	45/49.46	47/50.00	45/48.32	47/49.05	45/49.43	46/46.71	47/49.24
POLY-3 PERCENT (g)	90.7%	91.0%	94.0%	93.1%	95.8%	91.0%	98.5%	95.4%
TERMINAL (d)	34/38 (90%)	38/41 (93%)	38/41 (93%)	30/33 (91%)	34/36 (94%)	31/35 (89%)	31/31 (100%)	33/35 (94%)
FIRST INCIDENCE	301	431	543	535	440	461	503	142
STATISTICAL TESTS								
LIFE TABLE	P=0.123	P=0.312N	P=0.478N	P=0.252	P=0.384	P=0.453N	P=0.276	P=0.514
POLY 3	P=0.355	P=0.618	P=0.402	P=0.470	P=0.439	P=0.288N	P=0.427	P=0.659N
POLY 1.5	P=0.392	P=0.622	P=0.381	P=0.508	P=0.459	P=0.286N	P=0.512	P=0.642N
POLY 6	P=0.356	P=0.615	P=0.434	P=0.467	P=0.414	P=0.312N	P=0.315	P=0.684N
LOGISTIC REGRESSION	P=0.504	P=0.630N	P=0.332	P=0.618	P=0.369	P=0.300N	P=0.660	P=0.632
COCH-ARM / FISHERS	P=0.533	P=0.630N	P=0.357	P=0.630N	P=0.482	P=0.357N	P=0.500N	P=0.661N
ORDER RESTRICTED	P=0.465	(e)	(e)	(e)	P=0.311	(e)	(e)	(e)

(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Number of tumor-bearing animals / Poly-3 number
(d) Observed incidence at terminal kill.

(f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(g) Poly-3 adjusted lifetime tumor incidence.
(I) Interim sacrifice
(T) Terminal sacrifice
Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).